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Introduction 
1.1 Polyunsaturated fatty acids in health and disease 
Among the fatty acids, long-chain polyunsaturated fatty acids (PUFA) play an 
important role in many physiological processes. Since they cannot be 
synthesized de novo, they have to be consumpted from dietary sources. They are 
classified according to the location of the first double bond, seen from the 
methyl end (ω-end) of the carbon chain, resulting in ω -3 and ω -6 fatty acids 
(Fig. 1). 
COOH
linoleic acid,LA (18:2,ω-6)
EPA (20:5,ω-3)
COOH
DHA (22:6,ω-3)
α-linolenic acid, ALA (18:3,ω- 3)
COOH
arachidonic acid (20:4,ω-6)
COOH
COOH
 
Fig. 1 Omega-3 and Omega-6- PUFAs 
α-Linolenic acid (ALA) is a plant-derived, essential ω-3 fatty acid and can be 
converted to eicosapentaenic acid (EPA) and docosahexaenoic acid (DHA) in 
the body. However, the conversion rates are quite low [1]. Epidemiological 
studies in a population of Greenland eskimos and japanese people in the early 
1980s revealed the nutritional importance of ω-3 fatty acids. Over the years, 
various studies confirmed that consumption of seafood containing high amounts 
of EPA and DHA, reduced the incidence of cardiovascular diseases and 
inflammatory disorders [2]. After oral application of EPA and DHA (1-3 g/day), 
triacylglycerol and cholesterol levels were decreased [3] and fish oil intake at 
doses up to 5 g/day showed anti-inflammatory effects in the treatment of 
rheumatoid arthritis [4]. EPA and DHA are precursors for the biosynthesis of 
important anti-inflammatory lipid mediators termed resolvins and protectins [5]. 
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Moreover, a protective aspect for ω-3 PUFAs in Alzheimer’s disease [6], [7] and 
a benefit in the treatment of psychiatric disorders [8] is discussed.  
Linoleic acid (LA), mainly occurring in vegetable oils (e.g. corn, sunflower) is 
an important ω-6-PUFA, contributing around 90% to the dietary intake of ω-6-
PUFAs. In mammalian cells, the ω-6-PUFA arachidonic acid (AA) is generated 
from LA by enzymatic elongation and desaturation [9]. After incorporation in 
membrane phospholipids, AA serves as starting substance for the synthesis of 
eicosanoids. The name originates from the number of carbon atoms (Greek: 
eicosa = twenty for 20-carbon fatty acid). The (patho)physiological roles of 
eicosanoids derived from AA, in particular prostaglandins (PGs) and 
leukotrienes (LTs), drawed the attention of researchers for more than 40 years 
now [10].  
1.2 Eicosanoid biosynthesis 
The term eicosanoids describes a class of biologically active lipid mediators 
derived from twenty-carbon PUFAs. AA (C20:4,ω-6) represents the major 
precursor for the synthesis of eicosanoids. It starts with the cleavage of AA from 
membrane phospholipids by cytosolic phospholipase A2 (cPLA2) followed by 
conversion via several enzymatic and non-enzymatic routes (Fig. 2). 
The lipoxygenase (LO) pathway converts AA to leukotrienes (LTs), hepoxilins 
and lipoxins (LXs). Lipoxygenases (LOs) are iron-containing dioxygenases that 
catalyze the stereo-specific insertion of molecular oxygen into PUFAs. The 
animal LOs are classified according to the positional specifity after oxygenation 
of AA [11] (for details, see  1.5). 
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Fig. 2: Eicosanoid biosynthesis [12] 
Conversion of AA by cyclooxygenases (COX) and further conversion by 
specific prostanoid synthases results in PGs, prostacyclins (PGIs) and 
thromboxanes (TXAs), summarized as prostanoids. In humans, COX-1 as a 
constitutively expressed enzyme and COX-2, induced by inflammatory stimuli 
are responsible for the generation of the endoperoxide PGH2 which is then 
further converted  by specific synthases to prostanoids (for details, see chapter 
1.4).  
Alternatively, cytochrome P450 (CYP)-epoxygenases and ω-hydroxylases 
convert AA to epoxyeicosatrienoic acids (EETs) and hydroxyeicosatetraenoic 
acids (HETEs). The CYP metabolites possess high relevance for renal and 
cardiovascular functions [13]. Moreover, EETs activate Ca2+-activated K+-
channels resulting in vascular relaxation and were ascribed to have anti-
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inflammatory effects [14]. In contrast, the expression of CYP ω-hydroxylase in 
tumor cells and a pro-angionetic action of EETs implicates a role in 
carcinogenesis [12], [15]. 
The biological actions of the eicosanoids are mediated via G-protein-coupled 
receptors (GPCR). Their wide-ranging actions are regulated by different 
coupling to G-proteins, the cellular distribution of the enzymes and expression 
of the receptors on the cells. Eicosanoids play pathophysiologial roles in acute 
inflammation, cardiovascular diseases, cancer [16], atherosclerosis and many 
other inflammatory diseases [17]. In contrast, anti-inflammatory effects for AA 
metabolites were described as seen for lipoxins and related metabolites.   
Thus, the eicosanoid pathway offers a multitude of interventions such as the 
inhibition of synthesis of pathophysiologic mediators or by intervention with 
their biological actions at their receptors. 
1.3 Phospholipase A2 (PLA2) 
The level of free AA in mammalian cells is a strictly controlled process. AA 
itself functions as an activator of ion channels and NADPH oxidase, resulting in 
the “oxidative burst” and in induction of apoptosis [18]. In inflammatory cells, 
AA obtained either by biosynthesis from essential fatty acids or by dietary 
intake is esterified to the sn-2 position of phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) [19] and low levels of unesterified AA are 
present. Thus, the amount of free AA is determined by the balance between the 
incorporation of AA to phospholipids by CoA-dependent acyl transferases and 
transacylases and concomitant deacylation by phospholipases (“Lands cycle”). 
Upon cellular stimulation, the cycle is shifted towards the deacylation of AA, 
resulting in enzymatic cleavage of AA from the phospholipid.  
PLA2s catalyze the hydrolysis of the sn-2 ester bond of glycerophospholipids, 
resulting in a free fatty acid and a lyso-phospholipid [20]. More than 15 groups 
of phospholipase A2 are known, subdivided in five types: secreted sPLAs 
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(sPLA2), cytosolic cPLA2s (cPLA2), Ca2+-independent PLA2s (iPLA2), platelet 
activating factor acetyl hydrolases (PAF-AH) and lysosomal PLA2s [21].  
Group IVA PLA2 (cPLA2α) is specific for the cleavage of esterified AA in sn-2 
position. The active site contains a catalytic dyad composed of Ser228 and 
Asp549. cPLA2α binds two Ca2+-ions at a N-terminal C2 domain [22]. An 
increase of the intracellular Ca2+ concentration leads to binding of Ca2+ at the C2 
domain followed by translocation of the enzyme to the nuclear membrane and 
the endoplasmic reticulum. In addition, phosphorylation of cPLA2α at Ser505 by 
MAPK regulates the activity of cPLA2α [23]. Further regulatory mechanisms 
involve interactions with the lipid mediators ceramide-1-phosphate (C1P), or 
phosphatidylinositol (4,5) bisphosphate (PIP2) [20]. The important role of 
cPLA2α in eicosanoid production and inflammatory processes was investigated 
in cPLA2α-deficient knockout mice, where deletion of the cPLA2α gene led to 
significant decrease in PG and LT formation and a reduced allergic response 
[24]. 
1.4 Prostanoids 
Prostanoids are a family of lipid mediators arising from the oxygenation of AA 
by prostaglandin H synthases (PGHS), commonly referred to as COX. In 
mammals, COX exists in two isoforms: COX-1 is widely expressed in tissues 
and cells and is considered as “housekeeping” enzyme and COX-2, which is 
induced in response to certain inflammatory stimuli and in tumor development. 
However, a constitutive expression of COX-2 is also well-known in brain, 
kidney and the female reproductive tract [25]. The existence of COX-3 was 
assumed, but it was later identified as a splice variant of COX-1 [26], [27].  
COXs are important pharmacological targets of the widely used nonsteroidal 
anti-inflammatory drugs (NSAIDs) in the treatment of fever, pain, rheumatic 
diseases and inflammatory conditions [28]. COX-1 and -2 convert AA to the 
endoperoxide PGG2 by introduction of oxygen at C-15 (cyclooxygenase 
reaction) followed by reduction of the hydroperoxide to the corresponding 
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alcohol PGH2 (peroxidase reaction) [29]. PGH2 serves as substrate for cell-
specific downstream synthases and isomerases, yielding PGs, PGIs or TXs (Fig. 
3). 
 
Fig. 3 Prostanoid biosynthesis [30] 
The biological effects of prostanoids are mediated at specific GPCR and their 
functional roles were analyzed by targeted deletion of the receptors [31]. 10 
subtypes have been described so far: four receptor subtypes for PGE2 (EP1-EP4), 
two PGD2 receptors (DP1/DP2 ), two for TXA2 (TPα/TPβ) and for PGF2α (FPA and 
FPB) and PGI2 (IP) [32]. Additionally, PGE2 interacts with the PPARδ receptor. 
TXA2 has strong vasoconstrictory and thrombogenic properties and exerts its 
functions mainly in platelets. PGI2 acts as physiological antagonist of TXA2 and 
possesses vasodilatatory and inhibits platelet aggregation [33].  
PGI2 and PGE2 contribute to the protection of the gastric mucosa by increase of 
mucosal blood flow and stimulate bicarbonate secretion [34]. Depending on the 
EP receptor subtype, PGE2 was linked to osteoclastogenesis, development of 
fever and pain as well as to the regulation of blood pressure in the kidney.  
PGF2α  plays an important role in the reproductive tract at parturition and onset 
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of labor; PGD2 is generated by mast cells in allergic diseases [31]. Additionally, 
PGI2, TXA2 and PGF2α  influence renal functions [32]. 
The use of specific COX-2 inhibitors (“Coxibs”) was shown to reduce the 
unwanted gastrointestinal side effects of non-selective NSAIDs such as 
ibuprofen or diclofenac. However, a long-term-use of COX-2 inhibitors was 
related to higher risk of cardiovascular side effects such as myocardial infarction 
or cerebrovascular events [35]. The cardiovascular side effects of the Coxibs 
were ascribed to reduction of COX-2-derived antithrombotic PGI2, leading to an 
imbalance and an excess of pro-aggregating TXA2 resulting in cardiovascular 
events [36].  
COX-2 is functionally coupled to the downstream microsomal PGE2 synthase-1 
(mPGES-1). mPGES-1 catalyzes the conversion of COX-2 derived PGH2 to 
PGE2, which is considered as the major PG involved in inflammation, pain, 
arthritis and cardiovascular diseases [30]. Upon exposure to proinflammatory 
cytokines such as LPS, TNF-α or IL-1β, mPGES-1 expression is strongly 
upregulated [37]. Suppression of mPGES-1-derived PGE2 formation is supposed  
to have beneficial effects in various inflammatory diseases, cancer [38] and 
cardiovascular diseases [39]. A genetic knockout of mPGES-1 in a mouse model 
confirmed the role of mPGES-1 in cancer treatment [40]. Thus, selective 
inhibition of mPGES-1 represents a novel and specific therapeutic approach for 
anti-inflammatory therapy [30].  
1.5 Mammalian lipoxygenases  
Mammalian LOs are classified based on the phylogenetic aspect into epidermis-
type-LO, 5-LO, platelet-type 12-LO and 12/15-LO. In humans, five homologues 
were identified: the 5-(S)-LO, platelet-type 12-(S)-LO, epidermis-type 12(R)-
LO, reticulocyte type 15-(S)-LO (15-LO-1) and epidermis-type 15(R)-LO (15-
LO-2) [41].  
However, the nomenclature of the enzymes according to the positional 
specificity of the oxygenated LO products is not fixed. For example, the 
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mammalian reticulocyte-type 15-LO forms a mixture of C-12- and C-15 
oxygenated products [42]. Therefore, this enzyme is designated as 12/15-LO. 
Mammalian LOs consist of a single polypeptide chain with 662-676 amino acids 
with a molecular mass of 75-80 kDa. The catalytic domain of LOs contains a 
single non-heme iron atom surrounded by four conserved histidine residues and 
an isoleucine.  
The oxygenase reaction of LOs starts with the stereoselective abstraction of 
hydrogen from the fatty acid, resulting in a pentadienyl radical, followed by 
rearrangement of  the radical electron either in the direction of the methyl or the 
carboxylate end (Fig. 4). Then, oxygen is inserted at the antarafacial site of the 
hydrogen abstraction, resulting in a peroxy radical fatty acid. This peroxy 
radical is reduced by an electron from the catalytic iron which is reoxidized to 
its ferric (Fe3+) form.  
 
Fig. 4 Mechanism of the catalytic lipoxygenase reaction [11] 
The positional specificity of mammalian 5-, 12- and 15-LOs depends on the 
volume of the active site. The alkyl end of AA binds in the bottom of the cleft 
and the acid end interacts with a basic amino acid such as arginine (12- and 15-
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LO) or lysine (5-LO) [43]. Moreover, the orientation of the fatty acid seems to 
determine the position where the oxygenation occurs [44].  
Genetic disruption of LO genes provided insights to the different roles of the 
mammalian LOs. 5-LO-deficient mice showed reduced signs of inflammation in  
typical  models. In addition, 5-LO plays a role in host defense response against 
to airway infection with Klebsiella pneumoniae. A genetic knockout of platelet-
type-12-LO was linked to thrombotic diseases, tumor development and 
maintenance of the epidermal water barrier. Studies with 15-LO-deficient mice 
mouse showed a clear role in atherosclerosis and possible involvement in type 1 
diabetes and cardiovascular diseases [45]. 
1.6 Lipoxygenase interaction products (lipoxins) 
The combined action of 5-, 12- and 15-LOs by cell-cell interactions and 
transcellular biosynthesis of lipid mediators leads to the formation of an 
important class of anti-inflammatory mediators, the lipoxins (LXs) [46]. 
 
Fig. 5 Lipoxin biosynthesis [47], modified 
15(S)-H(P)ETE derived from the oxidation of AA by 15-LO, is converted by 5-
LO via an epoxytetraene to lipoxin A4 (LXA4) and lipoxin B4 (LXB4) . Another 
route involves LTA4 from the 5-LO pathway which is converted by 15-LO or 
platelet-type-12-LO (p12-LO) by mean of cell-cell-interactions yielding LXA4 
and LXB4 (Fig. 5).  
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An additional class of lipoxins is generated by acetylsalicylic acid (ASA)-treated 
COX-2 which acetylates the active site of COX-2. Now, AA is converted by the 
acetylated COX-2 to 15(R)-HETE. Then, 5-LO from PMNL further metabolizes 
15(R)-HETE to 15-epi-LXs, the “aspirin-triggered-lipoxins” (ATL) [47] (Fig. 
5). LXA4 and ATL bind to a specific receptor, termed ALX or FPRL1, a GPCR 
belonging to the formyl peptide receptor family [48].  
Beside AA, the ω-3 PUFAs EPA and DHA serve as precursors for resolvins, 
protectins and maresins, additional important mediators for the resolution of 
acute inflammation [5].  
1.7 Leukotrienes 
1.7.1 Leukotriene biosynthesis 
LTs represent a unique family of eicosanoids derived from AA. The term 
implicates the presence of three conjugated double bonds within the 20-carbon 
structure [49]. Leukotriene biosynthesis is mediated by the action 5-LO and 
other enzymes (Fig. 6).  
After release of AA from cellular membrane lipids by cPLA2, molecular oxygen 
is inserted at C-5 yielding 5(S)-hydroperoxy-6,8-trans-11,14-cis-
eicosatetraenoic acid (5-HPETE) followed by subsequent conversion to the 
unstable epoxide intermediate 5(S)-trans-5,6-oxido-7,9-trans-11,14-cis-
eicosatetraenoic acid (LTA4) [50]. A non-enzymatic hydrolysis of LTA4 is 
observed in vitro, resulting in the formation of the diastereomeric dihydroxy 
derivatives 5(S),12(R)-diHETE (6-trans-LTB4) and 5(S),12(S)-diHETE (6-trans-
12-epi-LTB4) [51].  
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Fig. 6 Leukotriene biosynthesis [52] 
5-HETE, the corresponding alcohol of 5-HPETE, can be metabolized by the 
microsomal enzyme 5-hydroxyeicosanoid dehydrogenase (5-HEDH). The 
resulting pro-inflammatory 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) 
is a strong chemoattractant for eosinophils [53]. In neutrophils, 5-oxo-ETE 
stimulates Ca2+ mobilization and cell migration and stimulates degranulation. It 
acts through the highly specific Gα-coupled OXE receptor, which is highly 
expressed on eosinophils and to a lower extent on neutrophils and macrophages. 
Moreover, prostate cancer cells contain high levels of 5-HEDH and an enhanced 
5-oxo-ETE synthesis was found in apoptotic cells, suggesting a role for 5-oxo-
ETE in cancer development [54]. 
LTA4 is further converted enzymatically by LTA4-hydrolase (LTA4H) to LTB4 
(5(S),12(R)-dihydroxy-6,8,10,14-eicosatetraenoic acid). LTA4H is a monomeric 
enzyme with a zinc-binding motif in the catalytic site and has a molecular 
weight of approximately 70 kDa [55]. LTA4H was isolated first from the 
soluble fraction of human leukocyte homogenates [56]. The conversion of LTA4 
to LTB4 by LTA4H involves the opening of the epoxide at C-5 and the 
nucleophilic addition of water at C-12 with the participation of Glu271, Asp375 
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and the catalytic zinc ion. Beside its epoxide hydrolase function, LTA4H 
possesses an aminopeptidase activity, which seems to be involved in peptide 
reactions related to host defense and inflammation [57].  
LTB4 and 5-HETE were identified in the early 1980s when PMNL from rabbit 
[58] or human origin were incubated with AA and calcium ionophore A23187 
[59]. LTB4 is a very potent chemotactic molecule and stimulator of various 
leukocyte functions [60]. Over the years, an important pathophysiological role in 
asthma, allergic diseases [61], [62], cardiovascular and inflammatory conditions 
was attributed to LTB4  [60]. 
Alternatively, LTA4 is conjugated with GSH leading to the cysteinyl-LT  LTC4, 
catalysed by LTC4 synthase (LTC4S), an 18-kDa, membrane-associated 
enzyme. For the reaction of LTA4 to LTC4, LTC4S binds GSH in its active site. 
LTC4S belongs to the MAPEG (membrane-associated protein in eicosanoid and 
glutathione metabolism) protein family along with the homologous mPGES-1 
[63], 5-lipoxygenase-activating protein (FLAP) and microsomal glutathione  S-
transferases (MGST) [64].  
After release of LTC4 from the cell, peptide cleavage by γ-glutamyl 
transpeptidase and dipeptidases lead to the other cysteinyl-LTs (cys-LTs) LTD4 
and LTE4, respectively [49]. LTC4, LTD4 and LTE4 were first referred to as 
“slow-reacting substances of anaphylaxis” (SRS-A), underlining the role of 
cysteinyl-LTs in allergic conditions [65]. Cys-LTs cause bronchoconstriction in 
airway smooth muscle cells, increase microvascular permeability, reduce 
myocardial contractility and coronary blood flow [50]. They are the most potent 
bronchoconstricting mediators in humans and exert pro-inflammatory effects. 
Cys-LTs are implicated in cancer, cardiovasular disorders such as myocardial 
infarction and unstable angina as well as in atopic dermatitis and rheumatoid 
arthritis [66].  
Additionally, LT biosynthesis occurs via transcellular mechanisms, where LTA4 
is transported and uptaken by other cells devoid of 5-LO. Thus, platelets 
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expressing LTC4S, but no LTA4H, take up LTA4 from 5-LO expressing cells 
and produce LTC4. In contrast, erythrocytes express no 5-LO, but LTA4H and 
convert the incorporated LTA4 to LTB4 [67].  
1.7.2 Leukotriene receptors 
LTs and Cys-LTs mediate their effects through cell-surface GPCRs. LTB4 binds 
with high affinity to the specific BLT1 receptor, which was cloned in 1997 [68]. 
BLT1 is highly expressed on peripheral blood leukocytes and mast cells [69] 
and with lower incidence in spleen and thymus. Binding of LTB4 to BLT1 
mediates leukocyte functions such as chemotaxis or production of ROS [70]. In 
contrast, the BLT2 receptor subtype is more ubiquitously expressed with about 
20-fold lower affinity for LTB4 and different pharmacological properties 
compared to BLT1 [71]. BLT2 binds also other eicosanoids such as 12-HHT, 
12-HETE and 15-HETE [72]. A recent study with BLT2-knockout mice 
suggested a role in inflammatory arthritis [73]. Another study observed an 
elevated BLT2 expression in bladder cancer [74]. However, a clear functional 
role for the BLT2 receptor subtype was not clarified yet.   
Additionally, LTB4 binds to the nuclear transcription factor PPARα, suggesting 
further anti-inflammatory functions [75]. Due to the important pathophysiologial 
roles of LTB4, multiple selective and non-selective antagonists at the BLT 
receptors have been developed and studied for the treatment of rheumatoid 
arthritis, COPD, cystic fibrosis, osteoporosis as well as different types of or 
cancer, but no substance entered the market so far [76].  
For the cys-LTs, two main receptor subtypes (CysLT1 and CysLT2) were 
characterized. The CysLT1 receptor binds LTD4 with high affinity, followed by 
LTC4 and LTE4 with less affinity. In contrast, the CysLT2 subtype has equal 
affinity for LTC4 and LTD4 and lower affinity for LTE4 [77]. The CysLT1 
receptor is expressed in blood cells such as eosinophils, monocytes, 
macrophages, neutrophils, in a subset of B-lymphocytes and mast cells and to a 
lesser extent in spleen, lung and smooth muscle cells. A significant increased 
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number of cells expressing the CysLT1 receptor in patients with stable or 
exacerbated asthma supports the role of cys-LTs in inflammatory airway 
diseases. In contrast, the CysLT2 receptor subtype is highly expressed in the 
heart and coronary arterial smooth muscle cells, in the brain, spinal cord and 
adrenal glands. Interestingly, the CysLT2 receptor was also found in eosinophils 
and mast cells in patients with allergic rhinitis, but the role was undefined yet 
[66],[78]. 
In the meantime, additional receptor subtypes for cys-LTs were reported. The 
phylogenetically related GPR17 receptor, a dual CysLT and nucleotide receptor, 
binds LTC4 and LTD4 in the nanomolar range [79]. In double-knockout mice 
deficient of both CysLT1 and CysLT2 receptors, a GPCR with preference for 
LTE4 was discovered [80]. 
Pharmacological influence on the action of cys-LTs was achieved with the 
development of specific antagonists for the CysLT1 receptor. Montelukast 
(Singulair ®), zafirlukast (Accolate ®) and pranlukast (Onon ®) are approved 
and clinically used in the treatment of asthma and allergic rhinitis. BAYu9773 
acts as dual antagonist at both receptor subtypes and shows partial agonism at 
the CysLT2 receptor and is used only for experimental purposes [81]. Hence, the 
development of  a selective CysLT2 receptor antagonist would be helpful for 
further characterization of the receptor function. Recently, the first selective 
CysLT2 receptor antagonist was described [82].  
1.8 5-Lipoxygenase (5-LO) 
1.8.1 Enzymatic reaction, structure and expression of 5-LO 
5-LO was first isolated from homogenates of human leukocytes [83] and 
catalyzes the first steps in the biosynthesis of LTs (for details, see Fig. 6). 5-LO 
mediates the incorporation of molecular oxygen into AA (oxygenase activity) 
followed by subsequent dehydration of the resulting 5-HPETE to the allylic 
epoxide LTA4 (LTA4 synthase activity). LTA4 serves as intermediate for the 
biosynthesis of LTB4, cys-LTs or lipoxins [84]. The oxygenase reaction of 5-LO 
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is initiated by the abstraction of pro-S hydrogen at C-7 of AA [51]. In the next 
step, molecular oxygen is inserted at C-5, leading to 5-HPETE. The subsequent 
conversion to LTA4 involves the abstraction of hydrogen at C-10 followed by 
allylic shifts to C-6 resulting in the formation of the 5,6-epoxide LTA4 [85]. 
These dual enzymatic properties of 5-LO were first observed in purified enzyme 
from potato tubers [86] and confirmed in leukocyte homogenates [87] and 
murine mast cells [88].  
5-LO is a monomeric enzyme with 673 amino acids, consisting of a large 
catalytical C-terminal domain (amino residues 121-673), whereas the N-terminal 
domain (1-114) is a Ca2+-binding C2 domain [89] with similarity to other 
proteins such as cPLA2 [90]. The residues in position 43-46 are involved in Ca2+ 
binding and three tryptophane residues (Trp75, Trp102 and Trp13) interact with 
phosphatidylcholine (PC), glycerides and coactosin-like protein (CLP) (Fig. 7). 
The catalytic centre of 5-LO contains a non-heme iron atom, surrounded by 
His372, His550 and the C-terminal Ile673 as permanent ligands [91] forming a 
2-His-1-carboxylate facial triad, a common structural LO motif. Asn554 and 
His367 were identified as replaceable ligands and H2O was assumed as sixth 
ligand for the iron [92]. The catalytic domain of 5-LO contains three motifs for 
phosphorylation by the kinases ERK2, MK2 and PKA (Fig. 7). 
For a long time, no crystal structure of 5-LO was available. Accordingly, all 
structural data were based on a homology model of rabbit reticulocyte 15-LO 
[43] or soybean-lipoxygenase-1 [93]. Recently, the crystal structure of 5-LO was 
presented at 2.4 Å resolution. Replacement of the Lys653-Lys655 sequence in 
the C-terminal region of 5-LO by the corresponding sequence of a 8R-LO 
enabled the stabilization of the enzyme for crystallization [94]. 
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Fig. 7 Structure of 5-LO [52]  
The N-terminal domain (residues 1–114; green) contains the Ca2+-binding C2 domain. 
Mutagenesis of the amino acids 43–46 (red) reduced Ca2+ binding to 5-LO. Trp13, Trp74 and 
Trp102 (yellow) mediate the effects of PC, glycerides and coactosin-like protein (CLP). 
Phosphorylated serine residues in the kinase motifs for MK2, ERK2 and PKA are shown in 
light blue.  
5-LO expression is mainly found in cells from myeloid origin such as 
leukocytes, monocytes, macrophages, mast cells, B-lymphocytes or dendritic 
cells [95]. Furthermore, 5-LO expression was reported in pulmonary endothelial 
cells [96] and arterial walls of atherosclerotic lesions [97]. For in vitro studies, 
5-LO expression can be induced by differentiation of promyelocytic HL-60 cells 
with DMSO [98]. Moreover, addition of 1,25-dihydroxyvitamin D3 (1,25(OH)2 
D3) together with TGF-β [99] upregulates the enzymatic activity in the DMSO-
treated HL-60 cells as well as in monocytic Mono Mac 6 cells [100]. 
1.8.2 The 5-LO gene  
The human 5-LO gene (ALOX5) contains 14 exons, divided by 13 introns, and 
has a length of approximately 82 kb. In contrast to all other lipoxygenases. 
ALOX5 is located on chromosome 10. The promoter region lacks TATA and 
CCAT sequences, resembling the structure of an ubiquitously expressed 
housekeeping gene [101]. In total, 10 GC-rich regions (GC boxes) are present in 
the sequence, whereof 8 GC boxes are located in the promoter region [102]. 5 
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GC boxes in the promoter region are arranged in tandem [101] and were 
identified as binding sites for the transcriptional factors Egr-1 and Sp-1 [103]. 
Additional putative binding sites for transcription factors such as NFκB and AP-
2 were found in the 5-LO promoter [104]. Naturally occurring mutations in the 
tandem GC boxes of the 5-LO promoter result in the deletion or addition of Sp-
1/Egr binding sites. These variations were shown to influence the transcription 
of 5-LO [105]. Moreover, an association between different promoter genotypes 
and a diminished response to an oral 5-LO inhibitor in asthmatic patients was 
reported [106]. Carriers of polymorphisms in the tandem GC boxes in the 5-LO 
promoter showed an increased carotid intima-media-thickness, a marker for 
atherosclerosis and significantly higher risk of atherosclerosis [107]. Variants of 
ALOX5 were associated to tuberculosis susceptibility, underlining the role of 
LTs in the defense of bacterial infections [108]. Furthermore, interactions of 
retinoid receptors (RXR) and vitamin D receptor (VDR) to vitamin D responsive 
elements (VDRE) were reported in the 5-LO promoter region. However, these 
sites are not responsible for the induction of 5-LO expression by 1,25(OH)2D3 
and TGFβ [109]. 5-LO gene expression is regulated by DNA methylation and 
histone acetylation. Demethylation of the promoter is required for transcription 
of the 5-LO gene [110], whereas inhibition of histone deacetylation by 
trichostatin A strongly enhances 5-LO promoter activity and increases gene 
expression [111]. Recently, several spliced isoforms of 5-LO where identified in 
leukocytes. Due to lack of amino acid sequences in the catalytic domain, a 
decreased product formation and a different cellular distribution compared to 
full length 5-LO was observed [112]. 
1.8.3 Factors regulating 5-LO activity in the cell and in vitro  
5-LO activity in the cell and in vitro is regulated in a complex manner involving 
several pathways and factors. One critical parameter is the availability of the 
substrate AA for 5-LO. In the cell, cPLA2 liberates AA from membrane 
phospholipids upon stimulation. Thus, stimulation of cells with naturally ligands 
such as fMLP, C5a or PAF results in a low LT synthesis in vitro, related to low 
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substrate supply. 5-LO product formation can occur also independently of 
cPLA2, since addition of exogenous AA strongly enhances 5-LO activity [113]. 
Over time, a variety of studies revealed that ATP, interaction with Ca2+ and PC, 
the intracellular peroxide tone, phosphorylation by kinases and the subcellular 
localization of the enzyme are important factors that control the enzymatic 
activity of 5-LO in vitro. 
1.8.3.1 ATP 
Experiments with peritoneal PMNL from guinea pigs showed that the activity of 
5-LO is stimulated by ATP. Other nucleotides such as ADP, AMP, cAMP, GTP 
or CTP showed weaker or no effects on the enzyme activity [114]. Other studies 
confirmed that this effect requires Ca2+ [83], [115]. Interestingly, hydrolysis of 
ATP to ADP is not necessary for the upregulation of 5-LO product formation. 
Affinity chromatography with ATP is used for the purification of recombinant 
5-LO. This fact raised the question for an ATP-binding site at the enzyme. 
Photoaffinity labeling studies with radioactive marked ATP analogues revealed 
a general nucleotide binding site, but not specific for ATP in the 5-LO sequence 
[116]. However, binding of ATP binding is characteristic for 5-LO, since other 
LOs do not have nucleotide binding sequences and seems to be important for the 
stabilization of the 5-LO structure.  
1.8.3.2 Ca2+, phospholipids and the C2 domain of 5-LO 
The observation that stimulation of human PMNL with A23187 results in strong 
formation of 5-HETE and LTB4 [59] substantiates the important role of Ca2+ for 
5-LO activity. For isolated recombinant 5-LO, the required concentration for 
half-maximal enzyme activity is about 1-2 µM, whereas for full activation 4-10 
µM is needed [117]. In contrast, much lower levels of intracellular Ca2+ of 350-
400 nM are necessary for cellular 5-LO product formation. Thus,  Ca2+ release 
from intracellular stores is sufficient for 5-LO activation in PMNL 
independently from cPLA2 activation [118].  
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5-LO binds two Ca2+ ions per molecule at its N-terminal domain with an Kd of 6 
µM thereby increasing the hydrophobicity of the enzyme [119]. The N-terminal 
β-barrel domain of 5-LO shares high similarity to Ca2+-binding C2 domains of 
other proteins such as PKC or cPLA2. Mutagenesis studies identified Asn43, 
Asp44 and Glu46 (Fig. 7) as putative Ca2+ ligands of 5-LO [89]. Ca2+ improves 
the binding of PC to 5-LO and thereby promotes the conversion of 5-HPETE to 
LTA4 [120]. Three surface-exposed tryptophane residues (Trp13, Trp75 and 
Trp102) in the C2 domain bind PC and mediate the translocation of 5-LO to 
membranes [121],[122] (Fig. 7). However, when high amounts of PC are 
present, Ca2+ is not strictly required for 5-LO activity [123]. Furthermore, 
binding of Ca2+ to the C2 domain protects the enzyme from the inhibitory effects 
of GPx-1 and leads to 5-LO activation at lower peroxide levels [124]. 
Mg2+ can substitute for Ca2+ in 5-LO activation steps, but for maximal activity, a 
high concentration of 4 mM Mg2+ is needed. Activation by Mg2+ was also 
dependent on phospholipid and AA concentrations [125]. Beside Mg2+, Mn2+, 
Sr2+ and Ba2+
 
ions can activate 5-LO in vitro, but with much weaker effects than 
Ca2+ [117].  
Interestingly, cellular 5-LO activation by chemical stress (sodium arsenite), 
osmotic stress (NaCl) or heat shock was independent of intra- and extracellular 
Ca2+ [126], showing that 5-LO activity is also regulated by Ca2+-independent 
mechanisms. 
1.8.3.3 Glycerides  
The diacylglycerol 1-oleyl-2-acetylglycerol (OAG) strongly stimulates 5-LO 
product formation in vitro in a calcium-independent manner [127]. OAG binds 
to three tryptophan residues (Trp13, Trp75 and Trp102) at the C2 domain of 5-
LO which serves also as binding site for phospholipids. Thus, the stimulatory 
effect of OAG is reversed by phospholipids. Other structural related glycerides 
showed weaker or no stimulatory effects on 5-LO product formation. Moreover, 
OAG increases the affinity of 5-LO for activating lipid hydroperoxides (LOOH) 
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necessary for catalysis and renders 5-LO activity resistant against GPx activity 
[128]. Additionally, the endogenous generation of diacylglycerides (DAG) 
resulting from hydrolysis of phosphatidylcholine mediated by phospholipase D 
(PLD) and phosphatidic acid phosphatase (PA-P) is a determinant for 5-LO 
product formation and 5-LO translocation to the nuclear membrane in PMNL 
[129]. Interestingly, gender-dependent PLD activity was recently reported 
resulting in higher 5-LO product formation in monocytes from female donors 
compared to cells from male donors. The suppressive effect on LT formation in 
male cells is caused by the sex hormone 5α-DHT resulting in phosphorylation of 
ERK2 and thus diminished DAG formation by PLD [130]. These findings 
exhibit DAGs as important determinants for the regulation of 5-LO activity in 
intact cells and in vitro. 
1.8.3.4 Coactosin-like protein (CLP) 
Investigations of protein interactions of 5-LO identified CLP, an F-actin binding 
16-kDa protein with high homology to coactosin from Dictyostelium discoideum 
[131]. The stoichometry of CLP binding to 5-LO is 1:1 and mutation of Lys131 
reduced the complex between 5-LO and CLP. Interestingly, the interaction 
between 5-LO and CLP is a calcium-independent process [132]. Additionally, 
Trp102 of 5-LO was found to mediate binding between 5-LO and CLP, which 
prevents non-turnover activation of 5-LO and stabilizes the 5-LO structure in the 
cell [133].  
In the presence of PC, CLP increases the Ca2+-induced 5-LO activity, promotes 
the formation of LTA4 and increases the ratio of 5-HETE/5-HPETE formation in 
vitro [134]. The subcellular distribution of CLP correlates with 5-LO. Upon cell 
activation, 5-LO and CLP comigrate to the nuclear fraction in contrast to a 
cytosolic localization in the resting state [133]. In neutrophils, the co-migration 
of 5-LO and CLP was observed together with a gender-related distribution 
pattern in cells from male and female donors [135]. 
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1.8.3.5 Lipid hydroperoxides (LOOH) and glutathione peroxidases (GPx) 
For 5-LO catalysis, a threshold level of LOOH is necessary for the oxidation of 
the catalytic iron of 5-LO from the inactive ferrous (Fe2+) to the active ferric 
(Fe3+) state [136]. Selenium-dependent GPx regulate the hydroperoxide tone in 
leukocytes by reduction of hydroperoxides such as 5-HPETE and thereby 
control 5-LO activity [137]. In the resting cell, intracellular peroxide 
concentrations are kept low by the activity of GPx which reduce LOOH. 
Conditions that lead to oxidative stress or depletion of GSH in vitro increase the 
peroxide concentration, resulting in activation of 5-LO [138]. An elevated 
peroxide concentration strongly impaired the efficacy of the non-redox-type 
inhibitors ZM230487 and L-739,010 [139].  
1.8.3.6 5-LO phosphorylation by kinases 
Proinflammatory stimuli, cell stress or heat shock lead to activation of p38 
MAPK in PMNL and increased LT synthesis. Accordingly, p38 MAPK 
activates the downstream kinases MK2/3, which phosphorylate 5-LO in vitro 
[140]. Mutation experiments revealed Ser271 as phosphorylation site and AA 
and other unsaturated fatty acids strongly enhance the phosphorylation state of 
5-LO. In contrast, the phosphorylation of 5-LO by CaMKII and the catalytic 
subunit of protein kinase A (PKA) was found to occur independently of 
exogenous AA addition [141].  
Furthermore, extracellular signal-regulated kinases (ERKs) regulate 5-LO 
activity. ERK2 phosphorylates 5-LO at Ser663 and as shown for MK2, addition 
of AA and other unsaturated fatty acids strongly enhanced the effect in vitro. 
The phosphorylation state correlated with the amount of product formation, 
suggesting the kinase actions as an important factor for cellular 5-LO activity. 
Product formation in PMNL induced by the physiological agonist fMLP or AA 
was reduced by the MEK inhibitor U0126, confirming the involvement of ERK2 
in this process [142]. Thus, AA-induced product formation in PMNL leads to 
phosphorylation of 5-LO at different sites by ERK2 and p38 MAPK-regulated 
MK2. Interestingly, AA-induced product formation in PMNL occurs 
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independently of  Ca2+, suggesting alternative mechanisms of 5-LO activation in 
the cell [143].  
Recently, a gender-dependent activation status of ERK was shown to cause 
different LT formation and the subcellular distribution of 5-LO in PMNL from 
male and female donors. The androgen 5α-DHT causes activation of ERK, 
resulting in lower 5-LO product formation in male cells [135]. In contrast, 
phosphorylation of 5-LO by PKA at Ser523 attenuates LT biosynthesis [144] 
and impairs the nuclear import of 5-LO [145]. An elevation of intracellular 
cAMP levels activates PKA and prevents 5-LO translocation and subsequently 
LT formation [146]. To sum up, phosphorylation of 5-LO by p38 MAPK-
regulated MKs, ERK and PKA regulates the catalytic activity of 5-LO in intact 
cells in a Ca2+-dependent manner. 
1.8.4 5-lipoxygenase-activating protein (FLAP) 
The integral membrane-bound, 18-kDa protein FLAP plays a substantial role for 
cellular LT biosynthesis [147]. Investigations with the leukotriene synthesis 
inhibitor MK-886 (using a radiolabelled derivative thereof) led to the 
identification of FLAP in rat neutrophil extracts [148]. The high relevance of 
concurrent FLAP and 5-LO expression for LT formation was shown in 
transfection experiments with osteosarcoma cell lines [147] and differentiated 
HL-60 cells [149]. FLAP directly binds AA and transfers it to 5-LO thereby 
affecting the ratio of formed 5-HPETE and LTA4 [150], [151]. The specific 
binding of AA to FLAP is competed by inhibitors such as MK-886 [150]. FLAP 
belongs to MAPEG family. In contrast to the other five human MAPEG 
members such as mPGES-1 or LTC4S, it has no enzymatic activity and its 
function is not modulated by GSH [152]. The three-dimensional structure of 
FLAP was solved in 2007 and shows a homotrimer, whereof each monomer 
consists of four transmembrane helices connected by two cytosolic and one 
lumenal loop [153] (Fig. 8). 
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Fig. 8 Structure of FLAP in complex with inhibitor MK-591 [153]  
The three FLAP monomers are colored in green, blue and magenta. The bound inhibitor MK-
591 is presented as stick model in yellow. C1 and C2 designate the cytosolic, L1 the luminal 
connecting loop of the FLAP homotrimer. 
The expression of FLAP has a pro-inflammatory and pathophysiological role 
and was linked to atherosclerosis, metabolic diseases and obesity [154]. 
Polymorphisms in the FLAP gene (ALOX5AP) were associated with higher risk 
of myocardial infarction and stroke due to enhanced LT formation and a higher 
inflammatory state [155]. However, a meta-analysis of studies investigating 
ALOX5AP gene polymorphisms doubted a significant correlation [156]. 
Nonetheless, FLAP is a specific, promising target for the development of potent 
LT biosynthesis inhibitors for the treatment of inflammatory and cardiovascular 
diseases. 
1.8.5 Subcellular distribution of 5-LO 
Early studies indicated that 5-LO is a mobile enzyme in the cell. The initial step 
of LT biosynthesis requires the calcium-dependent movement of 5-LO from the 
cytosol to a membrane compartment [157]. This translocation process was 
observed in osteosarcoma cells [158], HL-60 cells [159] and human leukocytes 
[160] after stimulation with Ca2+-ionophore A23187 or the chemoattractant 
fMLP, where 5-LO was detected in the membrane fraction after cell disruption. 
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Binding of Ca2 + to the N-terminal C2-domain increases the hydrophobicity of 5-
LO and promotes translocation to the nuclear membrane [119], [121]. The 
nuclear membrane is referred to as “metabolon”, since it is the site where LT 
synthesis takes place [161]. Upon elevation of intracellular calcium, both 5-LO 
and cPLA2 move from the cytosol to the nuclear membrane, where cPLA2 
liberates AA from membrane phospholipids [162]. Then, the integral membrane 
protein FLAP binds AA and transfers it to 5-LO where the catalytic reaction 
generates 5-HPETE and LTA4 [163] (Fig. 9).  
 
Fig. 9 Intracellular 5-LO distribution ( [52], modified)  
In the resting state, 5-LO is a cytosolic enzyme. 5-LO catalysis is activated by calcium or 
phosphorylation by ERK and p38 MAPK. Lipid hydroperoxides convert Fe2+ in the catalytic 
site to Fe3+and 5-LO translocates to the nuclear membrane where it colocalizes with cPLA2, 
CLP and FLAP followed by conversion of AA to 5-HETE and LTs. abbreviations: NIS: 
nuclear import sequence 
LTA4 serves as substrate for the integral membrane protein LTC4 synthase 
yielding LTC4 [63] or for the conversion to LTB4 by leukotriene A4 hydrolase. 
The ratio of generated LTC4 and LTB4 depends on the formation of different 
heteromers of FLAP and LTC4 synthase at the nuclear membrane [164]. The 
FLAP inhibitor MK-886 [165] and other indole- and quinoline-based 
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compounds [159] can inhibit and reverse the membrane association of 5-LO and 
thus reduce LT formation in the cell. The intracellular localization of 5-LO 
depends on the cell-type. 5-LO is located in the cytosol of resting neutrophils, 
monocytes and peritoneal macrophages [163]. In contrast, in resting human 
alveolar macrophages [166] and rat basophilic leukemia cells [167], 5-LO was 
present predominantly in the nucleus. The nuclear 5-LO showed enzymatic 
activity and also translocates to the nuclear envelope after cell activation. 
Adherence of neutrophils or recruitment to inflammatory sites caused a nuclear 
import of 5-LO and increased LT formation [168]. Nuclear localization 
sequences (NLS) at the residues 638-655 and two nuclear export sequences 
(NES) control the nuclear localization of 5-LO [169]. A nuclear localization of 
5-LO influences the capacity for LTB4 formation in stimulated cells [170]. 5-LO 
phosphorylation at Ser271 by p38 MAPK-regulated MKs prevents nuclear 
export of 5-LO and increases LTB4  formation [171]. In contrast, 
phosphorylation of 5-LO at Ser523 by PKA suppresses 5-LO activity by 
prevention of nuclear import [145]. 
Interestingly, 5-LO distribution in human neutrophils was found to be gender-
dependent. In resting male neutrophils, 5-LO was found in the cytosol as well as 
in the nuclear memrane fraction regardless of cell stimulation, resulting in lower 
LT formation in activated male cells. In contrast, in neutrophils from female 
donors, a clear 5-LO translocation from the cytosol to the nuclear membrane in 
response to A23187 or LPS/fMLP was observed. The observed gender-
dependent differences are related to the activation state of ERK regulated by the 
androgen 5α-DHT [135]. 
1.9 Pathophysiological implication of the 5-LO pathway 
The conversion of AA by 5-LO and the associated enzymes for LT biosynthesis 
yields lipid mediators with central importance in inflammatory, allergic and 
cardiovascular processes, the innate immune system and cancer. Studies with 
knockout mice confirmed the pathophysiological roles of the 5-LO pathway. 
Thus, it was observed that 5-LO-deficient mice showed a resistance to PAF-
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induced lethal shock and reduced inflammatory response to exogenous AA, 
underlining the proinflammatory properties of 5-LO-derived mediators [172]. 
Furthermore, 5-LO knockout mice showed an impaired bacterial phagocytosis 
and killing and compared to wild-type mice, a higher lethality in Klebsiella 
pneumoniae infection was observed [173]. Generally, LTs amplify killing of 
microorganisms and enhance phagocytosis of macrophages and neutrophils 
[174]. Thus, LT-deficient mice showed impaired immune responses in chronic 
fungal infection [175]. These results point out a participation of LTs in the host 
defense of infections and other immune responses.  
LTs are known as bronchoconstrictory and vasoactive molecules contributing to 
asthmatic and allergic responses [60]. In patients with aspirin-sensitive asthma, 
atopic dermatitis and allergic rhinitis, LTB4 levels are increased and thus 
treatment with BLT1 receptor antagonists or direct 5-LO inhibitors might be 
useful [61]. In particular, the contribution of Cys-LTs is clearly evident in 
allergic and asthmatic conditions due to their actions on the smooth muscle tone 
in the airways, microvascular permeability and their established pro-
inflammatory role. In allergic rhinitis, the use of the CysLT1 receptor 
antagonists zafirlukast, montelukast or pranlukast alone or in combination with 
antihistaminic drugs such as loratadine significantly reduced the symptoms [65]. 
Polymorphisms of the genes for FLAP (ALOX5P) and LTA4 hydrolase or 
genetic variations in the 5-LO promoter were associated to higher risk for 
atherosclerosios, stroke and myocardial infarction [176], [177]. Also, a possible 
role of the 5-LO pathway in abdominal aortic aneurysm seems likely as shown 
in various mouse models [178]. Since the expression of 5-LO, associated 
enzymes of  LT biosynthesis and LT receptors was detected in atherosclerotic 
lesions [97] and the 5-LO pathway is involved in various atherogenic processes 
[179], [180], anti-LT drugs may be useful in the treatment of cardiovascular 
diseases.  
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Moreover, expression of 5-LO, the associated enzymes for LT biosynthesis and 
LT receptors as well as elevated levels of LTB4 were reported in a large number 
of cancer cells and tissues such as colon, oesophageal, lung, prostate, pancreatic, 
breast and skin cancer. Accordingly, inhibition of the 5-LO pathway decreased 
cell proliferation, inhibited angiogenesis and induced apoptosis. In addition, the 
5-LO metabolites 5-HETE and LTB4 induce cell proliferation and promote 
tumor growth in various cancer cells [181], [182], [16]. In addition, FLAP 
inhibition [183] or targeted gene disruption of 5-LO [184] modulated the 
activity of γ-secretase suggesting the 5-LO pathway as a target in Alzheimer’s 
disease and other neurodegenerative disorders [185], [186]. 
1.10 Pharmacological inhibition of LT biosynthesis 
The broad involvement of the leukotrienes in numerous pathophysiological 
conditions proposes therapeutic benefit of pharmacological intervention with 
specific components of the biosynthetic pathway. Since 5-LO is the key enzyme 
for the formation of 5-H(P)ETE and LTA4 from AA, either a direct enzyme 
inhibition or the modulation of the catalytic activity of 5-LO is conceivable. In 
addition, other enzymes involved in LT biosynthesis such as LTA4 hydrolase, 
LTC4 synthase or FLAP are possible targets for specific inhibitors. For example, 
several LTA4H inhibitors were identified [187], [188] and designed by the use 
of a pharmacophore model [189]. Receptor antagonists at the LTB4 and Cys-LT 
receptors on the target cells offer an alternative mechanism to prevent the 
biological action of LTs and Cys-LTs.  
1.10.1 5-LO inhibitors 
Inhibitors of 5-LO product formation either directly intervene with 5-LO or 
prevent the catalytic activity. Direct inhibitors of 5-LO are classified into redox-
type inhibitors, iron-ligand or non-redox-type inhibitors according to their mode 
of action. A fourth class involves compounds with other or an unknown mode of 
action. 
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1.10.1.1 Redox-type-inhibitors 
In particular, lipophilic molecules comprising polyphenolic (Fig. 10), quinone, 
coumarin or similar structures are often found in natural sources. These 
compounds reduce 5-LO product formation via redox-active mechanisms by 
keeping the active site iron of 5-LO in the ferrous (Fe2+) state, reduce LOOHs or 
scavenge electrons and thus interrupt the catalytic cycle and prevent activation 
of 5-LO. In vitro, a very potent inhibition of 5-LO is often apparent in cellular 
and cell-free test systems. However, most of these compounds possess poor 
bioavailability and selectivity for 5-LO. Moreover, interference of these 
compounds with other biological redox systems leads to methemoglobin 
formation, production of ROS or other severe side-effects [190]. Despite further 
development of synthetic, orally active compounds such as AA-861 or BW-
755C (Fig. 10) with weaker reducing properties, the aforementioned 
disadvantages of this class yielded no approved compound so far. 
 
Fig. 10 Redox-type inhibitors of 5-LO  
1.10.1.2 Iron ligand inhibitors 
Iron ligand inhibitors chelate the active site iron of 5-LO and keep it in the 
ferrous state and in addition, exert weak reducing properties. Acetohydroxamic 
acid derivatives, exemplified by the compound BWA4C (Fig. 11) reduced LTB4 
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formation very potent in intact human leukocytes and homogenates in vitro as 
well as ex vivo after oral administration [191]. However, the hydroxamate 
moiety is rapidly inactivated in vivo to the corresponding carboxylic acid [192]. 
BWA4C
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Fig. 11 Iron-ligand inhibitors of 5-LO 
Beside their iron-chelating properties, the pseudoperoxidase activity of 5-LO 
contributes to the inhibitory mechanism of N-hydroxyurea and hydroxamate 
compounds leading to weak redox activity of the compounds towards 5-LO 
[193].  
Structural optimization by introduction of an amino moiety led to the orally 
active N-hydroxy urea derivative zileuton (N-(1-benzo[b]thien-2-ylethyl)-N-
hydroxyurea)) (Fig. 11). In vitro, zileuton reduced the biosynthesis of 5-LO-
derived products in cell-based models and human whole blood with IC50 values 
< 1 µM and also ex vivo, a very potent inhibition of LTB4 synthesis was 
apparent after peroral administration to rats and humans. Little or no inhbition of 
12- or 15-LOs as well as COX enzymes was observed at concentrations up to 
100 µM [194], [195]. Furthermore, the potent action of zileuton in asthmatic and 
other inflammatory airway and allergic diseases was confirmed in several 
clinical studies. Thus, zileuton was approved as direct 5-LO inhibitor on the 
market for the treatment of asthma. However, due to the short half-life of 
approximately 2.5 h, the four-times daily application and the elevation of 
hepatic enzymes limit the use of zileuton [196]. At present, an extended release 
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formulation for twice daily oral dosage is on the market in the USA (Zyflo CR), 
whereas the immediate release tablet was withdrawn in 2008. Recently, a use of 
zileuton for the treatment of acne was discussed [197], [198].  
Atreleuton (ABT-761 or VIA-2291) was reported as a new candidate of iron-
ligand inhibitors of 5-LO (Fig. 11). Atreleuton reduced the levels of LTs in 
patients with recent acute coronary syndrome in a placebo-controlled clinical 
trial with only low incidence of adverse events [199]. 
1.10.1.3 Non-redox-type inhibitors 
A third class of 5-LO inhibitors is referred to as “non-redox-type inhibitors”. 
These structurally diverse compounds (Fig. 12) are itself devoid of redox 
properties. Experimental data suggest a competition between activating LOOH 
and the compounds at a putative regulatory site of 5-LO.  
 
Fig. 12 Non-redox-type inhibitors of 5-LO 
In vitro, ZM230487 and L-739,010 (Fig. 12) suppressed LT formation in 
granulocytes very potently in the nanomolar range, but in cell homogenates the 
potency of the compounds was strongly impaired. The addition of thiols such as 
GSH or DTT to the homogenates resulted in IC50 values comparable to intact 
cells. It was observed that the efficacy of the compounds depends on the 
peroxide tone in the cell, regulated by selenium-dependent GPx. Accordingly, 
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inhibition of GPx and elevated oxidative stress reduced the potency in cellular 
assays [139]. In addition, the efficacy of ZM234087 and L-739,010 was shown 
to be dependent on the activation pathway of 5-LO. Inhibition of cell-stress-
induced 5-LO product formation required up to 100-fold higher concentrations 
compared to calcium-dependent activation of 5-LO by A23187 [200]. In 
contrast, the tetrahydropyrane-carboxamide CJ-13,610 (Fig. 12), inhibited 5-LO 
product formation indepently from the activation state of 5-LO activity in a 
competitive manner [201]. This fact shows an advantage of CJ-13,610 in the 
class of non-redox-type inhibitors, although the in vivo efficacy of all non-
redox-type inhibitors is impaired in inflammatory conditions due to the elevated 
peroxide concentrations. Additional candidates of this class comprise coumarin 
derivatives developed by the Merck Frosst group with high anti-inflammatory 
efficacy and without toxic side-effects [202]. 
1.10.2 Novel-type inhibitors 
Some compounds are described as inhibitors of 5-LO product formation, but 
cannot be classified among the abovementioned types of 5-LO inhibitors. 
Hyperforin, an acylphloroglucinol from St. John’s Wort was identified as dual 
inhibitor of 5-LO and COX-1 with IC50 values in the low micromolar range 
[203]. Subsequent studies revealed that hyperforin interrupts the interaction of 
CLP and 5-LO and inhibits the translocation of 5-LO to the nuclear membrane, 
an early activation step of 5-LO regulation [204]. Moreover, boswellic acids 
(BA) from the gum resin of Boswellia serrata inhibit 5-LO product formation in 
vitro [205],[206]. Investigations about the mode of action of the acetyl-11-keto-
BA (AKBA) suggested a binding of AKBA to a regulatory site of 5-LO [207]. 
These compounds demonstrate only two examples for several points of attack 
for the inhibition of 5-LO product formation. 
1.10.3 Leukotriene receptor antagonists 
The discovery of the LTB4 receptors BLT1 and BLT2 and the cysteinyl-LT 
receptor subtypes CysLT1 and CysLT2 along with the involvement of LTB4 and 
cysteinyl-LTs in various diseases suggest the use of receptor antagonists to 
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inhibit the actions of the lipid mediators. Accordingly, various compounds with 
affinity for the BLT receptors were described and investigated in clinical studies 
for COPD, rheumatoid arthritis, osteoporosis, psoriasis or cardiovascular 
diseases. Unfortunately, the selective blockade of the BLT receptors did not lead 
to sufficient efficacy. It was assumed that LTB4 is not the only contributing 
mediator in some diseases [76].   
A more promising approach is represented by the Cys-LT1 receptor antagonists. 
Currently, montelukast, zafirlukast and  pranlukast (Fig. 13) are approved nearly 
worldwide and used for the treatment of asthma, allergic rhinitis and urticaria. 
Especially in the treatment of asthma, the CysLT1 receptor antagonists are 
considered as additional or alternative therapy to inhaled corticosteroids [81]. 
The pathophysiological role of the cys-LTs in other conditions such as 
endothelial dysfunction, cerebral and myocardial ischemia expand the field of 
application for these compounds [179]. 
 
Fig. 13 Cys-LT receptor antagonists 
In contrast, the number of reported CysLT2 receptor antagonists is quite low. 
BAY u9773 (Fig. 13), an LTE4 analogue was described as CysLT2 antagonist, 
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but later characterized as dual antagonist at CysLT1 and CysLT2 receptor [208]. 
Recently, the potent and selective CysLT2 antagonist, HAMI 3379 (Fig. 13) was 
reported [82]. 
1.10.4 FLAP inhibitors 
The membrane-bound protein FLAP acts as a transfer protein for AA to 5-LO. 
Accordingly, an interference with the interaction between 5-LO and FLAP lead 
to total inhibition of 5-LO-derived products. The indole-based compound MK-
886 (Fig. 14) was the first described inhibitor of FLAP with an IC50 of 2.5 nM in 
PMNL [209], followed by quinoline-based compounds [210]. Shortly 
afterwards, a novel class termed quindoles with a hybrid structure of indole and 
quinoline, represented by MK-591 (Fig. 14) was described [211], [212]. 
Photoaffinity labeling studies confirmed a direct binding of the indole, quinoline 
and quindole compounds to FLAP which results in the inhibition of LT 
biosynthesis.  
 
Fig. 14: FLAP inhibitors 
FLAP inhibitors inhibit the cellular LT formation very potently whereas in cell-
free assays no or only marginal influence of the compounds is evident. 
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Moreover, the FLAP inhbitor MK-886 was described to inhibit and reverse the 
translocation of 5-LO to the nuclear membrane thereby preventing the catalytic 
reaction of 5-LO [165]. The quinoline derivative BAYX1005 (now DG031, 
veliflapon) (Fig. 14) and MK-591 were investigated in clinical trials for asthma 
[152]. However, a clinical trial by deCode genetics for veliflapon in prevention 
of heart attack and stroke was suspended for unknown reasons [213].  
Structural modifications based on the structures of MK-886 and MK-591 by 
Amira Pharmaceuticals led to a series of compounds such as AM103 [214] or 
the topical compound AM643 [215]. AM803 (Fig. 14), now designated as 
GSK2190915 [216] was investigated in various clinical studies in asthmatic 
indications [217]. 
1.10.5 The dual inhibition concept  
The observation that inhibition of the COX pathway shifts AA metabolism 
towards the 5-LO pathway led to the idea of dual COX/5-LO inhibition [218]. A 
specific intervention with PG and LT biosynthesis offers a better anti-
inflammatory effect and better gastrointestinal, renal and cardiovascular 
tolerability compared to NSAIDs [219], [220]. In addition, the co-expression of 
COX-2 and 5-LO in cancer and the effect of PGE2 and 5-LO-derived 
eicosanoids in carcinogenesis may allow the use of dual COX/5-LO inhibitors as 
anti-cancer drugs [221]. Accordingly, several compounds were reported such as 
the pyrazole derivative tepoxalin (Fig. 15). Although a potent anti-inflammatory 
activity and low gastrointestinal toxicity was observed [222], the compound 
showed a broad inhibition of redox enzymes and liver toxicity [223], limiting 
the use in humans. Today, tepoxalin is used as anti-inflammatory drug in the 
veterinary medicine. 
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Fig. 15 Dual COX/5-LO inhibitors 
Flavocoxid, a mixture of the flavonoids baicalein and catechin and marketed as 
“medical food” for the treatment of osteoarthritis, was described as dual 
inhibitor of COX and 5-LO with good anti-inflammatory properties in vitro 
[224], but caused acute liver injury [225].  
Beside its known function as COX-2 inhibitor for the treatment of pain and 
arthritis, celecoxib (Fig. 15) inhibits 5-LO product formation in neutrophils as 
well as in human whole blood and reduced LTB4 blood levels in rats [226]. 
Another promising dual COX/LOX-inhibiting compound is licofelone (ML-
3000) (Fig. 15). Licofelone inhibits COX-1 as well as FLAP and has anti-
analgesic, anti-platelet and anti-inflammatory activity. The gastroinstetinal side-
effects were significantly lower compared to naproxen [227]. Licofelone was 
investigated in several clinical studies, for example in osteoarthritis. Moreover, 
licofelone reduced mPGES-1-derived PGE2 formation in the low micromolar 
range in celllular and cell-free assays. Interestingly, COX-2-derived product 
formation was unaffected by licofelone in vitro [228]. 
Thus, dual inhibition of 5-LO and mPGES-1 appears superior over dual 
inhibition of COX and 5-LO, since mPGES-1 converts only COX-2-derived 
PGH2 to “pro-inflammatory” PGE2, while the conversion of PGH2 by other PGE 
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synthases is not altered. Concomitant inhibition of COX-2 and 5-LO or 5-LO / 
mPGES-1 seems to have a protective role in cancer [40]. Recently, synthetic 
pirinixic acid derivatives [229], benzo[g]indoles [230] and the 
acylphloroglucinol hyperforin [231] from plant origin were described as dual 
inhibitors of 5-LO and mPGES-1. 
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2 Aim of the study 
5-LO is the key enzyme for the biosynthesis of LTA4, which is further 
enzymatically converted to LTB4 and to the cysteinyl-LTs. Leukotrienes are 
arachidonic-derived lipid mediators with major roles in inflammatory diseases 
such as asthma, allergic rhinitis, rheumatoid arthritis [60] and also in 
atherosclerosis and other cardiovascular diseases [176], carcinogenesis [182] 
and neurological disease [232]. These wide-ranging pathophysiological 
implications require the development of specific leukotriene biosynthesis 
inhibitors for the treatment of the aforementioned diseases. 
Currently, the direct iron-ligand 5-LO inhibitor zileuton and CysLT1 receptor 
antagonists such as montelukast are approved drugs for the treatment of asthma 
and allergic rhinitis. However, the side effects of zileuton [196], an insufficient 
efficacy of the CysLT1 antagonists compared to inhaled corticosteroids in 
moderate to severe asthma and non-responders to anti-LT treatment [81] limited 
the success of these substance classes. The enzymatic activity of 5-LO and LT 
biosynthesis are regulated in a complex manner in cell-free assays and in the 
cell, which offers several points of attack for inhibitors. The catalytic activity of 
5-LO is influenced by Ca2+, ATP, glycerides, phospholipids, CLP, lipid 
peroxides and by phosphorylation of kinases. Moreover, in the cellular 
environment a compound might interfere with cPLA2, FLAP, the subcellular 
distribution of 5-LO, its catalytic cycle or other enzymes involved in LT 
biosynthesis resulting in reduced LT formation. This complex regulation of LT 
biosynthesis must be taken into account for in vitro experiments aiming to 
evaluate the pharmacological potential of a given test compound. 
In this study, different sets of compounds were designed and synthesized in 
cooperation with groups at the University of Erlangen, University of Salerno, 
University of Ankara and University of Tübingen. The structural design of the 
compounds was carried out by modification of natural or synthetic compounds 
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with known anti-inflammatory activity. For one set of compounds, a virtual 
screening approach using a ligand-based pharmacophore model was applied. 
In order to characterize the inhibitory action of the compound on 5-LO product 
formation in vitro, cell-based and cell-free test systems and a whole blood assay 
were used. For selected compounds, in vivo studies in different animal 
inflammation models were carried out in cooperation with other groups. In 
addition, one class of compounds was further characterized in molecular 
docking studies to define chemical interactions of the compounds with 5-LO. 
Moreover, the influence of some compounds on PG formation was studied. 
Thus, the inhibition of COX-1, COX-2 and mPGES-1 product formation was 
studied in cell-based and cell-free assays. Some compounds turned out to affect  
COX and 5-LO or mPGES-1 and 5-LO, which may enhance their anti-
inflammatory properties. 
Taken together, this study presents the identification of diverse leukotriene 
biosynthesis inhibitors. In addition, SAR studies and mechanistical 
investigations were carried out to elucidate the inhibitory effect of the 
compounds on LT and PG formation and the anti-inflammatory actions of 
selected compounds were confirmed in vivo.  
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3 Material and Methods 
3.1 Chemicals 
Acrylamide solution 30% (37.5:1),Tris: Applichem (Darmstadt, Germany),; 
DMSO, SDS, Triton X-100, Tween 20: Carl Roth (Karlsruhe, Germany); IPTG, 
Leupeptin: Applichem (Darmstadt, Germany); Lymphocyte separation medium 
LSM 1077, DMEM/RPMI 1640 (cell culture medium): PAA (Coelbe, 
Germany); PeqGold Protein Marker IV: peqLab Biotechnology (Erlangen, 
Germany). HPLC solvents were from Merck (Darmstadt, Germany). All other 
chemicals were purchased from Sigma Aldrich (Deisenhofen, Germany), unless 
stated otherwise. Cell culture material was obtained from Greiner (Nürtingen, 
Germany) 
3.2 Test compounds 
Indole- and benzo[g]indole-3-carboxylates were synthesized by Dr. Eva Haberl 
as part of her doctoral thesis and obtained from the group of Prof. Dr. R. 
Troschütz (University of Erlangen, Germany). 1,4-Benzoquinone and 
polyphenolic compounds were synthesized and obtained from the group of Dr. 
Rosanna Filosa (University of Salerno, Italy). Derivatives of pyrazole-3-
propanoic acid and derivatives of compounds 76 and 83 were synthesized and 
obtained from the group of Prof. Dr. Erden Banoglu (University of Ankara, 
Turkey). The test compounds described in chapter 4.4 were obtained from 
Ambinter Chemicals (Paris, France).  
All test compounds were dissolved at 10 or 30 mM in DMSO or ethanol and 
kept in the dark at -20 °C and freezing-thawing cycles were kept to a minimum. 
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3.3 Primary antibodies 
Table 1 primary antibodies used for Western blotting 
source of antibody: (m) mouse, (r) rabbit 
antibody (source) supplier dilution  
5-LO (m) provided by Prof. D. Steinhilber,  
(Frankfurt/Main, Germany) 
1:4 to 1:8 in TBS 
ERK (r) Cell Signaling (Boston, MA, USA) 1:1,000 in  
5% BSA-TBS-T 
p-ERK (m) 
(Thr202/Tyr204) 
Cell Signaling (Boston, MA, USA) 1:1,000 in  
5% BSA-TBS-T 
p-p38 MAPK (r) 
(Thr180/Tyr182) 
Cell Signaling (Boston, MA, USA)  1:1,000 in  
5% BSA-TBS-T 
3.4 Secondary antibodies 
Table 2 secondary antibodies used for Western blotting 
antibody supplier dilution  
anti-mouse-IgG  
anti-rabbit-IgG 
(alkaline phosphatase-
conjugated) 
Sigma-Aldrich  
(Deisenhofen, Germany) 
1:1,000 in TBS 
anti-mouse IgG  
(Cy3-conjugated)  
anti-rabbit IgG  
(Cy5- conjugated) 
GE Healthcare/Amersham 
(Munich, Germany) 
 
1:2,500 in TBS-T 
 
1:2,500 in TBS-T 
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3.5 Methods 
3.5.1 Isolation of PMNL and platelets from buffy coats  
Human polymorphonuclear leucocytes (PMNL) and platelets were freshly 
isolated from leukocyte concentrates (buffy coats) obtained at Blood Center, 
University Hospital, Tübingen, Germany. In brief, venous blood was subjected 
to centrifugation at 4,000 x g for 20 minutes at 20 °C for preparation of 
leukocyte concentrates. Buffy coats were pooled and diluted 1:1 (v/v) with 
phosphate buffered saline (PBS), pH 7.4 (1.06 mM KH2PO4, 3 mM Na2HPO4, 
154 mM NaCl) and then 1:4 (v/v) with dextrane solution (5% in PBS) to allow 
erythrocyte sedimentation for 45 minutes. After sedimentation, cells were 
further separated by centrifugation (1,000 x g, 10 min at RT w/o brake) on LSM 
1077 Lymphocyte separation medium cushions. PMNL were collected and 
resuspended in PBS, pH 7.4 followed by hypotonic lysis of erythrocytes and 
twice washing in PBS and centrifugation steps. PMNL were finally resuspended 
in PBS containing 1 mg/ml glucose (PG buffer) or in PBS containing 1 mg/ml 
glucose and 1 mM CaCl2 (PGC buffer). For isolation of platelets, platelet-rich-
plasma (PRP) was obtained from the supernatants, mixed with PBS, pH 5.9 and 
centrifuged (2100 × g, 15 min, RT). The pelleted platelets were washed in PBS, 
pH 5.9 / 0.9% NaCl (1:1, v/v), centrifuged again, and finally resuspended in 
PBS pH 7.4. Cells were counted after addition of trypan blue solution (0.2% 
(w/v) trypan blue, 0.9% (w/v) NaCl) under a light microscope using a “Bürker” 
haemocytometer.  
3.5.2 Determination of 5-, 12- and 15-LO product formation in PMNL 
PMNL (5 x 106 to 107/ ml) were finally resuspended in PGC buffer and cells 
were pre-incubated with the test compounds or vehicle for 15 minutes at 37 °C. 
5-LO product formation was started by addition of 2.5 µM Ca2+-ionophore 
A23187 alone or with the indicated concentrations of AA in 2.5 µl of methanol. 
When NaCl was used for stimulation, 100 µl of 3 M NaCl solution (final 
concentration: 0.3 M NaCl) was added 3 minutes prior to AA.  
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In experiments with Ca2+-depletion, 5 x 106 /ml PMNL were resuspended in 
PBS pH 7.4 containing 1 mM EDTA and pre-incubated with 30 µM BAPTA-
AM for 15 minutes prior to pre-incubation with the compounds for 15 minutes 
at 37 °C and then stimulated with 50 µM AA. After 10 minutes at 37 °C, the 
reaction was stopped with 1 ml of ice-cold methanol and 500 µl of PBS, 30 µl 1 
M HCl and 200 ng of prostaglandin B1 (internal standard) were added. The 
samples were centrifuged (800 x g, 10 min), and the supernatant was applied to 
C18 solid-phase extraction columns, pre-conditioned with 1 ml of methanol and 
1 ml of water. After washing with 1 ml of water and 1 ml of 25% (v/v) 
methanol, AA metabolites were eluted with 300 µl methanol and diluted with 
120 µl water. 50-100 µl extract was analyzed by HPLC on a NovaPak® C18-
column (5 x 100 mm, 4 µm particle size, Waters, Eschborn, Germany). HPLC 
analysis was carried out at a flow rate of 1.2 ml/min. The mobile phase consisted 
of MeOH / H2O / TFA (76/24/0.007 (v/v)). 12(S)-H(P)ETE, 15(S)-H(P)ETE and 
5-LO products and were detected by diode array detector or UV detector at 235 
nm (5-,12-,15-H(P)ETE)) and 280 nm (PGB1, LTB4 and isomers). 5-LO product 
formation includes LTB4 and its all-trans isomers, 5(S),12(S)-di-hydroxy-6,10-
trans-8,14-cis-eicosatetraenoic acid [5(S),12(S)-DiHETE], and 5(S)-
hydro(peroxy)-6-trans-8,11,14-cis-eicosatetra-enoic acid [5-H(p)ETE]. 5-LO 
product formation is expressed as percentage of remaining product formation of 
DMSO control. DMSO concentration never exceeded 0.5%. 12(S)-H(P)ETE and 
15(S)-H(P)ETE were also analyzed in cellular systems to investigate inhibition 
of p12-LO and 15-LO. Cys-LTs (LTC4, D4, and E4) and oxidation products of 
LTB4 were not determined. Quantification of AA metabolites was done by peak 
area integration and comparing the peak areas with that of internal standard 
PGB1 after correction of the different extinction coefficients of the compounds. 
3.5.3 Determination of 5-LO product formation in cell homogenates 
For determination of 5-LO product formation in homogenates, 1 mM EDTA was 
added to cells resuspended in PBS buffer, pH 7.4. Samples were cooled on ice 
for 5 minutes and homogenized by sonification (3 × 10 sec) at 4 °C with a 
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Branson cell disruptor model B15. After addition of 1 mM ATP, 5 mM GSH or 
1 mM DTT were added as indicated and aliquots of 1 ml were pre-incubated 10 
minutes at 4 °C with vehicle (max. 0.3% DMSO = 100% control) or compound, 
pre-warmed for 30 seconds at 37 °C and then 2 mM CaCl2 and the indicated 
concentrations of AA were added to start the reaction. After 10 minutes at 37 
°C, the reaction was stopped with 1 ml of ice-cold methanol and further steps 
and analysis were performed as described for intact cells. 
3.5.4 Expression and purification of recombinant human 5-lipoxygenase  
Human recombinant 5-lipoxygenase (5-LO) was obtained from E.coli (BL 21) 
transfected with pT3-5-LO plasmid. The bacteria culture was incubated over 
night under shaking at 37 °C in LB-medium supplemented with ampicillin (100 
µg/ml). The bacteria were reseeded in LB-medium containing ampicillin (100 
µg/ml), FeSO4 (10 µM) and MgSO4 (1 mM). Following incubation for 4 h at 30 
°C, the expression of 5-LO was induced by IPTG (190 µg/ml). The expression 
was continued over night under the same conditions. For harvesting, bacteria 
were centrifuged (7700 x g, 15 min, 4 °C) and the resulting pellet was 
resuspended in lysis buffer (1 mg/ml lysozyme, 50 mM TEA pH 8, 5 mM 
EDTA, 60 µg/ml STI, 2 mM DTT, 1 mM PMSF) and stored on ice for 30 
minutes. To complete disruption and lysis of the cells the samples were 
sonicated (3 x 15 sec) with a Branson cell disruptor model B15 followed by 
centrifugation (40,000 x g, 20 minutes, 4 °C). The resulting supernatant is 
referred to as S40 and was immediately used for inhibition assays. 
For some experiments, 5-LO was further purified by affinity chromatography 
using ATP-agarose columns (Sigma A2757, bed volume 2 ml). The column was 
equilibrated with PBS buffer, pH 7.4 containing 1 mM EDTA. After application 
of the 40,000 x g supernatant, the column was first washed with 7 ml of 
equilibration buffer followed by 10 ml of phosphate buffer containing 0.5 M 
NaCl (50 mM phosphate, pH 7.4, 1 mM EDTA, 0.5 M NaCl) and washed with 
10 ml of phosphate buffer (50 mM phosphate, pH 7.4, 1 mM EDTA). Finally, 
bound 5-LO was eluted with phosphate buffer containing 20 mM ATP (50 mM 
Material and Methods  44 
phosphate, pH 7.4, 1 mM EDTA, 20 mM ATP). Purified 5-LO was diluted with 
PBS buffer, pH 7.4 containing EDTA (1 mM) and immediately used for 
inhibition assays. 
3.5.5 Determination of 5-LO product formation in cell-free assay 
(recombinant 5-LO) 
Aliquots (1 ml) of S40 or purified 5-LO as indicated were supplemented with 1 
mM ATP and pre-incubated for 10 minutes at 4 °C with vehicle (max. 0.3% 
DMSO) or compound and pre-warmed for 30 seconds at 37 °C. Then, 2 mM 
CaCl2 and AA at the indicated concentrations were added. The reaction was 
stopped after 10 minutes at 37 °C by addition of 1 ml ice-cold methanol. Further 
steps and HPLC analysis were carried out as described for intact cells. 
3.5.6 DPPH assay 
Antioxidant activity of test compounds was assessed by the method of Blois 
[233], with slight modifications. Briefly, 100 µl of 1, 2.5, 5, 10, 25, 50 or 100 
µM test compound in ethanol (corresponding to 0.1, 0.25, 0.5, 1, 2.5, 5 or 10 
nmoles) were added to 100 µl of a solution of the stable free radical 
diphenylpicrylhydrazyl (DPPH) in ethanol (100 µM, corresponding to 10 
nmoles), buffered with acetate to pH 5.5, in a 96-well plate. The absorbance was 
read at 520 nm after 30 min incubation under gentle shaking in the dark. 
Ascorbic acid and L-cysteine were used as reference compounds and reduced 
the DPPH radical with a 1:2 (ascorbic acid : DPPH) or 1:1 (L-cysteine:DPPH) 
apparent stoichiometry. All analyses were performed at least in duplicates. 
3.5.7 Determination of 5-LO product formation in whole blood 
Aliquots of freshly withdrawn blood (1.5 ml) were pre-incubated with the 
compound or vehicle (0.1% DMSO) for 10 minutes at 37 °C and formation of 
LO products was started by addition of 30 µM Ca2+-ionophore A23187. Samples 
were further incubated for 10 minutes at 37 °C and the reaction was stopped on 
ice. The samples were placed on ice, centrifuged (600 × g, 10 min, 4 °C) and 
aliquots of the resulting plasma (500 µl) were then mixed with 2 ml of methanol, 
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and 200 ng prostaglandin B1 were added as internal standard. The samples were 
placed at -20 °C for 2 h and centrifuged again (600 × g, 15 min, 4 °C). The 
supernatants were collected, diluted with 2.5 ml PBS buffer, pH 7.4 and 75 µl 
1N HCl. Formed LO metabolites were extracted by solid phase extraction on 
C18-colums using two washing steps and analyzed by HPLC as described above 
for intact cells.  
3.5.8 Determination of COX-1 activity in intact platelets 
As COX-1 is the major enzyme in human platelets converting AA into PGH2  
which is metabolized to 12-HHT in an nonenzymatically process [234], it was 
used as parameter to determine COX-1 activity. Freshly isolated platelets 
(108/ml in PGC buffer) were pre-incubated with the compounds for 4 minutes at 
4 °C followed by 1 minute at 37 °C. After addition of 5 µM AA and further 
incubation for 5 minutes at 37 °C, the reaction was stopped by adding 1 ml ice-
cold methanol. 12-HHT was extracted by solid phase extraction and analyzed by 
HPLC (detection at 235 nm) as described above. 
3.5.9 Determination of COX-2 product formation in intact A 549 cells 
2 × 106 cells were plated in 175 cm2 flasks and incubated for 16 h at 37 °C and 5 
% CO2 atmosphere. Thereafter, medium was replaced by fresh DMEM/High 
glucose (4.5 g/l) medium containing 2% FCS and cells were stimulated with 
interleukin-1β (1 ng/ml) for 72 h. After trypsination, the cells were washed twice 
with PBS buffer, pH 7.4 and counted after addition of trypan blue solution 1:1 
(v/v) (0.2% trypan blue, 0.9% NaCl) under a light microscope using a Bürker  
haemocytometer.  
For determination of 6-keto-PGF1α, 106 cells/ml in PGC buffer were pre-
incubated with the compounds for 15 minutes at 37 °C. 6-keto-PGF1α  formation 
was initiated by addition of 3 µM AA. After 15 minutes at 37 °C, the reaction 
was stopped by cooling on ice. Cells were centrifuged (300 × g, 5 min, 4 °C) 
and the amount of released 6-keto PGF1α in the supernatant was quantified using 
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a 6-keto-PGF1α High Sensitivity EIA Kit (Assay Designs, Ann Arbor, MI) 
according to the manufacturer's protocol. 
3.5.10 Determination of mPGES-1 product formation 
For this assay, all steps were performed on ice due to the instability of the 
reagents. Microsomes of A549 cells stimulated with IL-1β expressing mPGES-1 
were diluted in homogenization buffer (phosphate buffer (0.2 M, pH 7.4) 
containing 0.25 M sucrose, 1 mM PMSF, 60 µg/ml STI, 10 µg/ml leupeptin and  
2.5 mM GSH). 50 µl of the diluted microsomes were plated into a 96-well-plate 
and pre-incubated for 15 minutes with test compounds or DMSO (max. 1%) and 
the control inhibitor MK-886. The samples were incubated with 20 µM PGH2 
for 60 sec. Then, the reaction was stopped by adding 100 µl stop solution (40 
mM FeCl2, 80 mM citric acid) containing the internal standard 11β-PGE2 (10 
µM). The samples were pre-cleared by solid phase extraction using RP-18 
columns conditioned with acetonitrile and water. The columns were washed 
with 2 x 500 µl of water and PGE2 was eluted with 200 µl of acetonitrile. 
Afterwards the eluate was diluted with 400 µl of water. Subsequently the PGE2 
formation was quantified via HPLC at 195 nm with a mobile phase consisting of  
acetonitrile / H2O / TFA (31.5 / 68.5 / 0.007 (v/v)). 
3.5.11 Subcellular localization of 5-LO by mild detergent lysis 
For studies of subcellular 5-LO distribution, freshly isolated human PMNL (3 × 
107 /ml) from female donors were resuspended in 1 ml of cold PGC buffer. Cells 
were pre-incubated for 15 minutes at 37 °C with compound or DMSO (max. 
0.3%). Then, 2.5 µM Ca2+-ionophore A23187 was added and samples were 
incubated for further 5 minutes at 37 °C. To stop the reaction, samples were 
chilled on ice. After 5 minutes on ice, samples were centrifuged (200 x g, 5 
minutes, 4 °C). The supernatant was discarded and pellets were resuspended in 
300 µL ice-cold NP-40 lysis buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 
mM MgCl2, 1 mM EDTA, 0.1% NP-40, 1 mM PMSF, 60 µg/ml STI, 10 µg/ml 
leupeptin). For lysis, samples were vortexed (3 x 5 seconds), kept on ice for 10 
minutes, and centrifuged again (1,000 x g, 10 minutes, 4 °C).   
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Resulting supernatants (non-nuclear fractions) were transferred to a new tube. 
The pellets containing the  nuclear fractions were resuspended in 300 µl ice-cold 
relaxation buffer (50 mM Tris-HCl pH 7.4, 250 mM sucrose, 25 mM KCl, 5 
mM MgCl2, 1 mM EDTA, 1 mM PMSF, 60 µg/ml STI, 10 µg/ml leupeptin). 
Both nuclear and non-nuclear fractions were centrifuged again (1,000 x g, 10 
min, 4 °C) for further purification. Lysis of cells and integrity of nuclei were 
confirmed by light microscopy with trypan blue exclusion. Nuclear fractions in 
relaxation buffer were disrupted by sonication on ice (3 x 5 seconds) with a cell 
disruptor B15 Branson sonifier. Aliquots of nuclear and nonnuclear fractions 
were immediately mixed with the same volume of cold 2× SDS loading buffer 
(20 mM Tris-HCl pH 8, 2 mM EDTA, 5% SDS, and 10% β-mercaptoethanol) 
and heated for 6 minutes at 95 °C. Distribution of 5-LO in both fractions was 
analyzed by SDS-PAGE and Western blotting.  
3.5.12 Determination of p42/44 MAPK (ERK) and p38 MAPK activation  
Freshly isolated PMNL (5 × 106) from female donors were resuspended in PGC 
buffer to a final volume of 100 µl. After pre-warming of the samples for 3 
minutes at 37 °C, followed by pre-incubation with the compounds or DMSO 
(max. 1%) for 15 minutes, stimulation with 0.1 µM fMLP, was performed for 3 
minutes at 37 °C. The reaction was stopped by addition of 100 µl of cold 2 × 
SDS loading buffer (20 mM Tris-HCl pH 8, 2 mM EDTA, 5% SDS, 10% β-
mercaptoethanol) and samples were heated for 6 min at 95 °C. Phosphorylation 
of p42/44-MAPK (Thr202/Tyr204) and p38 MAPK (Thr180/Tyr182) was 
analyzed by SDS-PAGE and Western blotting. 
3.5.13 SDS-PAGE  
20 µl of protein samples were mixed with 4 µl of bromophenol blue solution 
(50% (v/v) glycerol, 0.1% (w/v) bromophenol blue) and separated by SDS-
PAGE using a MiniProtean System (Bio-Rad, Hercules, CA, USA). 
Polyacrylamid concentration of the gels was 10% for subcellular distribution of 
5-LO and 12% for investigation of phosphorylated kinases. Molecular weight of 
the investigated proteins was estimated by comparison with prestained broad 
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range protein marker peqGOLD IV. For good separation, 90 Volt for the 
stacking gel and 120-140 Volt for the separation gel was used.  
3.5.14 Western Blotting 
After separation of the proteins by SDS-PAGE, proteins were blotted (tank 
blotting method) from polyacrylamide gels to nitrocellulose membranes (90 V 
for 90 min, in transfer buffer (48 mM Tris, 40 mM glycine, 20% (v/v) methanol, 
0.1 mM SDS). For investigation of phosphorylated proteins, transfer buffer 
without SDS was used. After electroblotting to a nitrocellulose membrane (GE 
Healthcare, Munich, Germany), correct loading of the gel and transfer of 
proteins was confirmed by staining the membrane with Ponceau S solution 
(0.1% (w/v) Ponceau S in 5% (v/v) acetic acid). Then, membranes were blocked 
with 5% BSA in blocking buffer (50 mM Tris/HCl, pH 7.4 and 100 mM NaCl 
(TBS plus 0.1% Tween 20 (= TBS-T)) for 1 h at RT. Membranes were washed 
again with TBS-T and incubated with the respective diluted primary antibodies 
overnight at 4 °C (for antibody dilutions see Table 1). 
Membranes were washed 3 times with TBS-T and incubated with respective 
secondary antibodies diluted in TBS-T (Table 2) Alkaline phosphatase-
conjugated IgG were applied for 2 h at RT or CyDye-conjugated secondary 
antibodies for 1 h at RT. Incubation with CyDye-conjugated antibodies and 
washing steps were performed in the dark to avoid bleaching of the fluorophoric 
group. After washing, proteins were visualized by NBT/BCIP detection for 
alkaline phosphatase-conjugated antibody. Alternatively, an ETTANDIGE 
Imaging system (GE Healthcare), was used for CyDye-conjugated antibodies 
using Cy3 (excitation filter: 540 nm; emission filter: 595 nm) and Cy5 
(excitation filter: 635 nm; emission filter: 680 nm) channels. Densitometric 
analysis of the bands was performed by ImageQuantTMTL Software (GE 
Healthcare) as indicated. 
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3.5.15 Isolation of monocytes and determination of cPLA2 inhibition  
Fresh blood was collected in heparinized tubes (16 I.E. heparin/ml blood) by 
venipuncture from fasted (12 h) adult male and female healthy volunteers, with 
consent (Blood Center, Jena, Germany). The subjects had no apparent 
inflammatory conditions and had not taken oral contraceptives (or other sex 
hormones) or anti-inflammatory drugs for at least ten days prior to blood 
collection. The blood was subjected to centrifugation (4,000 x g, 20 min, 20 °C) 
and peripheral blood mononuclear cells were promptly isolated by dextran 
sedimentation and centrifugation on LSM 1077 Lymphocyte separation medium 
cushions. Cells were collected, washed three times with cold PBS buffer, pH 7.4 
and then monocytes were separated by adherence for 1 h at 37 °C to culture 
flasks (Greiner, Nuertingen, Germany; cell density: 20 x 106 cells/ml in RPMI 
1640 medium containing 2 mM L-glutamine and 50 µg/ml penicillin / 
streptomycin), which gave a purity of > 85%, defined by forward- and side-light 
scatter properties and detection of the CD14 surface molecule by flow cytometry 
(BD FACS Calibur). Monocytes were finally resuspended in ice-cold PG buffer 
or PGC buffer. Monocytes (2 × 106 /ml RPMI) were incubated with 5 nM [3H]-
arachidonic acid for 2 h at 37 °C and 6% CO2. Cells were washed twice with 
PBS buffer, pH 7.4 containing 1 mg/ml glucose and 2 mg/ml BSA, resuspended 
in PG buffer (5 × 106 /ml), supplemented with 1 mM CaCl2, pre-incubated with 
the test compounds for 15 minutes at 37 °C and stimulated with 1 µM Ca2+-
ionophore A23187 for 5 minutes at 37 °C. The samples were stopped on ice for 
10 minutes and centrifuged at 1200 × g, 10 min. Aliquots of the supernatants 
were mixed with 2 ml Ultima GoldTM XR and measured on a scintillation 
counter (Micro Beta Trilux, Perkin Elmer, Waltham, MA, USA) to detect 
released [3H]-AA. 
3.5.16 Expression of recombinant cPLA2α and determination of cPLA2 
inhibition  
The cPLA2α coding sequence was cloned from pVL1393 plasmid (kindly 
provided by Dr. Wonhwa Cho, University of Illinois at Chicago) into 
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pFastBacTM HT A containing a 6 x his-tag coding sequence. The recombinant 
plasmid was transformed into DH10BacTM E. coli. Sf9 cells were transfected 
with recombinant bacmid DNA using Cellfectin® Reagent and the generated 
baculovirus was amplified. Overexpression of His-tagged cPLA2 in baculovirus-
infected Sf9 cells and isolation using Ni-NTA agarose beads was performed as 
described [23].  
Multilamelar vesicles (MLVs) were prepared by drying 1-palmitoyl-2-
arachidonyl-sn-glycero-3-phosphocholine (PAPC) and 1-palmitoyl-2-oleoyl-sn-
glycerol (POG) in a ratio of 2:1 (in chloroform) under nitrogen in glass vials. 
After addition of 20 mM Tris buffer, pH 7.4 containing 134 mM NaCl and 1 
mg/ml fatty acid free BSA, the MLV suspension was disrupted by several 
freeze-thaw cycles (liquid nitrogen) and then extruded 11 times with a mini-
extruder (Avanti Polar Lipids, Inc ) through a polycarbonate membrane (100 nm 
pore diameter) at RT (above transition temperature of the lipids) to produce 
large unilamelar vesicles (LUV). Final total concentration of lipids was 250 µM 
in 200 µl. Test compounds and 1 mM CaCl2 were added to the vesicles, and the 
reaction was started by addition of 500 ng his-tagged cPLA2 (in 10 µl buffer). 
After 1 h at 37 °C, 1.6 ml methanol was added, and AA was extracted by RP-18 
solid phase extraction. Following derivatisation with p-anisidinium chloride, the 
, the resulting derivate was analyzed by RP-HPLC at 249 nm as described [235].  
3.5.17 Carrageenan-induced pleurisy in rats 
Male Wistar Han rats (220-230 g, Harlan, Milan, Italy) were housed in a 
controlled environment and provided with standard rodent chow and water. 
Animal care complied with Italian regulations on protection of animals used for 
experimental and other scientific purpose (Ministerial Decree 116192) as well as 
with the European Economic Community regulations (Official Journal of E.C. L 
358/1 12/18/1986). 
Compounds were given i.p. 30 minutes before carrageenan, whereas vehicle-
treated group of rats received DMSO (4%, i.p.) 30 minutes before carrageenan. 
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Rats were anaesthetized with enflurane 4% mixed with O2, 0.5 l/min, N2O 0.5 
l/min and submitted to a skin incision at the level of the left sixth intercostal 
space. The underlying muscle was dissected, and saline (0.2 ml) or λ-
carrageenan type IV (isolated from Gigartina aciculaire and Gigartina 
pistillata, Sigma-Aldrich, Milan, Italy) 1% (w/v) (0.2 ml) was injected into the 
pleural cavity. The skin incision was closed with a suture, and the animals were 
allowed to recover. At 4 h after the injection of carrageenan, the animals were 
killed by inhalation of CO2. The chest was carefully opened, and the pleural 
cavity was rinsed with 2 ml saline solution containing heparin (5 U/ml). The 
exudate and washing solution were removed by aspiration, and the total volume 
was measured. Any exudate that was contaminated with blood was discarded.  
The amount of exudate was calculated by subtracting the volume injected (2 ml) 
from the total volume recovered. Leukocytes in the exudate were resuspended in 
PBS and counted under a light microscope using a Bürker haemocytometer after 
vital trypan blue staining. The amount of LTB4 in the supernatant of centrifuged 
exudate (800 x g, 10 min) was assayed by EIA immunoassay (Cayman 
Chemical, Ann Arbor, MI) according to manufacturer’s protocol. The results are 
expressed as nanograms per rat and represent the mean ± SEM of rats per 
experimental group as indicated.  
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4 Results 
4.1 2-substituted-indole-3-carboxylates as 5-LO inhibitors  
Synthesis and biological evaluation of a series of 2-amino-5-hydroxy-indole-3-
carboxylate derivatives as inhibitors of 5-LO was recently reported [236]. No 5-
LO inhibition was found for compounds with a primary amino group or 
dimethylamine moiety in position 2 at the 5-hydroxyindole nor for compounds 
including the nitrogen atom of the amino group into heterocycles as pyrrolidine, 
piperidine, methylpiperazine or morpholine, up to a concentration of 30 µM. 
Introduction of 4-arylpiperazine residues successfully generated 5-LO inhibitory 
properties. Especially a (4-chlorophenyl)piperazin-1-yl derivative blocked 5-LO 
product formation efficiently at 10 µM. The potency of the 4-arylpiperazine 
derivatives proved to be higher in the cell-free assay than in intact cells, 
suggesting low cell-permeability due to positive charging of the basic piperazine 
structure. Synthesis of another series of compounds containing secondary 
phenyl- and phenylethylamine moieties lead to even more potent compounds 
[236]. One of the most active compounds identified was methyl 2-(3-
chlorophenylamino)-5-hydroxy-1H-indole-3-carboxylate (1a) (IC50= 2.4 µM in 
A23187-stimulated PMNL and 0.3 µM in 40,000 x g homogenates of E.coli 
with recombinant 5-LO (referred to as S40), respectively.  
4.1.1 SAR of indole-carboxylates 
The hydroxy group in position 5 of the indole backbone is assumed to have anti-
oxidative properties and thus explaining the inhibitory effect on 5-LO by 
keeping the catalytic iron in the ferrous (Fe2+) state. In order to determine the 
influence of the 5-hydroxy moiety on the potency of the respective substance, 
several derivatives devoid of it were synthesized in the group of Prof. Dr. 
Troschütz at University of Erlangen and tested for their 5-LO inhibition (Table 
3).  
Results  53 
Table 3 5-LO inhibition of 2-amino-indole-3-methylcarboxylates  
PMNL were stimulated with 2.5 µM A23187+ 20 µM AA or to aliquots of 40,000x g 
homogenates of E.coli expressing recombinant 5-LO (S40), 1 mM CaCl2 and 20 µM AA were 
added. IC50 values are given as mean ± SEM; n ≥ 3  
* PMNL stimulated with 2.5 µM A23187 n.i. a: no inhibition up to 10 µM;  
 
inhibition of 5-LO activity 
IC50 [µM ± SEM] 
# R1 R2 R3 PMNL S40 
1a -OH -H 3-chlorophenyl 
7.3 ± 0.9 
2.4 ± 0.4 * 
0.3 ± 0.09 
1b -H -H 3-chlorophenyl 6.5 ± 1.9 8.1 ± 0.5 
1c -Cl -H 3-chlorophenyl 5.5 ± 2.1 3.5 ± 0.9 
1d -H -CH3 3-chlorophenyl 2.4 ± 0.3 n.i. a 
2a -H -H 2-chlorophenyl 9.8 ± 1.9 10.2 ± 0.5 
2b -H -H 4-chlorophenyl 7.2 ± 0.9 9.8 ± 4.0 
2c -H -H 3-fluorophenyl 7.9 ± 0.3 13.4 ± 2.9 
2d -H -H 2-bromophenyl 7.1 ± 0.5 7.6 ± 0.4 
2e -H -H 3-bromophenyl 3.5 ± 1.2 8.3 ± 1.4 
2f -H -H 2-chloro-(3-pyridinyl) 2.4 ± 0.2 1.4 ± 0.3 
3a -H -H -benzyl 4.0 ± 2.8 3.4 ± 1.8 
3b -H -H -allyl n.i. a n.i. a 
3c -H -allyl -allyl 12.5 ± 2.5 6.9 ± 1.4 
4 -H -H 1-naphtyl 3.6 ± 0.1 10.2 ± 0.3 
5a -H -H 3,5-dichlorophenyl 7.8 ± 0.9 2.9 ± 1.1 
5b -H -H 3,4-dichlorophenyl 4.6 ± 0.8 4.5 ± 1.3 
5c -H -H 2,6-dichlorophenyl 7.9 ± 1.9 8.5 ± 1.0 
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inhibition of 5-LO activity 
IC50 [µM ± SEM] 
# R1 R2 R3 PMNL S40 
5d -H -H 3-trifluormethylphenyl 6.5 ± 0.5 9.7 ± 2.5 
In direct comparison to parental compound 1a, the derivative lacking the 5-
hydroxy moiety (1b) was equipotent in PMNL, but 30-fold less potent in the 
cell-free assay. Replacement of the hydroxy group by chlorine (1c) did not 
significantly impair the efficacy in intact cells, but lowered the potency12-fold 
in the cell-free assay. When a methyl group was present at the amino moiety 
(1d), inhibition in the cell-free assay was diminished, whereas the potency in 
PMNL was enhanced almost 3-fold.  
Variation of the substituents at the aromatic ring by chlorine in ortho- (2a) or 
para-position (2b) as well as flourine in meta- (2c) or bromine in ortho-position 
(2d) caused no substantial improvement versus 1b, except meta-positioning of 
bromine (2e) (IC50= 3.5 ± 1.2 µM). Replacement of 2-chlorophenyl (2a) by 2-
chloro-3-pyridinyl (2f), increased the potency 4-fold in PMNL and 7-fold in the 
cell-free assay. The presence of an unsubstituted benzylamino moiety (3a) 
slightly enhanced the potency (IC50= 4.0 µM in PMNL). Structural variation of 
the N-aryl moiety with one N-allyl chain (3b) led to total loss of activity in both 
systems whereas the N-diallyl-compound (3c), resembling an aromatic phenyl 
ring, was active [236]. Enlargement of the aromatic system to naphtyl (4) was 
not detrimental for 5-LO inhibition in intact cells but impaired potency in the 
cell-free assay versus 1a.  
Modifications such as exchange of the nitrogen bridge of 1b by an oxygen atom 
or inclusion of the nitrogen into a bicyclic phenyl-piperidinyl system (not 
shown), retained the inhibitory potency with IC50 values between 7.0 and 9.5 
µM, but did not improve it. Insertion of two chlorine atoms (5a-c) or a meta-
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positioned trifluoromethyl group (5d) at the phenyl moiety was tolerated leading 
to IC50 values in the range of the other phenyl derivatives from this series, 
whereof simultaneous chlorine substitution in meta- and para-position (5b) was 
beneficial.  
Despite the lack of the hydroxy group in position 5, derivatives of 2-amino-
indole-3-carboxylates (Table 3) inhibit 5-LO. This suggests that the inhibition 
of 5-LO cannot only be explained by a redox-type-mechanism of the 
compounds. But since the hydroxy group was shown to be beneficial, a 5-
hydroxy-indole-3-ethylcarboxylate backbone was chosen for additional 
modifications. Moreover, substitution of the nitrogen in 2-position of the indole 
by carbon yielding compound 6a, led to slightly improved potency in PMNL, 
but with concomitant loss of potency in the cell-free assay compared to the 
methyl-carboxylate analogue 1a (Table 4). 
Table 4 5-LO inhibition of 5-hydroxy- indole-3-ethylcarboxylates 
PMNL were stimulated with 2.5 µM A23187 +20 µM AA. or to aliquots of 40,000x g 
homogenates of E.coli expressing recombinant 5-LO (S40), 1 mM CaCl2 and 20 µM AA were 
added. IC50 values are given as mean ± SEM; n ≥ 3 
N
H
COOEt
OH
R
 
inhibition of 5-LO activity 
IC50 [µM ± SEM] 
# R PMNL S40 
6a 3-chlorobenzyl 1.7 ± 0.8 2.0 ± 0.5 
6b 2-chlorobenzyl 1.7 ± 0.4 1.6 ± 1.6 
6c 4-chlorobenzyl 0.7 ± 0.4 1.2 ± 1.1 
6d 3-chlorophenyl 3.3 ± 0.6 4.8 ± 0.9 
6e 4-chlorophenyl 2.0 ± 0.05 2.1 ± 0.6 
6f 1-(3-chlorophenyl)ethyl 2.8 ± 0.5 1.7 ± 0.6 
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N
H
COOEt
OH
R
 
inhibition of 5-LO activity 
IC50 [µM ± SEM] 
# R PMNL S40 
6g 1-(4-chlorophenyl)ethyl 3.9 ± 1.8 0.7 ± 0.3 
6h 1-phenylethyl 5.5 ± 1.4 7.3 ± 1.6 
6i 2-chloro-6-fluorophenylamino 7.9 ± 2.5 1.6 ± 0.1 
Repositioning of chlorine to para position (6c) at the aromatic ring increased the 
potency about 2-fold to 0.7 µM ± 0.4 in PMNL and 1.2 ± 1.1 µM in the cell-free 
system, whereas ortho-positioning (6b) was equipotent with 6a. When a bulky 
benzyl residue was attached to the nitrogen of 6c (not shown), a 2-fold decrease 
of potency in PMNL (IC50= 1.6 µM), but a 12-fold increase of potency in the 
cell-free assay (IC50= 0.1 µM) was observed. After altering the connection 
between the indole and the aromatic ring to chlorophenyl (6d, 6e), 5-LO 
inhibition by the 3-chlorophenyl derivative 6d was lowered 2-fold in the cell-
based and 2.5-fold in the cell-free system. For 6e, an almost 3-fold decrease of  
potency was observed in intact cells and about 2-fold in the cell-free assay 
compared to the respective benzyl derivatives. Elongation of the bridge (6f-h) to 
2 carbon atoms caused a slight loss of potency in PMNL compared to the 
corresponding benzyl analogues, still with inhibitory potency in the range of 
phenyl analogues. Only for 6g an IC50 of 0.7 µM was observed in the cell-free 
system. Replacing the nitrogen at the indole part of 6h by oxygen (not shown) 
yielding a benzofuran core did not improve the potency with IC50 values of 3.8 ± 
1.8 µM and 9.7 ± 2.9 µM in PMNL and S40, respectively. The 2-chloro-6-
fluorophenylamino residue at 6i showed no substantial improvement in PMNL 
compared to the 2,6-dichlorophenylamino derivative 5c. The higher potency of 
6i in the cell-free assay is likely attributed to the 5-hydroxy group.  
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The next structural variation of the compounds involved the anellation of a 
benzene moiety at the indole core yielding 5-hydroxy-benzo[g]indole-3-
carboxylates as new core structure (Table 5).  
This modification enlarged the lipophilic core structure and the overall 
lipophilicity of the compounds. Annelation of a benzene ring to compound 1a 
generated the ethylcarboxylate analogue 7 with 10-fold higher potency in PMNL 
compared to 1a. Replacement of the nitrogen bridge in 7 by a methylene 
function leading to compound 8a further enhanced  the potency about 3-fold in 
both test systems. Due to the finding that the amino function in position 2 is not 
beneficial, synthesis of derivatives devoid of it was continued. 
Table 5 5-LO inhibition of benzo[g]indole-3-carboxylates  
PMNL were stimulated with 2.5 µM A23187+20 µM AA or to aliquots of 40,000 x g 
homogenates of E.coli expressing recombinant 5-LO (S40), 1 mM CaCl2 and 20 µM AA were 
added. IC50 values are given as mean ± SEM; n ≥ 3;  
Bn=Benzyl ; Et=Ethyl 
N
OH
COOR2
R1
R3
 
inhibition of 5-LO activity 
IC50 [µM ± SEM] 
# R1 R2 R3 PMNL S40 
7 -H -Et (3-chlorophenyl)amino 0.71 ± 0.25 0.24 ± 0.06 
8a -H -Et 3-chlorobenzyl 0.23 ± 0.07 0.086 ± 0.02 
8b -H -Et 2-chlorobenzyl 1.2 ± 0.07 0.097 ± 0.09 
8c -H -Et 4-chlorobenzyl 1.2 ± 0.19 0.084 ± 0.05 
8d -H -Et 3-fluorobenzyl 0.34 ± 0.03 0.14 ± 0.02 
8e -H -Et 4-fluorobenzyl 0.50 ± 0.01 0.096 ± 0.02 
8f -H -Et 3-bromobenzyl 0.45 ±0.14 0.15 ± 0.02 
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N
OH
COOR2
R1
R3
 
inhibition of 5-LO activity 
IC50 [µM ± SEM] 
# R1 R2 R3 PMNL S40 
8g -H -Et 4-bromobenzyl 0.60 ± 0.24 0.095 ± 0.01 
8h -H -Et 3-methoxybenzyl 0.52 ± 0.03 0.13 ± 0.15 
8i -H -Et 4-methoxybenzyl 0.65 ± 0.3 0.15 ± 0.02 
8j -H -Et 4-trifluoromethylbenzyl 1.7 ± 0.3 0.25 ± 0.18 
8k -H -Et 3-chlorophenyl 0.52 ± 0.10 0.045 ± 0.01 
8l -H -Et 4-chlorophenyl 0.32 ± 0.11 0.067 ± 0.02 
8m -H -Et 3-chlorophenylethyl 0.49 ± 0.15 0.031 ± 0.01 
8n -H -Et 4-chlorophenylethyl 2.8 ± 0.6 0.049 ± 0.04 
8o -H -Et phenylpropyl 0.44 ± 0.11 0.13 ± 0.02 
8p -Bn -Et 4-chlorobenzyl 1.8 ± 0.05 0.65 ± 0.09 
8q -H -Bn 3-chlorobenzyl 0.35 ± 0.09 0.13 ± 0.09 
8r -H -Bn 4-chlorobenzyl 0.48 ± 0.13 0.17 ± 0.02 
8s -H -Et 2-chloro-6-fluorobenzyl 0.99 ± 0.3 0.18 ± 0.03 
9 -H -Et (2-chloropyridin-3-yl)-methyl 0.98 ± 0.2 0.17 ± 0.05 
10 -H -Et 2-(tert-butoxycarbonylamino)ethyl 0.65 ± 0.6 0.28 ± 0.08 
Different positioning of chlorine (8a-c), fluorine (8d,e), bromine (8f,g) or 
methoxy groups (8h,i) at the aromatic system were tolerated yieding IC50 values 
between 0.23 µM and 1.7 µM in intact cells and still very potent inhibition of 5-
LO in the cell-free assay with IC50 values between 0.086 µM (8a) and 0.25 µM 
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for 8j. The meta-substituted chlorobenzyl derivative 8a was superior to flourine 
(8d) and bromine analogues (8f) followed by halogens in para-position (8c, 8e, 
8g) whereof in particular chlorine substitution was even more detrimental. 
Introduction of methoxy groups in meta (8h) or para position (8i) as well as 
trifluoromethyl groups (8j) instead of halogens were tolerated but appeared not 
to be improving. Variations of the distance by shortening (8k,l) or elongation 
(8m, n, o) between indole core and phenyl moiety slightly improved the potency 
in the cell-free assay compared to 8a (IC50= 0.086 ± 0.02 µM). However, in 
intact cells, the potency was almost 10-fold lower when an ethylene bridge was 
inserted (8n). For the meta-substituted derivatives (8k, 8m) only a slight 
influence of chain length on inhibitory potency was observed in PMNL. Further 
elongation of the bridge leading to phenylpropyl-substituted 8o did not 
significantly decrease potency. Introduction of a benzyl residue at N-1 of the 
indole at 8c influenced potency moderately (8p). Synthesis of corresponding 
benzyl esters to 8a and 8c showed that even substitution with voluminous 
residues at position 3 of the indole (8q, 8r) is not critical. More than one 
substituent at the aromatic residue such as chlorine and fluorine (8s) or 2-chloro-
pyridine (9) instead of benzene retained potency in the cell-free-assay, but 
slightly reduced it in PMNL to an IC50 of approximately 1 µM. Interestingly, 
bulky aliphatic substituents such as 2-(tert-butoxycarbonylamino)ethyl (10) 
were also tolerated and yielded a potency in the range of the halogenated benzyl 
derivatives. Based on these findings, 3-chlorobenzyl-substituted derivatives with 
benzo[g]indole scaffold were chosen for further modifications (Table 6). 
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Table 6 5-LO inhibition of 3-chlorobenzyl-benzo[g]indole-3-carboxylates  
PMNL were stimulated with 2.5 µM A23187 + 20 µM AA. or to aliquots of 40,000x g 
homogenates of E.coli expressing recombinant 5-LO (S40), 1 mM CaCl2 and 20 µM AA were 
added. IC50 values are given as mean ± SEM; n ≥ 3 
n.i. a: no inhibition up to 10 µM; n.i. b: no inhibition up to 30 µM   
N
ClR1R4
R3
R2
COOEt
 
inhibition of 5-LO activity 
IC50 [µM ± SEM] 
# R1 R2 R3                     R4 PMNL S40 
11a allyl -OH benzo n.i.b > 30 
11b 
4-methoxy-
benzyl 
-OH benzo n.i.a 0.8 ± 0.5 
11c 
4-methoxy-
benzyl 
(4-
trifluormethyl)- 
benzyloxy- 
benzo n.i.b n.i.b 
11d -CH3 -OCH3 benzo n.i.b > 30 
11e -H 4-chlorophenyl benzo n.i.b n.i.a 
11f -H 4-cyanophenyl benzo n.i.b n.i.a 
11g -H phenyl- benzo > 30 > 30 
11h -H benzoyloxy benzo n.i.a 3.4 ± 2.0 
12 -H -OH 2,3-dimethoxybenzo 7.0 ± 0.8 > 10 
13 -H -OH [2,3] pyrido 4.3 ± 0.9 0.58 ± 0.15 
14 -H -OH phenyl -H 5.7 ± 0.1 1.2 ± 0.20 
15 -H -OH 4-biphenyl -H 2.8 ± 0.7 0.33 ± 0.12 
Insertion of an allyl (11a) or bulky aromatic 4-methoxybenzyl (11b) moiety at 
the nitrogen of the indole as well as substitution with two bulky substituents 
(11c) at position 1 and 5 totally abolished 5-LO inhibition in cellular assay. 
Interestingly, compound 11b, which was inactive in PMNL, inhibited 5-LO 
directly with an IC50 value below 1 µM. Smaller substitutents such as methyl 
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and methoxy groups (11d) showed weak inhibiton in the cell-free-assay. 
Replacement of the hydroxy group in position 5 with lipophilic residues such as 
4-chlorophenyl (11e), 4-cyanophenyl (11f) phenyl (11g), or esterification with 
benzoic acid (11h) could not generate potent 5-LO inhibitors. Anellation of 
dimethoxybenzene (12) or heterocyclic pyridine (13) instead of benzene or 
introduction of a phenylic (14) and biphenylic (15) residue in C-7 position were 
tolerated, but proved to be detrimental for 5-LO inhibition compared to lead 
compound 8a. Except for 12, the potency of the compounds was better in cell-
free-assay suggesting a lower uptake into intact cells due to bulky substituents. 
4.1.2 Pharmacological characterization of selected compounds 
Inhibition of 5-LO product formation might be caused by various mechanisms. 
Beside direct inhibition of the enzyme, competitive inhibition or influence on 
the activation of 5-LO are reasonable [237]. In order to assess the mechanisms 
of action, 8a was chosen for further experiments. 
4.1.2.1 Reversibility of 5-LO inhibition 
In order to find out whether the binding of 8a to 5-LO is reversible, a wash-out 
experiment was conducted. After pre-incubation of semi-purified human 
recombinant 5-LO with 0.5 µM of 8a, followed by 10-fold dilution with assay 
buffer to 0.05 µM and addition of CaCl2 and 20 µM AA, enzyme activity was 
recovered to 50% of vehicle control (Fig. 16).  
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Fig. 16 Reversibility of 5-LO inhibition by 8a vs. zileuton  
Aliquots of purified recombinant 5-LO were incubated with 0.05 or 0.5 µM 8a, 1 or 0.1 µM 
zileuton (Zil), or vehicle (DMSO) for 10 min at RT. Then, one aliquot of the sample 
containing 0.5 µM 8a or 1 µM Zil was diluted with assay buffer 10-fold, whereas the other 
aliquot was not altered. Samples were pre-warmed for 30 sec at 37 °C, and 2 mM CaCl2 and 
20 µM AA were added to start the 5-LO reaction. After 10 min, 5-LO products were analysed. 
Data shown as mean ± SEM; n = 4.  
** p< 0.01 vs. undiluted sample, one-way ANOVA with post-test 
As control inhibitor, zileuton was used at concentrations of 0.1 µM and 1 µM 
that inhibited 5-LO in a direct and reversible manner, as expected [194]. It has to 
be noted that enzyme activity was not completely reversed after dilution of 8a. 
Nevertheless, 8a can be considered as reversible inhibitor of 5-LO. 
4.1.2.2 Influence of substrate concentration on 5-LO inhibition 
Next, the influence of different substrate concentrations was investigated. After 
stimulation of PMNL with 2.5 µM A23187, endogenous AA is liberated from 
the nuclear membrane by cPLA2 [20] leading to formation of LTs and 5-
H(P)ETE [59]. When 20 or 50 µM AA were added together with A23187, 
circumventing liberation of endogenous AA by cPLA2, no significant change in 
potency was observed (Fig. 17A) 
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Fig. 17 Effect of different AA concentrations on 5-LO inhibition of 8a  
PMNL were pre-incubated with 8a for 15 min at 37 °C. Then, 2.5 µM A23187 was added 
without (-) or together with 20 or 50 µM AA (A). Alternatively, aliquots of E.coli 
homogenates of recombinant 5-LO (S40), were diluted in 1 ml PBS, pH 7.4 and 1 mM EDTA, 
and pre-incubated with the test compounds for 10 min at 4 °C. Samples were pre-warmed for 
30 sec at 37 °C, and 2 mM CaCl2 and AA were added as indicated to start the 5-LO reaction. 
(B) After 10 min at 37 °C, 5-LO products were analysed by HPLC. Data shown as mean ± 
SEM; n =2-12; 
*p<0.05, **p < 0.01 vs. control, one-way ANOVA with post-test 
Taken together, the potency of 8a was not influenced significantly when 
different concentrations of AA were present in the assay suggesting a non-
competitive 5-LO inhibition. Also inhibition at the stage of substrate supply 
(cPLA2) could be excluded by this approach. Interaction of 8a with FLAP seems 
also unlikely, since it has been shown that FLAP inhibitors fail to completely 
suppress 5-LO at high substrate concentrations. Moreover, FLAP inhibitors are 
not active in cell-free systems [238]. 
4.1.2.3 Influence on cellular distribution of 5-LO 
Several FLAP inhibitors such as MK-886 contain an indole-based structure and 
suppress LT formation by inhibiting substrate supply mediated by FLAP. This 
class of leukotriene formation inhibitors was shown to inhibit translocation of 5-
LO from the cytosolic compartment to the nuclear membrane and thus activation 
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of 5-LO [165]. Since 8a shows structural but not mechanistical properties of 
FLAP inhibitors, it was not surprising that no influence on Ca2+-induced 5-LO 
translocation was observed [239]. 
4.1.2.4 5-LO inhibition of 8a in whole blood assay 
Physiological factors such as albumin-binding or regulatory components in 
blood plasma can influence the bioavailabilty of a drug in vivo. These effects are 
not considered in the assay systems used so far in this study. Hence, 5-LO 
inhibition by two selected 5-hydroxy-benzo[g]indole-3-carboxylates in human 
whole blood stimulated with 30 µM A23187 or LPS/fMLP was investigated. As 
shown in Fig. 18A, formation of LTB4 and 5-H(P)ETE was inhibited 
concentration-dependently by 8a and 8l with IC50 values of 1.6 ± 0.3 and 1.3 ± 
0.15 µM after stimulation with A23187. After priming of human whole blood 
with LPS for 30 min and subsequent stimulation with fMLP, 8a reduced 5-LO 
product formation with an IC50 of 0.83 ± 0.07 µM (Fig. 18B).  
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Fig. 18 5-LO inhibition in human whole blood by 8a and 8l 
Aliquots of human whole blood (1.5 ml) were pre-incubated with 8a or 8l or vehicle (DMSO 
0.1%) for 10 min at 37 °C and then stimulated with 30 µM A23187 (A) or primed with LPS (1 
µg/ml) for 30 min and then stimulated with 1 µM fMLP  (B). After 10 min (A23187) or 15 
min (LPS/fMLP) at 37 °C, 5-LO products were analysed by HPLC. Data shown as mean ± 
SEM.; n = 3-4. **p< 0.01 vs. control, one-way ANOVA with post-test 
 Experiments were carried out together with Dr. C. Pergola. 
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4.1.2.5 In vivo effectiveness of 8a in carrageenan-induced pleurisy 
Since the investigation in whole blood assay cannot entirely represent the in 
vivo characteristics of compound 8a, it was applied in carrageenan-induced 
pleurisy in rats, an established model of acute inflammation involving 5-LO 
[240]. After i.p. or peroral administration of the test compound, pleurisy was 
induced by injection of a λ-carrageenan solution into the pleural cavity. 4h after 
pleurisy induction, exudate volume, LTB4 levels and number of inflammatory 
cells were measured and compared to vehicle-treated control animals. 4 mg/kg 
of 8a significantly reduced inflammatory response in the range of 10 mg/kg 
zileuton (Table 7).  
Table 7 Effect of compound 8a on carrageenan-induced pleurisy in rats  
30 min before injection of carrageenan, rats (n=10 for each experimental group) were treated 
i.p. with 4 mg/kg 8a, 10 mg/kg zileuton, or vehicle (DMSO 4%). Exudate volume, LTB4 levels 
and accumulation of inflammatory cells in the pleural cavity were assessed 4 h after 
carrageenan injection. Data are expressed as mean ± S.E., n = 10. 
* p<0.05; **p<0.01; *** p<0.001 vs. vehicle.  
Animal experiments were made in the group Prof. L. Sautebin, University of Naples, Italy  
Exudate volume, number of inflammatory cells as well as the amount of LTB4 in 
the pleural exudate were significantly reduced by 8a, comparable to zileuton at 
10 mg/kg. In fact, zileuton was more potent at 10 mg/kg than 8a but still a 
significant decrease of LTB4 formation could be shown for 8a. 
treatment 
exudate volume 
(ml) 
inflammatory cells 
(× 106) 
LTB4 
(ng/rat) 
vehicle 0.48 ± 0.08 46.7 ± 3.53 1.17 ± 0.21 
8a 
(4 mg/kg) 
0.11 ± 0.0026 *** 28.0 ± 6.83 * 0.60 ± 0.096 * 
zileuton 
(10 mg/kg) 
0.11 ± 0.065 ** 27.54 ± 4.41 ** 0.40 ± 0.044 ** 
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4.1.3 5-Hydroxy-indoles as dual inhibitors of 5-LO and mPGES-1 
Beside assessing the compounds for 5-LO inhibition, selected derivatives were 
screened for inhibition of mPGES-1. Due to structural similarity with known 
mPGES-1 inhibitors such as MK-886, a set of hydroxy-indole-based compounds 
was investigated [230]. Starting from compound 1a as lead structure, mPGES-1-
derived PGE2 production was not reduced significantly (Table 8). 
Table 8 Inhibition of mPGES-1-derived PGE2 formation of selected 5-hydroxy-indole-
carboxylates and 5-hydroxybenzo[g]indole carboxylates [230]. 
Compounds were tested in microsomal preparation of A549 cells, after 15 min pre-incubation 
at 4 °C, 20 µM PGH2 was added for another 1 min. and reaction was stopped and PGE2 
formation was analysed by HPLC.  
n.d.: not determined  
N
H
R3
R2
R1
OH
COOEt
 
# R 1 R2 R3 
IC50 [µM] 
mPGES-1 
1a H H 
N
H
Cl
 
n.d. 
6a H H 
Cl
 
> 10 
15 H 4-biphenyl 
Cl
 
3.1 
7 benzo [g] 
N
H
Cl
 
1.6 
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N
H
R3
R2
R1
OH
COOEt
 
# R 1 R2 R3 
IC50 [µM] 
mPGES-1 
8a benzo [g] 
Cl
 
0.6 
8b benzo [g] 
Cl
 
0.1 
8f benzo [g] 
Br
 
0.2 
As described above for 5-LO, removing of the aminogroup in position 2 (6a) 
and enlarging the indole scaffold by anellation to benzo[g]indole-carboxylates 
strongly increased the potency towards mPGES-1. Introduction of a 4-biphenyl 
residue in position 7 (15) strongly enhanced the potency (IC50 = 3.1 µM). 
Besides 5-LO, compound 8a inhibits mPGES-1 in a reversible and non-
competitive manner (IC50 = 0.6 µM). COX-1 and COX-2 were not significantly 
or only barely attacked even at high concentrations in cellular assays. A more 
potent inhibition of mPGES-1 was found for the 2-chlorophenyl- (8b) and the 3-
bromophenyl- substituted derivative (8f) with IC50 values of 0.1 µM and 0.2 µM, 
respectively.  
Taken together, benzo[g]indol-hydroxyindole-3-carboxylates, exemplified by 8a 
and 8l are potent, reversible and non-competitive 5-LO inhibitors. Structural 
optimization of 5-hydroxy-indole carboxylates by creating benzo[g]indoles 
further enhanced the potency and led to dual inhibition of 5-LO and mPGES-1, 
whereas other enzymes of the AA cascade such as COX-1 and COX-2 were not 
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affected [230]. Furthermore, an in vivo effect was demonstrated for 8a in an 
animal model of acute inflammation [239].  
4.2 1,4-Benzoquinone and polyphenolic derivatives as 5-LO inhibitors 
Natural sesquiterpenoids containing a 1,4-benzoquinone or hydroquinone 
structure such as Bolinaquinone (BLQ) or Ilimaquinone (Fig. 19) are present in 
the marine sponge species Dysidea and Smenospongia. They were ascribed to 
have anti-inflammatory [241], anti-microbial [242], cytotoxic and anti-
proliferative properties [243].  
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Fig. 19 Structures of the natural sesquiterpenoids Bolinaquinone (BLQ) and Illimaquinone  
The anti-inflammatory properties of BLQ were demonstrated by potent 
inhibition of several sPLAs, but BLQ had no effect on group IV cPLA2 [241]. 
Another study described an effect of BLQ on 5-LO activity and release of LTB4 
in human neutrophils with IC50 values of 1.3 and 2.1 µM. Moreover, PGE2 and 
NO production in zymosan-stimulated mouse peritoneal macrophages was 
reduced with an IC50 of approximately 1 µM. In the mouse ear edema model, 
BLQ showed inhibitory effects on PGE2, LTB4 and TNF-α generation. 
Moreover, BLQ exhibited anti-inflammatory effects in several established in 
vivo models of acute and chronic inflammation [244]. 
The 1,4-benzoquinone structure is associated with anti-inflammatory activities 
in human neutrophils [245] and inhibition of PLA2 preventing release of AA 
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[246]. In the cellular environment, the 1,4-benzoquinone structure can be 
reduced to hydrochinone, which may keep the iron in the catalytic centre of 5-
LO in the reduced (Fe2+) state, preventing catalytic activity of the enzyme.  
Polyphenolic compounds have often been shown to inhibit 5-LO activity, 
basically due to the presence of one or more hydroxygroups [190]. For the 
present study, compounds with 1,4-benzoquinone structures based on BLQ and 
a set of compounds containing polyphenolic structural elements of resorcin and 
veratrol were synthesized by the group of Dr. R. Filosa, University of Salerno, 
Fisciano, Italy.  
4.2.1 SAR of benzoquinones and polyphenolic compounds 
For biological investigation of the compounds two approaches were used: a cell-
free assay using semi-purified recombinant 5-LO which allows to assess direct 
interactions with 5-LO and intact human PMNL stimulated with A23187 and 
exogenous AA to include effects of cell-permeability and possible influence on 
5-LO activation or regulation to reduce 5-LO product formation.  
BWA4C was used as control at 0.3 µM, with remaining activity of 14.7 ± 2.9% 
in PMNL and 56.5 ± 11.9% in purified 5-LO, respectively. For the 2-hydroxy-5-
methoxy-1,4-benzoquinones (16a,b) and for the 2,5-dihydroxy-1,4- 
benzoquinone derivative 16c, inhibition of 5-LO was only observed at high 
concentrations (IC50 > 10 µM) in both assay systems (Table 9)  
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Table 9 5-LO inhibition of 2,5-dihydroxy-or 2-hydroxy-5-methoxy-benzoquinones  
PMNL were stimulated with 2.5 µM A23187+20 µM AA or purified 5-LO was incubated with 
1 mM CaCl2 and 20 µM AA; Data shown as % of remaining 5-LO activity at 10 µM vs. 
DMSO control and IC50; mean ± SEM, n ≥ 3  
n.i.a: no significant inhibition up to 10 µM; n.i.b: no significant inhibition up to 50 µM 
O
O
R1
OH
RO
 
# R R1 
PMNL 
   %               IC50 
   
(µM) 
purified 5-LO 
   %      IC50 
     
(µM)
 
16a -CH3 (2-naphtyl)methyl 56.1 ± 7.4 > 10 92.3 ±16.3 43 
16b -CH3 benzyl 103.3 ± 12.2 n.i.a 109.6 ± 15.1 n.i.b 
16c -H cyclohexylmethyl 90.4 ± 12.5 n.i.a 95.2 ± 15.8 > 30 
16d -H 
(decahydronaphthalen-2-yl) 
methyl 
5.4 ± 2.6 0.58 51.0  ± 8.9 11 
Insertion of an enlarged decahydronaphtylmethyl residue instead of cyclohexyl 
(16c) led to active compound 16d in PMNL (IC50= 0.58 µM), but only moderate 
potency in the cell-free asssay (IC50= 11 µM). For 16d, intact cells are obviously 
needed to suppress 5-LO product formation, presumably due to metabolic 
activation of 16d in the cells by reduction of the benzoquinone to hydroquinone. 
Possibly, interference with FLAP, CLP, cPLA2 or other factors regulating 5-LO 
such as phosphorylation, or the hydroperoxide tone can contribute to the 
inhibitory effect on 5-LO in intact cells but not in a cell-free system. Removal of 
one hydroxy group and a shift of R1 to position 2 resulted in compounds shown 
in Table 10. 
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Table 10 5-LO inhibition of 3-hydroxy- or 3-methoxy-benzoquinone derivatives  
PMNL were stimulated with 2.5 µM A23187+ 20 µM AA or purified 5-LO was incubated with 
1 mM CaCl2 and 20 µM AA; Data shown as % of remaining 5-LO activity at 10 µM vs. 
DMSO control and IC50; mean ± SEM; n ≥ 3 
n.i.a: no significant inhibition up to 10 µM  
O
O
RO
R1
 
# R R1 
PMNL 
   %          IC50  (µM) 
purified 5-LO 
   %             IC50 (µM) 
16e -H (2-naphtyl)methyl 5.3 ± 2.4 2.3 8.7 ± 3.7 0.78 
16f -CH3 naphthalen-6-yloxy 21.2 ± 8.6 6.7 7.1 ± 3.2 0.28 
16g -H 
6-carboxy-2-
naphthylmethyl 
74.0 ± 5.6 n.i.a 45.2 ± 4.0 9.0 
16h -H 4-dibenzofuranyl 74.1 ± 2.2 > 10 30.8 ± 14.9 0.8 
16i -H benzyl 93.3 ± 16.6 n.i.a 74.3 ± 6.1 n.i.a 
16k -H 3-nitrophenyl 61.3 ± 7.8 > 10 8.0 ± 2.5 4.6 
16l -H hexyl 15.9 ± 2.7 3.0 14.2 ± 8.6 1.4 
All compounds (except 16h) directly inhibited 5-LO. Compound 16e, carrying a 
naphthalene residue, was identified as most potent compound of this series in 
intact neutrophils (IC50= 2.3 µM). Variation of the methylene bridge between 
the naphtalene and the 5-hydroxy-1,4-benzoquinone core by insertion of an 
oxygen and subsequent methylation of the hydroxy group at position 5 (16f) 
decreased the potency almost 3-fold in the cell-based test system, whereas the 
potency of 16f was increased in the cell-free assay to an IC50 of 0.28 µM. 
Introduction of a carboxy group at position 6 of the naphthalene ring (16g) was 
clearly detrimental compared to 16e, leading to a more than 30-fold higher IC50 
value in cell-free assay and no inhibition in PMNL. A larger heterocyclic 
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substituent such as dibenzofurane (16h) restored the potency in the cell-free 
assay with an IC50 of 0.8 µM comparable to 16e. Interestingly, the replacement 
of the naphtalene moiety by benzyl (16i) completely abrogated 5-LO inhibition. 
The direct connection of the benzoquinone core with 3-nitrophenyl (16k) led to 
weak potency in intact cells, but some bioactivity was retained in the cell-free 
assay. The nitro group of 16k is probably reduced in the cell to an amino group 
leading to loss of inhibition in PMNL. The weak inhbition of 16g-16k in PMNL 
is explainable by a hindered cellular uptake (16h, i) or metabolic reactions (16g, 
k) leading to inactivation in the cells. When an aliphatic side chain (16l) was 
present at the hydroxy-benzoquinone, the potency was in a comparable range to 
16e (IC50= 3.0 µM in PMNL and 1.4 µM in the cell-free assay, respectively). In 
addition to the benzoquinones, various polyphenolic derivatives based on 
resorcin (Table 11) as well as catechol and veratrol (Table 12) were synthesized 
and evaluated for 5-LO inhibition.  
Table 11 5-LO inhibition of resorcin derivatives 
PMNL were stimulated with 2.5 µM A23187+20 µM AA or purified 5-LO was incubated with 
1 mM CaCl2 and 20 µM AA; Data shown as % of remaining 5-LO activity at 10 µM vs. 
DMSO control and IC50; mean ± SEM; n ≥ 3 
n.i .a: no significant inhibition up to 10 µM 
OH OH
R
 
# R 
PMNL 
%           IC50 (µM) 
purified 5-LO 
%             IC50 (µM) 
17a (2-naphtyl)methyl 8.9 ± 1.0 2.3 37.2  ± 4.9 7.4 
17b 4-dibenzofuranyl 84.1 ± 12.6 n.i.a 30.7 ± 8.8 6.3 
17c benzyl 60.0 ± 2.2 > 10 47.6 ± 4.4 9.4 
17d phenyl 22.7 ± 5.3 4.2 9.4 ± 2.4 2.8 
17e 3-nitrophenyl 64.1 ± 7.4 > 10 84.3 ± 8.2 > 10 
17f hexyl 18.6 ± 6.1 2.8 25.6 ± 7.1 4.7 
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Combination of the resorcinol structure with aromatic residues such as 
naphylmethyl (17a), dibenzofuranyl (17b) or phenyl (17d) yielded compounds 
with moderate potencies in the low micromolar range in the cell-free assay. 
However, enlargement of the aromatic system to dibenzofuranyl (17b) abolished 
the inhibitory effect in intact cells as observed before for the quinone series. 
Variation of the distance between the resorcinol core and the substituent by 
introduction of by a methylene spacer (17c) as well as insertion of a nitro group 
at the phenyl ring (17e) was detrimental compared to 17d. Replacement of the 
aromatic structures by an aliphatic hexyl chain (17f) yielded an active 
compound, but did not further enhance the potency in both read outs. 
Within the catechol series (Table 12), 18a and 18b emerged as most active 
catechol derivatives in the cell-free assay with IC50 values of 130 nM and 76 
nM, respectively. However, 18a, carrying a 4-nitrophenyl residue, was 
completely inactive in the cell-based assay, probably due to metabolic 
conversion of the nitro group which does not occur under the conditions of the 
cell-free assay.  
Table 12 5-LO inhibition of catechol (R=H) and veratrol (R=CH3) derivatives  
PMNL were stimulated with 2.5 µM A23187 +20 µM AA or purified 5-LO was incubated with 
1 mM CaCl2 and 20 µM AA; Data shown as % of remaining 5-LO activity at 10 µM vs. 
DMSO control and IC50; mean ± SEM; n ≥ 3,  
n.i. a: no significant inhibition up to 10 µM 
OR
OR
R1
 
# R R1 
PMNL 
         %            IC50 (µM) 
purified 5-LO 
     %            IC50 (µM) 
18a -H 4-nitrophenyl 132.7  ± 42.4 n.i.a 0 ± 0 0.13 
18b -H 4-dibenzofuranyl 2.7 ± 1.2 0.6 0 ± 0 0.076 
19a -CH3 4-nitrophenyl 66.5 ± 7.9 > 10 94.9 ± 5.9 n.i.a 
19b -CH3 naphtyl-6-oxymethyl 21.7 ± 5.0 2.9 84.2 ± 5.5 n.i.a 
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OR
OR
R1
 
# R R1 
PMNL 
         %            IC50 (µM) 
purified 5-LO 
     %            IC50 (µM) 
19c -CH3 naphtylmethyl 35.4 ± 5.3 5.2 87.3 ± 6.5 n.i.a 
In contrast to the 1,4-benzoquinones and resorcinol derivatives, substitution of 
the catechol core with dibenzofuranyl (18b) was advantageous leading to the 
most potent representative with IC50 values of 600 nM and 76 nM in PMNL and 
the cell-free-assay, respectively. Reducing conditions in the cell lead to 
inactivation of 18a due to reduction of the nitrophenyl group to an aniline group, 
since 18a is completely inactive in the cell-based assay, whereas purified 5-LO 
was potently inhibited with an IC50 of 0.13 µM. Thus, 18b is apparently not 
influenced by reducing conditions in the cell and acts as 5-LO inhibitor. In 
contrast to the catechol compounds, the veratrol analogues 19a-c were 
completely inactive in the cell-free assay, showing that the hydroxy groups of 
18a play an important role for 5-LO inhibition compared to 19a.  
Variation of the assay conditions by pre-incubation of PMNL with the veratrol 
derivatives (19a-c) up to 60 min did not influence the potency. This suggests 
that metabolic changes such as potential cleavage of the methoxy group have no 
influence on the inhibitory action. This approach also excluded cytotoxic effects 
of the compounds up to 10 µM, since after 60 min pre-incubation time, 5-LO 
product formation in PMNL was the same as after 15 min pre-incubation time 
with the compounds (data not shown). 
4.2.2 Pharmacological characterization of selected compounds 
4.2.2.1 Investigation of scavenging properties  
Since polyphenols and benzoquinones are assumed to act via their redox-
activity, selected compounds were assessed in the DPPH assay which 
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determines radical scavenging and reducing properties of a compound. This 
assay investigates the ability of a compound to reduce the 1,1-diphenyl-2-picryl-
hydrazyl (DPPH) radical to diphenylpicryl-hydrazine. Ascorbic acid and 
cysteine were used as positive controls, since DPPH reacts in a 1:1 
stoichiometry with cysteine to cystine, whereas for oxidation of ascorbic acid 2 
mol DPPH are needed. When DPPH is reduced by the test compound, the colour 
change from violet to transparent is measured photometrically at 520 nm [247]. 
Weak reducing properties were found for the 3-hydroxybenzochinone 16l, since 
only one oxidable hydroxy group is present in the molecule, whereas the 
polyphenolic catechol derivatives 18a and 18b showed strong reducing activities 
equipotent to ascorbic acid (Fig. 20A).  
µM
0 20 40 60 80 100
A 
52
0 
n
m
(%
 
o
f c
o
n
tr
o
l)
0
20
40
60
80
100
120
Asc 
Cys 
16d 
17f 
19b 
µM
0 20 40 60 80 100
A 
52
0 
n
m
(%
 
o
f c
o
n
tr
o
l)
0
20
40
60
80
100
120
Asc 
Cys 
16l 
18a 
18b 
A B
 
Fig. 20 Radical scavenging activities of benzoquinones and polyphenols (DPPH assay)  
Ethanolic solutions of test compounds were incubated for 30 min at RT with acetate-buffered 
solution of 100 µM DPPH in ethanol. Extinction at 520 nm was measured and DMSO (2%) 
sample was set as 100 %. Data shown are representative for one experiment out of up to three 
experiments. Asc=ascorbic acid; Cys=Cysteine 
Interestingly, the 2,5-dihydroxybenzoquinone derivative 16d showed no 
reducing properties up to 100 µM (Fig. 20B). Due to stabilisation of the 
dihydroxybenzoquinone structure, its vinylogic acid structure and formation of 
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hydrogen bonds between the proximate keto and hydroxy groups, 16d did not 
reduce DPPH under these conditions. No reducing properties were found, 
neither for 17f due to energetically disadvantageous 1,3-positioning of the 
hydroxy groups. As expected, the veratrol derivative 19b, carrying non-
oxidizable methoxy groups could not reduce the DPPH reagent in this assay.  
To sum up, the polyphenolic compounds and benzoquinone derivatives are 
potent inhibitors of 5-LO in vitro. Since not all compounds have direct reducing 
properties, their inhibitory action is achieved following metabolic activation in 
the cell and might not only be ascribed to their polyphenolic or quinone 
structure. 
4.2.2.2 Inhibition of 12- and 15-LOs 
Next, the selectivity of the compounds towards 12-and 15-LOs was analysed in 
PMNL. Inhibition of 12-HETE formation, formed by oxidation of AA by p12-
LO and 15-HETE, formed by 15-LO were analysed for selected compounds in 
PMNL (Fig. 21).  
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Fig. 21 Effects of selected compounds on p12-LO and 15-LO product formation  
PMNL were pre-incubated for 15 min at 37 °C. Then, 2.5 µM A23187 + 20 µM AA was 
added. After 10 min at 37 °C, 12- and 15-HETE formation was analysed by HPLC. 5-LO 
products include LTB4, its trans-isomers and 5-HETE. Data shown as mean ± SEM; n= 2-3 
For all compounds, 15-HETE formation was not influenced or rather increased 
concentration-dependently. This effect might be interpreted as a shunt of AA to 
15-LO in neutrophils and subsequent product formation. 12-HETE formation 
was diminished by the hydroxybenzoquinones 16d and 16e with IC50 values 
greater than 10 µM. The resorcinol derivative 17a and the catechol compound 
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18b inhibited 5-LO selectively without influence on 12-HETE formation up to 
10 µM. 
4.2.2.3 Inhibition of 5-LO in human whole blood  
In order to describe the in vivo behaviour of selected compounds, 5-LO 
inhibition in A23187-stimulated human whole blood was assessed. 5-LO 
products were hardly reduced between 8 and 22% by 10 µM of 16e, 17a and 17f 
(data not shown). On the other hand, 16d and 18b reduced 5-LO product 
formation in a concentration-dependent manner with IC50 values of 
approximately 9 µM (Fig. 22). 
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Fig. 22 5-LO inhibition of 16d and 18b in human whole blood  
Aliquots of human whole blood (1.5 ml) were pre-incubated with the compounds for 10 min at 
37 °C and then stimulated with 30 µM A23187. After 10 min at 37 °C, 5-LO products were 
analysed by HPLC. Data shown as mean ± SEM; n=2-3 
3 µM BWA4C was used as positive control that inhibited 5-LO product 
formation in whole blood as expected [191]. Unfortunately, no statistical 
significance of 5-LO inhibition was evident, presumably due to the low sample 
size. Priming of human whole blood with LPS following stimulation with the 
chemotactic peptide fMLP resulted in an IC50 of 4.1 ± 0.6 µM for 16d [248]. 
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4.2.2.4 Molecular docking studies 
In order to identify the exact binding mode, interactions of the molecules and 
amino acids in the active site of 5-LO were studied by docking experiments. 
Molecular docking experiments were performed in the group of Prof. P. 
Reddanna at University of Hyderabad, India.  
The free energy of binding during the docking procedure was chosen to describe 
the affinity of the ligands to the active site of 5-LO and compared with the 
experimental IC50 values obtained in the in vitro experiments. A good 
correlation was found between the inhibition in the cell-free assay and the free 
binding energy. The molecular docking experiments predicted the 1,4-
benzoquinones to be more active than the resorcinol derivatives, correlating to 
the potency in the cell-free assay [249].  
4.2.2.5 In vivo experiments  
Two well-established animal models of inflammation were applied for further 
characterization of the anti-inflammatory effectiveness of 16d, the carrageenan-
induced mouse paw edema and the mouse air pouch model. All animal 
experiments were conducted at University of Naples, Italy [248]. When 16d was 
given i.p. at 0.1-10 mg/kg 30 minutes prior to intraplantar injection of 
carrageenan hind paw swelling was significantly reduced over the whole time 
period of 72 h with maximal effects at a dose of 1 mg/kg. 16d was also 
investigated in the air pouch model, where sterile air is injected subcutaneously 
several times into the back of mice followed by administration of zymosan or 
another inflammatory stimulus. 16d significantly reduced zymosan-induced cell 
migration in the exudate at 0.1 mg/kg after i.p. administration 30 minutes prior 
to zymosan [248] 
In summary, this chapter decribes the discovery of a series of 1,4-benzoquinones 
and polyphenolic compounds as inhibitors of 5-LO. SAR studies revealed that 
the substitution pattern strongly determines the potency of the compounds. 
Docking experiments demonstrated a direct binding of selected compounds to 5-
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LO, which correlated to the results from the in vitro experiments with 
recombinant 5-LO. Further investigations of the 1,4-benzoquinone compound 
16d confirmed its good anti-inflammatory efficiency in two in vivo animal 
models. 
4.3  Derivatives of pyrazole-3-propanoic acid as 5-LO inhibitors  
1,5-Diarylpyrazol-3-propanoic acids were recently reported as inhibitors of 
COX-1, COX-2 or 5-LO [250]. In order to improve the inhibition of LT 
formation, esters and amide derivatives of 1,5-diarylpyrazol-3-propanoic acid 
were synthesized by the group of Prof. E. Banoglu at the University of Ankara, 
Turkey and biologically evaluated for their effects on 5-LO product formation in 
our lab. A cell-based assay using human neutrophils was applied to demonstrate 
effects resulting in reduced LT formation apart from direct inhibition of 5-LO. 
Additionally, cell-free assays using recombinant human 5-LO from 
homogenates of E.coli (S40) or further purified 5-LO by ATP-affinity 
chromatography (semi-purified 5-LO) were carried out. 
4.3.1 SAR of pyrazole-3-propanoic acid derivatives 
The first set comprised 18 derivatives based on 3-(1-(6-chloropyridazin-3-yl)-5-
phenyl-1H-pyrazol-3-yl)propanoic acid. The compounds were investigated for 
5-LO inhibition at a concentration of 10 µM in isolated human neutrophils 
(PMNL) and supernatants of E.coli lysates expressing human recombinant 5-LO 
(S40). PMNL were activated by 2.5 µM Ca2+-ionophore A23187 to elevate 
intracellular calcium concentration and 20 µM AA to circumvent inhibition at 
the stage of substrate supply by cPLA2 (Table 13
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Table 13 Inhibition of 5-LO product formation by pyridazinyl-substituted-pyrazole-3-
propanoic acid derivatives  
PMNL were stimulated with 2.5 µM A23187+20 µM AA or aliquots of 40,000 x g E. coli 
homogenates expressing recombinant 5-LO (S40) were incubated with 2 mM CaCl2 and 20 
µM AA; Data shown as % of remaining 5-LO activity at 10 µM (mean ±  SEM) versus vehicle 
(0.3% DMSO and IC50 if available), n=3;  
n.d.: not determined 
 
# R1 R2 
PMNL 
% at 10 µM 
S40 
% at 10 µM  
IC50 PMNL  
[µM] 
26 -F 
H
N OCH3
 
88.3 ± 7.7 91.6 ± 14.9 n.d 
27 -CH3 
H
N
N
N O
 
106.2 ± 6.4 90.0 ± 11.0 n.d 
28 -CF3 N C NH2
O
 
104.3 ± 6.3 102.9 ± 17.3 n.d 
29 -CF3 N C OCH2CH3
O
 
62.0 ± 7.9 72.6 ± 9.2 15 
30 -CH3 N N CH2
O
 
86.0 ± 11.5 105.6 ± 16.4 n.d 
31 -CH3 N N S
O
CH2CH3
O
 
96.3 ± 5.0 93.6 ± 6.9 n.d 
32 -CF3 N N C
O O
 
81.8 ± 10.1 125.5 ± 22.7 n.d 
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# R1 R2 
PMNL 
% at 10 µM 
S40 
% at 10 µM  
IC50 PMNL  
[µM] 
33 -F N N CH2
 
23.4 ± 4.6 55.3 ± 10.5 1.8 
34 -F N N C
O O
 
95.0 ± 5.4 90.8 ± 9.6 n.d 
35 -F O
 
67.3 ± 15.8 92.7 ± 4.3 n.d 
36 -CH3 O
 
46.4 ± 9.3 92.7 ± 12.7 8 
37 -F O O(CH2)6CH3
 
90.1 ± 7.7 86.5 ± 8.7 n.d 
38 -CH3 O O CF3
 
86.5  ± 4.2 95.0 ± 10.9 n.d 
39 -CH3 O OCF3
 
70.5 ± 12.3 115.8 ± 6.5 n.d 
40 -CF3 O
 
77.2 ± 6.9 92.0 ± 6.3 n.d 
41 -F O N
N
 
111.4 ± 4.4 71.7 ± 10.9 n.d 
42 -F O S
 
90.8 ± 6.6 83.4 ± 24.9 n.d 
Results  83 
 
# R1 R2 
PMNL 
% at 10 µM 
S40 
% at 10 µM  
IC50 PMNL  
[µM] 
43 -CF3 O N
 
94.1 ± 11.3 90.8 ± 14.9 n.d 
Four compounds within this series inhibited 5-LO product formation remarkably 
in the cell-based assay at 10 µM. Two piperazine analogs substituted with ethyl 
piperidinecarboxylate (29) and tert-butylbenzylpiperazine (33) inhibited LT 
formation at 10 µM leading to 62% and 23% of remaining 5-LO activity in the 
cell-based asssay, respectively. Derivatization of pyrazole-3-propanoic acid with 
primary amines such as 4-methoxyaniline (26) or 6-morpholino-pyridine-3-
amine (27) led to inactive compounds. Linkage of the carboxylic group with 
piperidinecarboxamide (28) was also not successful, but with more lipophilic 
ethyl piperidinecarboxylate (29) the IC50 in PMNL was raised to 15 µM. When 
piperazine was linked with the carboxylic group, only the lipophilic bulky tert-
butylbenzyl substituent (33) was tolerated, whereas the other more polar 
piperazine analogs (30-32, 34) were not active. For the esterified compounds, a 
remarkable decrease of 5-LO product formation in PMNL was observed only for 
the tert-butylphenoxy (35) and isopropylphenoxy (36) substituents, whereof 36 
was more potent with an IC50 of 8 µM in PMNL. Variations at the phenolic 
moiety involved introduction of heptyloxy (37), trifluoromethylphenoxy (38), 
trifluoromethoxy (39) or cyclopentyl (40) substituents with poor outcome. In 
general, heterocycles such as imidazole (41), thiophene (42) or pyrrole (43) 
seem to diminish the potency of the compounds. In the cell-free assay, an IC50 of 
approximately 10 µM was observed for compound 33, suggesting rather 
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influence on the cellular regulation of 5-LO. None of the other compounds 
showed remarkable 5-LO inhibition in the cell-free assay. 
A second series of compounds was designed and synthesized based on the 
identified active compounds (29, 33, 35, 36) from the first set. Simultaneously, 
modifications at the pyrazole core were made by exchange of the 
chloropyridazinyl residue at N-1 by phenyl (44-47) or isoquinoline moieties (48-
51) (Table 14). It has to be noted that stimulation of the PMNL was done with 
2.5 µM A23187 without exogenous AA in order to identify inhibitors of FLAP.  
Table 14 Inhibition of 5-LO product formation by pyrazole-propanoic acid derivatives 
PMNL were stimulated with 2.5 µM A23187 or aliquots of E. coli homogenates expressing 
recombinant 5-LO (S40) were incubated with 2 mM CaCl2 and 20 µM AA; Data shown as % 
of remaining 5-LO activity at 10 µM (mean ±  SEM) versus vehicle (0.3% DMSO); n ≥ 3 
 
# R1 
PMNL 
% at 10 µM 
S40 
% at 10 µM 
44 N N CH2
 
30.5 ± 7.4 58.9 ± 11.1 
45 N C OCH2CH3
O
 
7.2 ± 3.5 102.5 ± 11.6 
46 O
 
6.2 ± 2.5 95.3 ± 6.2 
47 O
 
107.6 ± 19.2 80.7 ± 1.8 
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# R1 
PMNL 
% at 10 µM 
S40 
% at 10 µM 
48 N N CH2
 
68.3 ± 2.1 51.5 ± 6.1 
49 N C OCH2CH3
O
 
65.8 ± 12.7 69.9 ± 9.9 
50 O
 
40.1 ± 7.8 79.6 ± 12.3 
51 O
 
n.a. (compound insoluble) 
Compounds 44-46, carrying a phenyl residue at N-1, as well as the isoquinoline-
substituted derivative 50, reduced 5-LO product formation significantly in 
PMNL at 10 µM. Again, no or only moderate inhibition (44 and 48) in the cell-
free assay was observed at 10 µM. Further modifications involved shortening of 
the side chain at C-3 of the pyrazole. In comparison to the isoquinoline-
substituted compounds 48-51, potency was impaired for the isoquinoline 
derivatives 52-55 (Table 15), suggesting that the propanoic acid structure is 
superior to direct connection of R2 with the pyrazole. 
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Table 15 Inhibition of 5-LO product formation by N1-substituted pyrazole derivatives 
PMNL were stimulated with 2.5 µM A23187 or aliquots of E. coli homogenates expressing 
recombinant 5-LO (S40) were incubated with 2 mM CaCl2 and 20 µM AA; 
Data shown as % of remaining 5-LO activity at 10 µM (mean ±  SEM) versus vehicle (0.3% 
DMSO), n ≥ 3 
 
# R1 R2 
PMNL 
% at 10 µM 
S40 
% at 10 µM 
52 
N
 
N N CH2
 
80.7 ± 21.3 75.4 ± 15.1 
53 
N
 
N C OCH2CH3
O
 
75.8 ± 7.8 74.8 ± 10.0 
54 
N
 
O
 
85.8 ± 4.0 91.4 ± 7.7 
55 
N
 
O
 
92.7 ± 8.0 89.5 ± 10.9 
 
56 
 
N N CH2
 
59.4 ± 7.2 76.8 ± 5.1 
57 
 
N C OCH2CH3
O
 
44.7 ± 7.2 68.8 ± 5.9 
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# R1 R2 
PMNL 
% at 10 µM 
S40 
% at 10 µM 
58 
 
O
 
97.1 ± 8.9 87.7 ± 6.0 
59 
 
O
 
94.5 ± 10.5 98.2 ± 12.8 
Further structural modifications by addition of benzyl (56-59) or repositioning 
of the benzyl to N-2 of the pyrazole (60-63) failed to increase the potency 
(Table 16). BWA4C was used as control inhibitor at a concentration of 0.3 µM 
leading to 13.0 ± 3.8% remaining 5-LO activity in PMNL and 31.5 ± 7.9% in 
the cell-free assay, respectively.  
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Table 16 inhibition of 5-LO product formation by benzyl-substituted pyrazole derivatives 
PMNL were stimulated with 2.5 µM A23187 or aliquots of E. coli homogenates expressing 
recombinant 5-LO (S40) were incubated with 2 mM CaCl2 and 20 µM AA;  
Data shown as % of remaining 5-LO activity at 10 µM (mean ±  SEM) versus vehicle (0.3% 
DMSO); n ≥ 3 
 
# R 
PMNL 
% at 10 µM 
S40 
% at 10 µM 
60 N N CH2
 
107.0 ± 12.2 92.6 ± 5.6 
61 N C OCH2CH3
O
 
90.6 ± 2.8 72.1 ± 12.0 
62 O
 
105.1 ± 9.7 113.7 ± 5.9 
63 O
 
103.0 ± 4.6 102.7 ± 11.3 
In the next step, compound 33 was subject of further structural modifications. 
Variations of the p-substituent on the phenyl ring at C-5 of pyrazole by 
trifluoromethyl, methyl or flourine and replacement of chloropyridazine at N-1 
of the pyrazole (33,64,65) by aromatic moieties such as 4-chlorophenyl (66-68), 
phenyl (69,70), 6-methoxypyridazin-3-yl (71-73) or quinolin-2-yl (74,75) led to 
compounds listed in Table 17.  
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Table 17 Inhibition of 5-LO product formation by derivatives based on compound 33 
PMNL were stimulated with 2.5 µM A23187 +20 µM AA or aliquots of E. coli homogenates 
expressing recombinant 5-LO (S40) were incubated with 2 mM CaCl2 and 20 µM AA; 
Data shown as % of remaining 5-LO activity at 10 µM (mean ±  SEM) versus vehicle (0.3% 
DMSO); n=2-3 
 
# R1 R2 
PMNL 
% at 10 µM 
purified 5-LO 
% at 10 µM 
IC50 [µM] 
PMNL 
33 -F 
N N
Cl
 
23.4 ± 4.6 102.8 ± 11.2 1.8 
64 -CF3 
N N
Cl
 
17.4 ± 8.1 88.8 ± 28.4 2.9 
65 -CH3 
N N
Cl
 
14.6 ± 0.5 107.4 ± 25.0 2.8 
66 -F Cl
 
13.2 ± 3.4 143.3 ± 3.5 2.6 
67 -CF3 Cl
 
43.9 ± 9.9 137.8 ± 37.5 8.0 
68 -CH3 Cl
 
27.7 ± 8.4 111.3 ± 23.6 2.9 
69 -F 
 
3.7 ± 2.2 78.5 ± 20.4 2.5 
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# R1 R2 
PMNL 
% at 10 µM 
purified 5-LO 
% at 10 µM 
IC50 [µM] 
PMNL 
70 -CF3 
 
12.7 ± 4.4 109.3 ± 25.2 2.9 
71 -F 
N N
OMe
 
50.1 ± 14.1 69.2 ± 3.5 > 10 
72 -CF3 
N N
OMe
 
36.2 ± 15.4 56.1 ± 21.8 8 
73 -CH3 
N N
OMe
 
27.1 ± 4.6 86.1 ± 8.2 3.3 
74 -F 
N
 
10.4 ± 5.2 114.1 ± 31.6 2.8 
75 -CF3 
N
 
44.5 ± 16.3 87.3 ± 24.8  3 
Introduction of chlorophenyl (66-68) and quinoline (74,75) instead of 
chloropyridazine retained potency with IC50 values in the range of 1.8 µM  (33) 
and 3 µM (75). For 67, trifluoromethyl substitution at p-position of C5-phenyl 
was detrimental leading to almost 3-fold loss of potency compared to the 
corresponding chloropyridazine compound 64. Replacement with phenyl 
residues (69, 70) as seen before for compound 44 and variation of the p-position 
of the phenyl ring kept potency in the range of the corresponding 
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chloropyridazine derivatives. However, introduction of methoxypyridaztine 
residues (71-73) at the central pyrazole core was disadvantageous, especially 
together with fluoro- or trifluormethyl substitution at the para-position of the 
phenyl ring at C-5. As described for the derivatives before, recombinant semi-
purified 5-LO was not remarkably inhibited at concentrations up to 10 µM.  
4.3.2 Pharmacological characterization of selected compounds  
In order to study the influence of the substitution patterns at C-5 and N-1 of the 
pyrazole core on the mode of action, 9 compounds were chosen and subjected to 
further investigations (Fig. 23). For this purpose, the chloro-pyridazine-
substituted derivatives 29, 33, 36 and the respective phenyl- and isoquinoline-
substituted derivatives (44-46 and 48-50) were chosen for further experiments.  
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Fig. 23 Selected  compounds for pharmacological characterization 
For example, the influence of the substrate concentration, alternative stimulation 
of the cells, selectivity towards other LOs, COXs and mPGES-1 or influence on 
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the regulation of 5-LO were investigated to characterize the inhibitory actions of 
the compounds. 
4.3.2.1 Influence of AA concentration in PMNL 
The substrate concentration is an important parameter to identify a possible 
competitive mode of action. Accordingly, PMNL were stimulated with calcium 
ionophore with or without AA at different concentrations (Fig. 24). 
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Fig. 24 Efficiency of the compounds at different substrate concentrations  
PMNL (5 x 106/ml with exogenous AA) or 1 x107/ml (without exogenous AA) were pre-
incubated for 15 min at 37 °C with the compounds or DMSO. Then, 2.5 µM A23187 was 
added together with or without the indicated amounts of AA. After 10 min at 37 °C, 5-LO 
products were analysed by HPLC. Data shown as mean ± SEM; n=3-8 
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For the chloro-pyridazine-substituted derivative 33, no significant influence of 
substrate concentration on the efficacy was observed. Stimulation of the cells 
with A23187 together with 20 µM AA resulted in an IC50 of 1.8 µM. Only a 
small shift to approximately 3 µM occurred after stimulation with A23187 as 
well as together with 40 µM AA. Interestingly, the derivatives 29, 36 and 48 
inhibited 5-LO only in presence of exogenous AA. The IC50 of 29 was about 15 
µM and 10 µM for 36 when the cells were stimulated with 20 µM or 40 µM of 
AA. The reduced LT formation only in presence of exogenous AA might be 
caused by formation of vesicles consisting of AA and the test compound 
resulting in higher reduction of product formation in vitro. While for 44 a 
competitive mode of action seems not reasonable, 45 and 46 were most potent 
upon stimulation without exogenous AA. For both, the efficiency was strongly 
impaired when exogenous AA was added together with A23187. The IC50 
values varied between 1.1 µM to 20 µM for 45 and 2.1 µM to 25 µM for 46 
without or together with increasing amounts of exogenous AA, respectively. In 
contrast, the respective isoquinoline-substituted derivatives 49 and 50 showed a 
different pattern. Especially compound 50 did not completely suppress 5-LO 
product formation up to 30 µM regardless of the substrate concentration.  
4.3.2.2 Effects on 5-LO inhibition after stimulation by cell stress  
The efficiency of 5-LO inhibitors, especially for non-redox type inhibitors was 
shown to depend on 5-LO activation in PMNL [200]. Chemical or osmotic cell-
stress causes activation of 5-LO followed by formation of LTs and 5-HETE in 
PMNL. This mode of 5-LO activation was found to be independent from 
intracellular calcium concentration and is accompanied by strong activation of 
p38 MAPK [126]. Accordingly, it was investigated if the efficiency of the 
pyrazole derivatives was influenced when PMNL were stimulated by osmotic 
cell stress using a hyperosmotic solution of NaCl and 40 µM AA compared to 5-
LO activation by A23187 (Fig. 25).  
Results  94 
49 [µM]
0 1 3 10 30
5-
LO
 
pr
o
du
c
t f
o
rm
a
tio
n
 
[%
 
o
f c
o
n
tr
o
l]
0
20
40
60
80
100
120
140
45 [µM]
0 1 3 10 30
5-
LO
 
pr
o
du
ct
 
fo
rm
at
io
n
 
[%
 
o
f c
o
n
tr
o
l]
0
20
40
60
80
100
120
140
29 [µM]
0 1 3 10 30
5-
LO
 
pr
o
du
ct
 
fo
rm
a
tio
n
 
[%
 
o
f c
o
n
tr
o
l]
0
20
40
60
80
100
120
140
NaCl 
A23187
50 [µM]
0 1 3 10 30
5-
LO
 
pr
o
du
ct
 
fo
rm
at
io
n
 
[%
 
o
f c
o
n
tr
o
l]
0
20
40
60
80
100
120
140
46 [µM]
0 1 3 10 30
5-
LO
 
pr
o
du
ct
 
fo
rm
at
io
n
 
[%
 
o
f c
o
n
tr
o
l]
0
20
40
60
80
100
120
140
36 [µM]
0 1 3 10 30
5-
LO
 
pr
o
du
ct
 
fo
rm
at
io
n
 
[%
 
o
f c
o
n
tr
o
l]
0
20
40
60
80
100
120
140
48 [µM]
0 1 3 10 30
5-
LO
 
pr
o
du
c
t f
o
rm
a
tio
n
 
[%
 
o
f c
o
n
tr
o
l]
0
20
40
60
80
100
120
140
44 [µM]
0 1 3 10 30
5-
LO
 
pr
o
du
ct
 
fo
rm
at
io
n
 
[%
 
o
f c
o
n
tr
o
l]
0
20
40
60
80
100
120
140
33 [µM]
0 1 3 10 30
5-
LO
 
pr
o
du
c
t f
o
rm
a
tio
n
 
[%
 
o
f c
o
n
tr
o
l]
0
20
40
60
80
100
120
140
 
Fig. 25 Efficiency of the compounds after stimulation by osmotic cell stress vs. A23187 
PMNL (5 x 106/ml) were pre-incubated for 15 min with the compounds or DMSO (max. 
0.3%). Then, 0.3 M NaCl was added 3 min prior to 40 µM AA. After 10 min at 37 °C, 5-LO 
products were analysed by HPLC. Data shown as mean ± SEM; n =2-4 
For 33 and 45, an inhibitory effect of the compounds was observed after 
stimulation of PMNL by osmotic cell stress, but the potency was lowered more 
than 10-fold for both. The potency of the phenyl compound 44 and the 
isoquinoline derivative 49 did not differ between the different stimuli, 
suggesting that the inhibitory action is independently from the stimulus. No 
reduction of 5-LO product formation was observed for 46 after activation of 5-
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LO by NaCl. Interestingly, the isoquinoline-substituted compound 48 was 
inactive in A23187-activated PMNL. However, an IC50 of approximately 3 µM 
was observed after addition of NaCl and 40 µM AA and 5-LO product 
formation was reduced to 25% at 30 µM. 5-LO products were neither 
diminished in PMNL after activation by A23187 nor by NaCl and 40 µM AA by 
29 and 36 up to 30 µM. As mentioned before (see 4.3.2.1), exogenous AA was 
required for these compounds to observe an inhibitory effect. 
4.3.2.3 Influence of cellular components in the cell-free assay 
As noted above, the compounds were more potent in the cell-based assay than in 
the cell-free assay. To assess the influence of factors remaining from the 
purification of recombinant 5-LO, the efficacy of the compounds in 
homogenates of E. coli expressing recombinant 5-LO (S40) and semi-purified 5-
LO was compared (Fig. 26). 
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Fig. 26 Inhibition of purified 5-LO and S40 by compounds 33 (A) and 48 (B) 
Aliquots of 40,000 x g homogenates of E. Coli expressing recombinant 5-LO (S40) or semi-
purified 5-LO in PBS containing 1 mM EDTA and 1 mM ATP were pre-incubated for 10 min 
at 4 °C. Samples were  pre-warmed for 30 sec at 37°C and 2 mM CaCl2 and 20 µM AA were 
added to start the reaction. After 10 min at 37 °C, 5-LO products were analysed by HPLC. 
Data shown as mean ± SEM; n=3-7  
n.s.: not significant * p< 0.05, **p < 0.01, unpaired t-test 
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Recombinant 5-LO from E. coli homogenates (S40), but not semi-purified 5-LO 
was significantly inhibited by 33 at 10 and 30 µM versus control (p < 0.05). The 
absence of remaining cellular components in semi-purified 5-LO reduced the 
inhibitory effect of 33, suggesting that these components somehow influence its 
potency (Fig. 26A). A similar effect, but with higher statistical significance was 
observed for the isoquinoline-substituted analogue 48 (Fig. 26B).  
The corresponding phenyl derivative 44 showed an equal inhibition of 5-LO at 
10 µM and 30 µM leading to remaining 5-LO activity of approximately 65%. 
However, this reduction was not considered as being statistically significant. 45 
also inhibited 5-LO significantly compared to vehicle control in the cell-free 
assay, however only at high concentrations of 30 µM. The other pyrazole 
derivatives did not or only hardly inhibit 5-LO product formation in the cell-free 
assays up to 30 µM as described above (data not shown).  
4.3.2.4 Influence of the redox tone on 5-LO inhibition in PMNL 
homogenates 
Non-redox-type inhibitors of 5-LO, for example ZM 230487 or L-739,010, were 
shown to be very potent in intact cells, but lost their potency in cell-free systems 
and broken cell preparations. Exogenous addition of thiols such as GSH or DTT 
to reconstitute glutathione peroxidase restored the potency [139]. As shown 
above, the pyrazole derivatives inhibit 5-LO in intact PMNL, but show weak 
efficacy towards recombinant 5-LO. Therefore, it was investigated if the 
pyrazole compounds share properties with non-redox-type inhibitors. For this 
approach, homogenates of PMNL were prepared, 5 mM GSH was added and 
after pre-incubation with the compounds, 5-LO product formation was measured 
and compared to PMNL homogenates without addition of GSH (Fig. 27).  
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Fig. 27 Influence of GSH on 5-LO inhibition in PMNL homogenates  
PMNL (5 x 106/ml) were resuspended in PBS containing 1 mM EDTA and disrupted. To 
aliquots (1 ml) of homogenates, 1 mM ATP and 5 mM GSH were added as indicated. After 
pre-incubation for 10 min at 4 °C with the compounds or DMSO (max. 0.3%), the reaction 
was started by addition of 40 µM AA. After 10 min at 37 °C, 5-LO products were analysed by 
HPLC. Data shown as mean ± SEM; n=2-4 
For none of the compounds, a statistical significant inhibition of 5-LO in 
homogenates versus the DMSO control was found. In particular, for the phenyl-
substituted derivatives 44-46, neither a statistical significant inhibition versus 
control nor differences in the efficiencies with or without GSH was found. 
Alternatively, 1 mM DTT was added as thiol reagent to PMNL homogenates 
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pre-incubated with 44-46 leading to similar results (data not shown). These data 
suggest that the efficacy of the pyrazole derivatives is independent of the redox 
tone and the activity of GPx. Consequently, the selected pyrazol-propanoic acid 
analogs share no mechanistical properties of described non-redox-type inhibitors 
of 5-LO.  
4.3.2.5 Inhibition of recombinant cPLA2 and AA-release in monocytes 
Endogenous substrate supply for 5-LO in the cell is regulated by cPLA2. AA is 
cleaved by cPLA2 from phospholipids in sn-2 position followed by conversion 
through 5-LO to the respective mediators. Inhibition at this early stage leads to 
reduced inflammatory effects due to reduced supply of 5-LO with AA [20]. 
Several compounds (33, 36, 44-46, 48-50) were investigated at 10 µM in a cell-
free assay with recombinant cPLA2. Vesicles of arachidonate-containing lipids 
were incubated together with the test compounds and recombinant cPLA2. 
Released AA was derivatized and quantified by HPLC.  
All experiments with recombinant cPLA2 and [3H]-AA-labelled human 
monocytes described here were made by B. Jazzar in Tübingen and A. Schaible 
in Jena, respectively. 
Except 44 and 48, the compounds failed to inhibit recombinant cPLA2 at 10 µM. 
As shown in Fig. 28A, 44 and 48 significantly inhibited recmbinant cPLA2 in a 
concentration-dependent manner with IC50 values of 1.7 µM and 4.9 µM, 
respectively. 5 µM of pyrrolidine-1 was used as control inhibitor leading to 18.6 
± 3.2% remaining cPLA2 activity. However, in a cell-based assay using [3H]-
labelled human monocytes, the release of AA by cPLA2 was barely attenuated 
by 10 µM of 44 and 48, whereas the control inhibitor pyrrolidine-1 inhibited 
AA-release at 1 µM, as expected [251] (Fig. 28B).  
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Fig. 28 Inhibition of recombinant cPLA2 (A) and [3H]-AA-release in monocytes (B)  
Experiments were performed by B. Jazzar in Tübingen (A) and A. Schaible (B) in Jena, 
respectively. Recombinant human cPLA2 was expressed in SF9 insect cells. LUVs of PAPC 
and POG (total lipid concentration 250 µM in 200 µl) were incubated with the test 
compounds and 1 mM CaCl2. Reaction was started by addition of 500 ng recombinant cPLA2. 
After 1 h at 37 °C, methanol was added, released AA was derivatized and analysed by HPLC 
(A) Alternatively, isolated human monocytes (2 x 106/ml) were incubated with 5 nM [3H]-AA 
for 2 h at 37 °C and 6% CO2. Cells were washed and resuspended in PGC buffer (1 mM 
CaCl2 ), pre-incubated with the test compounds for 15 min at 37 °C and stimulated with 1 µM 
A23187 for 5 min at 37 °C. Released [3H]-AA was measured in the supernatant on a 
scintillation counter (B); n=3-4 (A); n=2 (B); pyrr=pyrollidine-1 
** p < 0.01 vs. control; one-way-ANOVA with post-test  
4.3.2.6 Influence of Ca2+depletion on the efficiency of the compounds  
Ca2+ was shown to be an important factor to activate 5-LO. However, also in 
absence of intra- and extracellular calcium, 5-LO products were formed in 
PMNL after addition of AA. Moreover, stimulation of PMNL with exogenous 
AA alone leads to activation of p38 MAPK and ERK resulting in 
phosphorylation of the kinases [143]. In order to investigate if inhibition of 5-
LO product formation depends on the presence of Ca2+, intracellular Ca2+was 
removed by addition of 30 µM BAPTA-AM and extracellular Ca2+ by 1 mM 
EDTA. Then, the cells were pre-incubated with the compounds following 
stimulation with 50 µM AA and 5-LO product formation was determined (Fig. 
29). 
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Fig. 29 5-LO inhibition in PMNL after depletion of intra-and extracellular Ca2+ 
PMNL (5 x 106/ml) in PBS containing 1 mM EDTA (PBS-EDTA) were pre-incubated for 15 
min at 37 °C with 30 µM BAPTA-AM. Then, test compounds or vehicle (DMSO max. 0.5%) 
were added for further 15 min at 37 °C and 50 µM AA was added. After 10 min at 37 °C, 5-
LO products were analysed by HPLC. 5-LO product formation of DMSO control: 126.8 ± 
11.1 ng/106 cells; Data shown as mean ± SEM; n=2;  
* p < 0.05 vs. control; one-way-ANOVA with post-test  
No significant reduction of 5-LO product formation was observed for 36, 45, 46 
and 50 up to 30 µM. In contrast, 33 and 48 reduced 5-LO product formation at 
10 and 30 µM by half, suggesting that the inhibitory effect is independently 
from intra- and extracellular Ca2+. Only at high concentrations of 30 µM, a 
reduction was seen for 29, 44 and 49. However, due to the low sample size, only 
a statistical significance for 5-LO inhibition of 44 at 30 µM was found.  
4.3.2.7 Interference with 12-and 15-LO, COX and mPGES-1  
The influence of the pyrazole compounds on other targets of the AA pathway 
such as 12-LO and 15-LO, mPGES-1, COX-1 and COX-2 was assessed in 
several cellular assays (Table 18). For 12- and 15-LO, formation of 12- and 15-
H(P)ETE was measured in PMNL after stimulation with A23187 and 20 µM 
AA. The influence on COX-1 activity by the compounds was measured by 12-
Results  101 
HHT formation as a stable product of PGH2 [234]. For the assessment of COX-2 
activity, A549 lung carcinoma cells were stimulated with IL-1β to induce COX-
2 expression [37]. After addition of AA, the amount of 6-keto-PGF1α as COX-2 
derived product was measured by EIA. mPGES-1 activity was determined by 
measurement of PGE2 formation in microsomal preparations of IL-1β-stimulated 
A549 cells by HPLC. 
Table 18 Effects of selected compounds on 12- LO, 15-LO, COX-1, COX-2 and mPGES-1 
Data shown as mean ±  SEM of % remaining activity at 10 µM (unless otherwise stated) 
versus vehicle control (0.3% DMSO), n=3-8 * p<0.05, ** p<0.01 vs. control 
a 15- and 12-LO remaining activity at 10 µM, unless otherwise stated; 15-H(P)ETE was 
analyzed as product of 15-LO and 12-H(P)ETE as product of 12-LO in PMNL stimulated with 
2.5 µM A23187+20 µM AA; n=2-3  
b COX remaining activity at 10 µM, unless otherwise stated (% 12-HHT formation (COX-1) or 
6-keto-PGF1α formation (COX-2) of control); n=3-8 
c 
mPGES-1 remaining activity at 10 µM (% PGE2 of control); n=3-6 
# 12-LO a 15-LO a COX-1 b COX-2 b mPGES-1 c 
29 90.4 ± 25.4 71 ± 45 102.2 ± 24.4 87.6 ± 13.2 103.0 ± 6.4 
33 102.9 ± 13.4 175 ± 43 82.9 ± 3.2 84.2 ± 9.2 75.6  ± 7.0 
36 77.1 ± 29.0 
119.5 ± 7.5 
(at 3 µM) 51.1 ± 3.9 106.7 ± 16.1 91.4 ± 4.6 
44 118.4 ± 32.4 261 ± 49 21.0 ± 2.9 * 96.9 ± 11.7 83.8 ± 2.2 
45 98.0 ± 6.1 196 ± 30 57.1 ± 12.1 86.3 ± 9.1 83.1 ± 2.9 
46 67.2 ± 0.2 124 ± 22 10.6 ± 1.3 ** 117.7 ± 19.5 105.6 ± 6.5 
48 120.6 ± 21.7 168  (n=1) 8.2 ± 1.0 84.7 ± 19.6 75.0 ± 4.2 
49 117.9 ± 16.3 167 ± 7.7 
49.3 ± 6.8  
(at 1µM) 88.4 ± 13.4 84.0 ± 4.1 
50 82.7 ± 9.7 106.4 ± 2.5 
16.7 ± 3.0  
(at 1µM) 103.9 ± 7.1 88.0 ± 4.4 
None of the compounds affected 12- or 15-LO remarkably up to 30 µM or 
mPGES-1 and COX-2 at 10 µM. COX-1-derived 12-HHT formation was not 
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reduced by the chloropyridazine-substituted derivatives 29 and 33 in isolated 
human platelets. Interestingly, 36 reduced 12-HHT formation to 51% at 10 µM. 
However, this inhibition was not considered statistically significant. In contrast, 
the phenyl- substituted compounds 44 and 46 potently reduced 12-HHT 
formation in platelets with IC50 values of 1.8 µM and 0.3 µM respectively (Fig. 
30A).  
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Fig. 30 Inhibition of COX-1 by phenyl-(A) and quinoline-substituted (B) pyrazole 
derivatives in human platelets 
Human platelets were pre-incubated for 4 min at RT and 1 min at 37 °C with compound or 
vehicle (DMSO 0.1%) and then stimulated with 5 µM AA. After 10 min at 37 °C, 12-HHT 
formation was analysed by HPLC. Indomethacin (Indo) was used as positive control. Data 
shown as mean ± SEM; n≥ 3 ; * p< 0.05, ** p< 0.01, one-way –ANOVA with post-test 
The isoquinoline-substitited derivatives 48 and 50 acted equally or even more 
potent on COX-1 with IC50 values of 0.043 µM and 0.014 µM than the control 
inhibitor indomethacine (IC50= 0.047 µM) (Fig. 30B).  
A dual inhibition of 5-LO and COX is supposed to have stronger anti-
inflammatory effects and simultaneous less occurrence of gastrointestinal side 
effects [220]. Here, it seems apparent that a quinoline moiety at the pyrazole 
combined with a tert-butylbenzylpiperazine (48) or isopropylphenoxy 
substituent (50) favors a dual 5-LO/COX-1 inhibition.  
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4.3.2.8 Influence of the compounds on 5-LO translocation 
An important step in 5-LO regulation is the subcellular localization of the 
enzyme. Upon activation by elevated Ca2+ concentration, 5-LO moves from the 
cytosolic compartment to the nuclear membrane where it colocalizes with 
cPLA2. Then, AA is liberated from phospholipids in the nuclear membrane and 
transferred to FLAP [252]. It was recently shown that the distribution pattern of 
5-LO is different in neutrophils from female and male donors [135]. The FLAP 
inhibitor MK-886 was the first compound described to block translocation of 5-
LO [165]. Over time, several 5-LO inhibitors such as hyperforin [204], 
licofelone [238] or sulindac sulfide [253] have been described to reverse the 
agonist-induced translocation of 5-LO. Hence, the pyrazoles were investigated 
for possible effects on 5-LO translocation in female PMNL (Fig. 31). 
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Fig. 31 Effects of pyrazole derivatives on 5-LO translocation  
PMNL from female donors (3 x 107/ml) were pre-incubated for 15 min at 37 °C with vehicle 
(0.1% DMSO) or test compounds as indicated. After stimulation with 2.5 µM A23187 for 
further 10 min, reaction was stopped on ice and cells were lysed with buffer containing 0.1% 
NP-40 and fractionated by centrifugation. Soluble fractions (non-nuclear) and pellets 
(nuclear fraction) were separated by SDS-PAGE and analysed for 5-LO by Western blot. 
Hyperforin (Hyp) was used as positive control at 10 µM. Equal protein loading on the 
membranes was controlled by Ponceau staining (not shown).  
Numbers above the panels represent arbitrary units of optical density compared to 
unstimulated sample (non-nuclear fraction) or stimulated sample (nuclear fraction) by 
densitometric analysis with ImageQuant® Software (GE Healthcare). The experiment shown 
is representative for at least two to three independent experiments. 
The phenyl- and quinoline-substituted pyrazole derivatives 45, 46, 48 and 49 
caused a slight increase of 5-LO in the nuclear fraction at 30 µM. For 45 and 46 
this effect was already apparent at 10 µM (not shown). On the other hand, a 
slight reversal of translocation was apparent for 36 and 50, however, at a very 
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high concentration of 30 µM. It has to be noted that the intensity of the reversal 
effect of the compounds on 5-LO translocation was not comparable to the 
observed effect of the control compound hyperforin at 10 µM. 
4.3.2.9 Activation of ERK and p38 MAPK in neutrophils 
Mitogen-activated protein kinases (MAPK) such as ERK2 and p38 MAPK 
contribute to the regulation of 5-LO [142],[140]. ERK2 and MK2, a p38 
MAPK-regulated kinase, phosphorylate 5-LO at Ser663 and Ser271. This 
process is strongly upregulated in vitro after addition of polyunsatureted fatty 
acids [141]. In particular, the p38 MAPK pathway is related to inflammatory 
reactions [254]. Therefore, it was investigated if the pyrazole derivatives block 
5-LO product formation by preventing phosphorylation of ERK or p38 MAPK 
after stimulation of the cells with the chemotactic peptide fMLP.  
As shown in Fig. 32A, none of the compounds influenced the phosphorylation 
state of ERK2 up to a concentration of 30 µM. The MEK inhibitor U0126 was 
used at 3 µM as control and inhibited ERK-phosphorylation almost completely 
as expected [255]. In contrast, phosphorylation of p38 MAPK (p-p38) was 
enhanced approximately 5-fold by 44 at 30 µM compared to vehicle control as 
measured by densitometric analysis. Compound 48 also enhanced p38 MAPK 
phosphorylation at 30 µM, whereas the other compounds showed no effects up 
to 30 µM (Fig. 32B). 
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Fig. 32 Phosphorylation of ERK2 (A) and p38 MAPK (B) by pyrazole derivatives  
PMNL (5 x 106 /100 µl PGC buffer) from female donors were pre-warmed at 37 °C for 3 min 
and pre-incubated with the test compounds or DMSO (max. 0.5%) for 15 min at 37 °C. Then, 
1 µM fMLP was added and incubation was continued for 3 min. The reaction was stopped by 
addition of 100 µl of 2x SDS loading buffer. Proteins were detected with specific antibodies 
for phosphorylated ERK (p-ERK) and phosphorylated p38 MAPK (p-p38). Equal protein 
loading was checked by Ponceau staining (not shown). The results in the figure are 
representative for two to three independent experiments. SB=SB230580 
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The strong phosphorylation of p38 MAPK after addition of 44 might be caused 
by the compound itself and probably occurs also without fMLP stimulation. 
However, this aspect was not investigated.  
4.3.2.10 Effects on 5-LO inhibition in human whole blood 
Investigation of 5-LO product formation in a human whole blood assay may 
provide information regarding the in vivo action of a compound. Hence, human 
whole blood was stimulated with 30 µM A23187 after pre-incubation with the 
compounds and 5-LO products were measured (Fig. 33).  
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Fig. 33 5-LO inhibition in whole blood  
Aliquots (1.5 ml) of human whole blood were pre-incubated with the compounds for 10 min at 
37 °C and stimulated with 30 µM A23187. After 10 min at 37 °C, the reaction was stopped on 
ice and 5-LO products in the plasma were analysed by HPLC. Data shown as mean ± SEM; 
n=2-4, unless otherwise stated  
5-LO product formation/ml plasma of DMSO control (100%): 265 ± 85 ng/ml; n.a.: data not 
available 
At a concentration of 10 µM, 5-LO product formation was not significantly 
attenuated by any of the test compounds. However, 45 reduced 5-LO product 
formation at 30 µM to 28% of vehicle control. The control inhibitor BWA4C 
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clearly reduced 5-LO product formation already at 3 µM in the human whole 
blood assay as expected.  
To sum up, derivatives of pyrazole-propanoic acid were found to be potent 
inhibitors of 5-LO product formation. They failed or only barely affect 5-LO in 
cell-free systems. In addition, depending on the substitution pattern of the 
pyrazole core, they reduced PG formation, showing properties of dual COX-1/5-
LOX-inhibitors. However, the exact mode of action could not be elucidated, 
since their inhibitory properties cannot be clearly classified among the known 5-
LO inhibitors.  
4.4 Identification of LT biosynthesis inhibitors by virtual screening  
Pharmacological intervention with LT biosynthesis to treat inflammatory, 
allergic and cardiovascular dieseases comprises several strategies. One approach 
involves the use of antagonists at the Cys-LT1 receptor, e.g. montelukast, 
pranlukast or zafirlukast [81] or direct inhibition of 5-LO with zileuton as the 
only approved drugs [256]. Another approach aims at inhibition of 5-LO product 
biosynthesis with FLAP as promising target [152]. In order to identify new 
chemotypes for 5-LO/FLAP inhibitors, a virtual screening using a 
pharmacophore model that combines docking and ligand-receptor interaction 
fingerprints was applied.  
4.4.1 Development of virtual screening and selection of test compounds  
First, a set of 202 compounds known as FLAP inhibitors from literature was 
defined. This set was aligned to a complex of the inhibitor MK-591 bound to 
FLAP by using several modules of Molecular Operating Environment (MOE) 
software (MOE 2010.10, Chemical Computing Group, Canada). After alignment 
of the training set, a pharmacophore query was generated and used to screen 
libraries from Chemical Computing Group with 2.8 mio vendor compounds, 
whereof 1792 hits were identified. These hits were subjected for docking to the 
FLAP binding site. After refinement of the docking scores, 192 virtual hits were 
selected as candidates. The interactions of the compounds with the FLAP 
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binding site were further characterized by using the protein-ligand interaction 
fingerprint (PLIF) application of MOE [257].  
Development of the pharmacophore model, docking experiments and final 
selection of the test compounds were made by Dr. W. Altenhofen (Chemical 
Computing Group Cologne Germany) and the group of Prof. Banoglu 
(University of Ankara, Turkey), respectively. Finally, 8 compounds were 
selected based on chemical intuition and in consideration of the pharmacophore 
features for the evaluation of 5-LO inhibition . 
4.4.2 5-LO inhibition of virtual screening hits 
The test compounds identified in the pharmacophore model were obtained from 
Ambinter Chemicals (Paris, France) and investigated for 5-LO inhibitory 
activity in intact human PMNL stimulated with A23187 and semi-purified 5-LO 
from E.coli homogenates expressing recombinant human 5-LO (Table 19).  
Table 19 5-LO inhibition of selected screening hits 
PMNL were stimulated with 2.5 µM A23187 or aliquots of E. coli homogenates expressing 
recombinant 5-LO (S40) were incubated with 2 mM CaCl2 and 20 µM AA;  
Data shown as % of remaining 5-LO activity at 10 µM (mean ± SEM) versus vehicle (0.3% 
DMSO); n ≥ 3 
# structure 
PMNL 
% at 10 µM 
S40 
% at 10 µM 
 
76 
 
44 ± 6 58 ± 23 
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# structure 
PMNL 
% at 10 µM 
S40 
% at 10 µM 
 
77 
 
41 ± 10 53 ± 29 
 
78 
 
10 ± 8 16 ± 2 
 
79 
 
81 ± 7 62 ± 13 
80 
 
58 ± 13 116 ± 32 
 
81 
 
91 ± 30 85 ± 17 
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# structure 
PMNL 
% at 10 µM 
S40 
% at 10 µM 
 
82 
 
79 ±14 55 ± 14 
 
83 
 
4 ± 2 77 ± 15 
Six compounds (76-81) share structural similarities. Their scaffolds consist of a 
central heterocyclic element such as pyrazole (76,77), isoxazole (78) or triazole 
(79-81) substituted with diaryl residues such as dimethoyxyphenyl (76) or 
chlorophenyl (77-81). In contrast, the scaffold of 82 contains a dihydro-
chromeno-pyrrol-dione with an aliphatic 3-isopropoxypropyl and an aromatic 
3,4-dichlorophenyl substituent. The chlorobenzyl-substituted benzimidazole 
scaffold of 83 contains shows structural similarity to the indole-based FLAP 
inhibitor MK-886.  
Compounds 76, 77 and 82 seem to act as direct, but weak inhibitors of 5-LO 
with IC50 values of ≥ 10 µM in the cell-free assay. The 2-(4H-1,2,4-triazole-3-
ylthio)acetic acid derivatives 79-81 inhibited 5-LO product formation weakly 
with IC50 values >10 µM in the cell-based as well as in the cell-free assay. In 
contrast, the diaryl-substituted methyl-isoxazole 78 reduced 5-LO product 
formation potently in both assays. Additionally, the benzimidazole derivative 83 
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almost completely blocked 5-LO product formation in PMNL at 10 µM. 
However, in the cell-free assay, 83 recombinant 5-LO was barely affected at 10 
µM. The results of further experiments with these compounds will be presented 
in detail in the following chapter. 
4.4.3 Pharmacological characterization of identified screening hits 
4.4.3.1 Effects of compound 78 on 5-LO product formation 
The diarylmethylisoxazole derivative 78 ((2-(4-(4-chlorophenyl)-3-methyl-
isoxazol-5-yl)-5-(2-methyl-benzyloxy)phenol) was identified as a potent 
inhibitor of 5-LO and subjected to further investigations. In the cell-based assay, 
5-LO product formation was concentration-dependently reduced by 78 (IC50 = 
4.4 µM). Addition of 40 µM exogenous AA together with 2.5 µM A23187 
attenuated the inhibitory effect in PMNL leading to an IC50 of about 6 µM. 
Recombinant semi-purified 5-LO was also inhibited by 78 leading to around 
40% of remaining activity up to 30 µM (Fig. 34). 
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Fig. 34 5-LO Inhibition of compound 78 in PMNL and cell-free assay  
PMNL (5 x 106/ml with exogenous AA or 1 x 107/ml without exogenous AA) in PGC buffer 
were pre-incubated with compound 78 or DMSO for 15 min at 37 °C. Then, 2.5 µM A23187 
was added with or without 40 µM AA as indicated. Alternatively, recombinant semi-purified 
5-LO was pre-incubated for 10 min at 4 °C. Samples were pre-warmed for 30 sec at 37 °C 
and 2 mM CaCl2 and 20 µM AA were added to start the reaction. After 10 min at 37 °C, 5-LO 
products were analysed by HPLC. Data shown as mean ± SEM; n= 2-7 
* p< 0.05, ** p< 0.01, one-way –ANOVA with post-test 
4.4.3.2 Effect of compound 78 on COX-1 and 12-LO product formation 
The influence of 78 on COX-1-derived prostaglandin formation was evaluated 
by the measurement of 12-HHT in isolated human platelets. 78 caused no 
reduction of 12-HHT formation at 10 µM (97 ± 9% remaining 12-HHT 
formation compared to DMSO control). 12-HETE formation, resulting from 
oxygenation of AA by 12/15-LO in neutrophils or p12-LO in adhering platelets, 
was barely attenuated by 10 µM of 78 (72% remaining 12-HETE formation 
compared to DMSO control).  
4.4.3.3 Effects of compound 83 on 5-LO product formation  
As second active compound, 83 (1-(2-chlorobenzyl)-2-(1-(4-isobutylphenyl) 
ethyl)-1H-benzo[d]imidazole) was identified in the virtual pharmacophore 
model. In A23187-stimulated PMNL, 5-LO product formation was reduced by 
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83 in a concentration-dependent manner with an IC50 of 0.31 µM. However, 
after addition of 20 or 40 µM of exogenous AA together with A23187, 5-LO 
activity was not completely suppressed by 83 up to 30 µM (Fig. 35A). In 
preparations using crude homogenates (S40) or semi-purified recombinant 5-
LO, only a weak inhibition of 5-LO up to 50 µM was apparent, excluding a 
direct interaction of 83 with 5-LO (Fig. 35B). 
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Fig. 35 Effect of 83 on 5-LO product formation in PMNL (A) and recombinant 5-LO (B) 
PMNL (5 x 106/ml with exogenous AA) or 1 x 107/ml without exogenous AA) were pre-
incubated with 83 or DMSO for 15 min at 37 °C. Then, 2.5 µM A23187 was added without or 
together with AA. (A) Alternatively, aliquots (1 ml) of supernatants of E.coli homogenates 
expressing recombinant 5-LO (S40) or semi-purified 5-LO were diluted in 1 ml PBS, pH 7.4 
and 1 mM EDTA and pre-incubated with 83 or DMSO for 10 min at 4 °C. Samples were pre-
warmed for 30 sec at 37 °C and 2 mM CaCl2 and 20 µM AA were added to start the reaction 
(B). After 10 min at 37 °C, 5-LO products were analysed by HPLC. Data shown as mean ± 
SEM; n ≥ 3; * p< 0.05, ** p< 0.01 vs. DMSO control, one-way –ANOVA with post-test 
High concentrations of AA in vitro attenuate the influence of FLAP in the cell 
and thus, AA is directly converted by 5-LO. Hence, 5-LO product formation is 
not further reduced at high inhibitor concentrations and remains on a level 
around 20 to 30%. This fact was observed for 83 and has been described for 
licofelone and MK-886 [238]. In addition, FLAP inhibitors do not inhibit 5-LO 
in cell homogenates or recombinant 5-LO. Accordingly, 83 failed to reduce 5-
LO product formation in homogenates of PMNL up to 50 µM. Addition of 5 
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mM GSH to the cell homogenates had no influence on the potency, excluding 
that 83 acts as a non-redox-type inhibitor of 5-LO (data not shown). 
4.4.3.4 Effects of compound 83 on 12- LO, 15-LO and PG formation 
12-/15-LO, also referred to as 15-LO-1, oxygenates AA at position 12 and 15 to 
12- and 15- H(P)ETE and is expressed, for example, in eosinophils [258]. 
Furthermore, platelet-type-12-LO (p-12-LO), forming 12-HETE is present from 
adherent platelets in the cell preparation. Thus, the effect of 83 on 12- and 15-
HETE formation was investigated. No inhibitory effect neither on 12- nor on 15-
HETE formation by 83 was observed up to 30 µM (Fig. 36). Interestingly, 15-
HETE formation was even increased at higher concentrations of 83, caused by a 
shunt of AA and thus conversion by 15-LO. 
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Fig. 36 Effects of 83 on 12-LO and 15-LO product formation 
12- and 15-HETE formation were measured in PMNL stimulated with 2.5 µM A23187 + 40 
µM AA and were analysed by HPLC. Data shown as mean ± SEM; n ≥ 3 
Next, the effect of 83 on PG formation was investigated. For this purpose, 
formation of 12-HHT as non-enzymatic COX-1 derived product of PGH2 was 
measured. For determination of COX-2 inhibition, 6-keto-PGF1α as stable 
product of PGI2 was measured by EIA. Neither COX-1 nor COX-2-derived 
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product formation was affected by 83 up to 50 µM. Additionally, mPGES-1-
derived PGE2 formation was not altered by 83 at 10 µM (data not shown).  
4.4.3.5 Influence of compound 83 on 5-LO translocation 
5-LO translocation describes the movement of the enzyme in the cell from the 
cytosolic compartment to the nuclear membrane after activation by calcium or 
other stimuli. FLAP colocalizes with 5-LO and cPLA2 at the nuclear membrane, 
and converts AA to LTs and 5-HETE [161]. FLAP inhibitors such as MK-886 
have been reported to inhibit agonist-induced subcellular translocation of 5-LO 
from the cytosol to the nuclear membrane [165]. Due to a certain structural 
similarity of 83 with MK-886, the influence on cellular 5-LO redistribution was 
investigated. As shown in Fig. 37, the translocation of 5-LO in PMNL to the 
nuclear membrane was partly reversed by 83 starting from 1 µM.  
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Fig. 37 Influence of compound 83 on 5-LO translocation  
PMNL from female donors (3x 107/ml) were pre-incubated for 15 min at 37 °C with vehicle 
(0.1% DMSO) or 83 as indicated. After stimulation with 2.5 µM A23187 for further 10 min, 
the reaction was stopped on ice and cells were lysed with buffer containing 0.1% NP-40 and 
fractionated by centrifugation. Soluble fractions (non-nuclear) and pellets (nuclear fraction) 
were separated by SDS-PAGE and analysed for 5-LO by Western blot. Equal protein loading 
on the membranes was controlled by Ponceau staining (not shown). Numbers above the 
panels represent arbitrary units of optical density compared to unstimulated sample (non-
nuclear fraction) and stimulated sample (nuclear fraction) by densitometric analysis with 
EttanDIGE® system and ImageQuant® Software (GE Healthcare). The experiment shown is 
representative for at least 3 independent experiments. 
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4.4.3.6 5-LO inhibition of compound 83 in human whole blood 
In order to study the inhibitory action under more physiological conditions, 83 
was investigated in the human whole blood assay. Here, the formation of LTB4 
and 5-HETE in the plasma was reduced by 83 in a concentration-dependent 
manner with an IC50 of 10.1 µM (Fig. 38). Albeit the potency of 83 in whole 
blood is 40-fold lower compared to human neutrophils, this concentration might 
be reached in the blood plasma after oral administration of the compound. 
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Fig. 38 Effects of 83 on 5-LO inhibition in human whole blood  
Aliquots of human whole blood (1.5 ml) were pre-incubated with 83 or vehicle (DMSO 0.1%) 
for 10 min at 37 °C and then stimulated with 30 µM A23187. After 10 min at 37 °C, the 
reaction was stopped on ice and 5-LO products in the plasma were analysed by HPLC. Data 
shown as mean ± SEM; n = 3-5. ** p< 0.01 vs. DMSO control, one-way –ANOVA with post-
test 
4.4.3.7 In vivo experiments 
An in vivo characterization of 83 was carried out in the carrageenan-induced rat 
pleurisy, an animal model of acute inflammation in the group of Prof. L. 
Sautebin at the University of Naples. As shown in Table 20, 10 mg/kg of 83 
reduced significantly the amount of exudate volume, the number of 
inflammatory cells and LTB4 formation in the exudate compared to vehicle-
treated rats. Admittedly, in a comparable experiment, 10 mg/kg zileuton showed 
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a stronger anti-inflammatory effect in this in vivo model than 83 (for data of the 
control inhibitor zileuton see Table 7. 
Table 20 In vivo effects of compound 83 on carrageenan-induced pleurisy in rats 
30 min before intrapleural injection of carrageenan, male rats (n=10 for each experimental 
group) were treated i.p. with 10 mg/kg 83 or vehicle (DMSO 4%). Exudate volume, LTB4 and 
inflammatory cell accumulation in pleural cavity were assessed 4 h after carrageenan 
injection. Data are expressed as mean ± SEM, n = 10 
**p<0.01; ***p<0.001 vs. vehicle (t student) 
Animal experiments were made in the group Prof. L. Sautebin, University of Naples, Italy  
 
4.4.4 SAR of 4,5-diarylisoxazole derivatives  
Next, 78 was chosen as lead compound for structural modifications and 
subjected to SAR studies. Modifications of 78 involved the removal of the 
phenolic hydroxyl group and repositioning of the methyl group at the benzyloxy 
moiety to para-position (84) or replacement by fluorine at C-3 (86, 88, 89, 92). 
Furtheron, the chlorine at the phenyl ring connected with the isoxazole was 
varied between para- (78, 85, 86, 89, 90) and meta-position (87, 88, 91, 92) 
(Table 21).  
treatment 
exudate volume 
(ml) 
inflammatory cells 
( × 106) 
LTB4 
(ng/rat) 
vehicle 0.325 ± 0.021 50.4 ± 2.67 0.512 ± 0.04 
83 
(10 mg/kg) 
0.217 ± 0.026 ** 
(33 %) 
36.8 ± 2.10 *** 
(27 %) 
0.366 ± 0.02 ** 
(29 %) 
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Table 21 5-LO inhibition of 4,5-diarylisoxazole derivatives  
PMNL were stimulated with 2.5 µM A23187 or aliquots of semi-purified recombinant 5-LO 
(purified 5-LO) were incubated with 2 mM CaCl2 and 20 µM AA; Data shown as % of 
remaining 5-LO activity at 10 µM (mean ± SEM) versus vehicle (0.3% DMSO) or IC50  
n ≥ 3; n.i: no inhibition at 10 µM 
# structure 
5-LO activity 
(% of control  
at 10 µM) 
IC50 [µM] 
(PMNL) 
 
IC50 [µM]  
pur. 5-LO) 
78 
 
 
3.0 ± 0.7 4.4 2.6 
 
# R1 R2 R3 
5-LO activity 
(% of control  
at 10 µM) 
IC50 [µM] 
(PMNL) 
IC50 [µM]  
(pur. 5-LO) 
84 4-CH3 4-Cl COOEt 61.4 ± 12.4 > 10 n.i. 
85 2-CH3 4-Cl COOEt 71.9 ± 10.3 > 10 n.i. 
86 3-F 4-Cl COOEt 55.3 ± 12.1 > 10 n.i. 
87 2-CH3 3-Cl COOEt 83.4 ± 16.2 > 10 n.i. 
88 3-F 3-Cl COOEt 80.8 ± 11.8 > 10 n.i. 
89 3-F 4-Cl COOH 19.6 ± 9.5 1.2 0.58 
90 2-CH3 4-Cl COOH 13.1 ± 3.9 1.7 0.7 
91 2-CH3 3-Cl COOH 0.7 ± 0.7 2.0 1.15 
92 3-F 3-Cl COOH 8.4 ± 5.1 1.6 0.75 
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Interestingly, the introduction of ethyl carboxylate instead of a methyl group at 
C-3 of the isoxazole (84-88) led to a complete inactivity of the compounds in 
intact cells and in the cell-free assay. In contrast, the respective free carboxylic 
acids (89-92) inhibited 5-LO product formation potently with IC50 values 
between 1.2 and 2 µM in PMNL. For example, meta-positioning of flourine 
enhanced the potency of 89 almost 4-fold in PMNL compared to the lead 
compound 78. Interestingly, the IC50 values for 89-92 were approximately 2-fold 
higher in the cell-based assay compared to semi-purified 5-LO. To sum up, the 
results propose the 4,5-diarylisoxazole carboxylic acid analogs as direct 5-LO 
inhibitors. Since 5-LO product formation from recombinant 5-LO as well as in 
PMNL was affected, the 4,5-diarylisoxazoles still may share characteristics with 
FLAP inhibitors but also seem to directly interfere with 5-LO.  
4.4.5 SAR of benzimidazole derivatives 
In order to study the influence of structural modifications and define SARs, 83 
was defined as lead compound and a series of derivatives was synthesized by the 
group of Prof. E. Banoglu, University of Ankara, Turkey. Table 22 shows the 
influence on 5-LO inhibition after modifications at N-1 of the benzo[d] 
imidazole scaffold in A23187-activated PMNL. Removal of the 2-chlorine at the 
N-benzyl of the lead compound 83, yielding an unsubstituted ring (93) 
decreased the potency to 0.98 µM. Repositioning of the chlorine to the para-
position (94) caused approximately 15-fold loss of activity compared to the lead 
compound. Other residues at C-4 of the benzyl ring were tolerated (95-101), but 
failed to increase the potency on 5-LO with IC50 values between 2.3 and 6.0 µM. 
Especially bulky substituents such as isopropyl (102), tert-butyl (103) or an 
acetoxygroup (104) further diminished the potency resulting in IC50 values from 
7.2 µM to greater than 10 µM.  
Results  120 
Table 22 5-LO inhibition of benzoimidazole derivatives based on lead compound 83 
PMNL were stimulated with 2.5 µM A23187; Data shown as % of remaining 5-LO activity at 
1 µM or 10 µM (mean ±  SEM) versus vehicle (0.3% DMSO), unless otherwise stated; n ≥ 3 
n.i.: no inhibition up to 10 µM 
 
# R 
 
remaining 5-LO activity 
(% ± SEM at 1 µM) 
IC50 [ µM ] or  
remaining 5-LO activity 
 (% ± SEM at 10 µM) 
83 2-chlorobenzyl 13.2 ± 4.4 0.31 
93 benzyl 47.7 ± 6.2 0.98 
94 4-chlorobenzyl 66.5 ± 11.7 4.8 
95 4-methoxybenzyl 63.0 ± 7.8 3.8 
96 4-methylbenzyl 67.1 ± 8.9 2.9 
97 4-cyanobenzyl 100.4 ± 35.2 2.3 
98 4-iodobenzyl 78.2 ± 3.6 5.0 
99 4-bromobenzyl 79.7 ± 6.4 6.0 
100 4-fluorobenzyl 65.8 ± 10.7 3.4 
101 4-(triflouromethyl)benzyl 83.9 ± 5.6 4.9 
102 4-isopropylbenzyl 83.8 ± 6.6 7.2 
103 4-tert-butylbenzyl 98.3 ± 7.0 
n.i. 
(77.8 ± 10.6 ) 
Results  121 
 
# R 
 
remaining 5-LO activity 
(% ± SEM at 1 µM) 
IC50 [ µM ] or  
remaining 5-LO activity 
 (% ± SEM at 10 µM) 
104 4-acetoxybenzyl 99.8 ± 13.1 
>10 
(56.5 ± 24.1) 
105 3-acetoxybenzyl 109.2 ± 10.8 
n.i. 
(86.7 ± 22.1) 
106 3-fluorobenzyl 71.1 ± 11.9 4.0 
107 3-cyanobenzyl 91.1 ± 18.5 
> 10 
(60.8 ± 31.4) 
108 2-hydroxybenzyl 84.8 ± 8.3 4.5 
109 2-methoxybenzyl 9.2 ± 4.9 0.44 
110 2-acetoxybenzyl 8.4 ± 3.1 0.25 
111 2-cyanobenzyl 43.5 ± 9.8 0.45 
112 2-methylbenzyl 18.1 ± 10.0 0.5 
113 2-fluorobenzyl 43.9 ± 7.3 0.7 
114 2,6-dichlorobenzyl 89.4 ± 2.2 4.4 
115 2,4-dichlorobenzyl 24.6 ± 12.5 0.5 
116 3,4,5-trimethoxybenzyl 120.3 ± 4.7 9.4 
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# R 
 
remaining 5-LO activity 
(% ± SEM at 1 µM) 
IC50 [ µM ] or  
remaining 5-LO activity 
 (% ± SEM at 10 µM) 
117 3,4-diethoxybenzyl 96.1 ± 16.2 
n.i. 
(91.5 ± 13.0) 
118 2-pyridinylmethyl 85.3 ± 11.4 2.5 
119 3-pyridinylmethyl 93.6 ± 20.5 2.8 
120 4-pyridinylmethyl 74.1 ± 14.1 1.95 
121 2-isoquinolylmethyl 112.6 ± 13.6 4.4 
122 benzoyl 88.7 ± 6.0 10 
123 2-acetoxybenzoyl 94.4 ± 2.9 6 
124 3-chlorobenzoyl 92.2 ± 18.1 
>10 
(58.7 ± 9.5) 
125 2-chlorobenzoyl 103.5 ± 11.3 
> 10 
(58.8 ± 6.5) 
126 methyl acetate 86.0 ± 17.5 
> 10 
( 56.7 ± 16.9) 
127 2-carboxymethyl 135.0 ± 23.6 
n.i. 
( 85.5 ± 6.9) 
Substitution of the N-benzyl in position 3 (105-107) resulted in notable loss of 
activity. Only the 3-fluoro-substituted derivative (106) was active in the range of 
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the para-substituted compounds (IC50 = 4.0 µM). A free hydroxy group at 
position 2 of the N-benzyl (108) lowered the IC50 to 4.5 µM. However, 
modifications of the hydroxy group by methylation (109) or acetylation (110) 
restored the potency. Especially acetylation at this site improved the inhibitory 
potency to 0.25 µM compared to 83. Other small residues such as cyano (111), 
methyl (112) or fluoro groups (113) were well tolerated, yielding potent 
compounds with IC50 values from 0.45 µM to 0.7 µM. Introduction of two 
chloro substitutents at the N-benzyl lowered the potency around 9-fold for the 
2,6-dichloro-substituted compound (114) compared to the 2,4-dichloro-
derivative (115). Introduction of multiple alkoxy groups such as 3,4,5-
trimethoxy (116) or 3,4-diethoxy (117) clearly impaired the potency. This result 
confirms that bulky substitutents are not tolerated at other positions than 
position 2. Exchange of the N-benzyl ring by a heterocyclic element such as 
pyridinylmethyl (118-120) or isoquinolylmethyl (121) resulted in still active 
compound, with IC50 values between 1.95 and 4 µM. Especially the bulky 
isoquinoline moiety further diminished the inhibitory potency. In the next step, a 
benzoyl group instead of N-benzyl was inserted into the molecule. This variation 
seemed to be ineffective, since the unsubstituted (122) as well as the 3-
chlorobenzoyl (124) and 2-chlorobenzoyl (125) analogues of 83 showed an IC50 
of 10 µM or higher. Solely, the 2-acetoxybenzoyl derivative  (123) slightly 
restored the potency, underlining the preference of an acetoxy substitiution in 
position 2. Replacement of the aromatic substitutents by aliphatic residues such 
as methyl acetate (126) or the free carboxylic acid (127) failed to efficiently 
reduce 5-LO product formation.  
All derivatives described so far were available as racemates. In order to examine 
the influence of stereochemical aspects on the efficacy, achiral analogues of the 
lead compound (128, 129) were synthesized in the group of Prof. Banoglu at the 
University of Ankara (Table 23).  
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Table 23 5-LO inhibition of achiral derivatives and with modified isobutyl structure. 
PMNL were stimulated with 2.5 µM A23187; Data shown as % of remaining 5-LO activity at 
1 µM (mean ±  SEM) versus vehicle (0.3% DMSO), unless otherwise stated; n ≥ 3 
 
# R’= R’’ 
remaining 5-LO activity  
(% ± SEM at 1 µM) 
IC50 [ µM ] 
128 -CH3 33.3 ± 10.3 0.7 
129 -H 25.6 ± 11.2 0.5 
 
# R 
remaining 5-LO activity  
(% ± SEM at 1 µM) 
IC50 [ µM ] 
130 4-CH3 80.9 ± 13.9 2.8 
131 3-benzoyl 90.2 ± 2.3 3 
When two methyl groups were present at the bridging carbon atom (128), the 
potency was decreased more than 2-fold compared to 83, whereas replacement 
by two hydrogen atoms (129) had only marginal influence. Additionally, the 
role of the isobutyl moiety at the lead compound 83 was studied while replacing 
it by 4-methyl (130) or a 3-benzoyl group (131). However, these modifications 
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retained the activity, but failed to enhance it, suggesting a benefit for the 
isobutyl fingerprint of 83 (Table 23). BWA4C was used in all incubations at 0.3 
µM as control inhibitor with 3.3 ± 1.3 % remaining activity. In addition to the 
aforementioned derivatives, another structural optimization was made by 
modifications at C-5 of the benzimidazole core. Especially, the 5-methoxy and 
5-hydroxy derivative as well as substitution with 2-pyridinylmethyl at this site 
further enhanced the potency compared to 83 with IC50 values between 0.12 and 
0.19 µM [257]. As described before, the lead compound 83 only weakly 
inhibited 5-LO under cell-free conditions. Accordingly, no inhibitory effects on 
semi-purified recombinant 5-LO were also found for selected potent compounds 
at 10 µM (data not shown). 
To sum up, the benzimidazole scaffold was found to be suitable for the design of 
novel anti-LT drugs. In a docking study, an interaction with the binding site of 
FLAP could be demonstrated for the lead compound 83 as well as some 
analogues [257]. The anti-inflammatory properties of 83 in vivo were 
demonstrated in the carrageenan-induced pleurisy model in rats. Several 
chemical modifications at different sites of the molecule further improved the 
inhibitory efficiency in vitro. Therefore, the benzimidazole structure carrying an 
ibuprofen fingerprint was identified as new and useful tool for the development 
of new anti-LT agents.  
4.5 Modified NSAIDs as dual inhibitors of 5-LO and mPGES-1  
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for the 
treatment of pain, fever and inflammatory diseases. Their anti-inflammatory 
actions are based on the inhibition of prostaglandin and thromboxane formation 
[259]. However, the application of NSAIDs goes along with side-effects due to 
blockade of COX-1 and COX-2. Although the use of selective COX-2 inhibitors 
(“Coxibs”) led to less gastrointestinal side effects compared to COX-1-
inhibiting substances [260], a higher risk of cardiovascular events especially for 
rofecoxib was found [261]. In the last years, the inhibition of mPGES-1-derived 
PGE2 formation has become an interesting approach for the treatment of 
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inflammatory diseases. Therefore, the dual inhibition of 5-LO and mPGES-1 is 
believed to have a broad anti-inflammatory efficiency and a lower rate of side 
effects [219]. 
4.5.1 Rationale for selection of the test compounds 
The present test compounds were synthesized by M. Elkady in the group of 
Prof. S. Laufer (University of Tübingen, Germany) (Table 24). The structures of 
the test compounds are based on common acidic NSAIDs such as ibuprofen 
(132, 133), ketoprofen (134, 135), naproxen (136, 137), indomethacine (138, 
139), diclofenac (140) and lonazolac (141-145). The carboxylic acid function 
was synthetically modified by introducing a sulfonamide moiety. This 
modification was described before to improve the dual mPGES-1/5-LO 
inhibition for licofelone, a dual COX/LOX-inhibitor [262].  
4.5.2 Effects of the compounds on 5-LO and mPGES-1 product formation 
All compounds were screened at 10 µM for mPGES-1 inhibition in a cell-free 
assay using microsomes of A549 cells. Inhibition of 5-LO product formation 
was tested in A23187-stimulated human PMNL. Additionally, recombinant, 
semi-purified 5-LO was used to identify direct interactions of the compounds 
with 5-LO. BWA4C at 0.3 µM was used as control for 5-LO inhibition (IC50 = 
0.16 µM and 0.04 µM in PMNL and semi-purified 5-LO, respectively) and 1 
µM MK-886 acted as control for inhibition of mPGES-1 (IC50= 2.3 µM). 
Results  127 
Table 24 5-LO and mPGES-1 Inhibition of modified NSAIDs  
PMNL were stimulated with 2.5 µM A23187, mPGES-1 activity was measured in microsomal 
preparations of A549 cells (20 µM PGH2); Data shown as % of remaining enzyme activity at 
10 µM (mean ±  SEM) versus vehicle (0.3% DMSO) or (*) IC50 (µM ± SEM); n ≥ 3 
# structure 
mPGES-1  
(% of control 
at 10 µM) 
(*) IC50 [µM] 
5-LO PMNL  
(% of control 
at 10 µM) 
(*) IC50 [µM] 
purified 5-LO 
(% of control 
at 10 µM) 
132 
 
78.6 ± 6.4 67.7 ± 8.9 86.8 ± 7.6 
133 
 
67.9 ± 15.8 91.2 ± 4.3 94.9 ± 23.0 
134 
 
76.3 ± 10 78.9 ± 12.7 95.8 ± 13.4 
135 
 
78.6 ± 2.1 90.7 ± 10.6 132.0 ± 10.7 
136 
 
72.8 ± 6.9 148.9 ± 26.9 102.1 ± 19.2 
137 
 
92.5 ± 4.8 109.8 ± 16.7 102.3 ± 3.6 
138 
 
30.2 ± 3.3 
(*) 6.4 ± 1.4 µM  
8.1 ± 8.1 
(*) 2.9 ± 0.8 µM  
76.2 ± 3.9 
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# structure 
mPGES-1  
(% of control 
at 10 µM) 
(*) IC50 [µM] 
5-LO PMNL  
(% of control 
at 10 µM) 
(*) IC50 [µM] 
purified 5-LO 
(% of control 
at 10 µM) 
139 
 
73.6 ± 8.4 64.9 ± 10.3 92.9 ± 19.4 
140 
 
107.0 ± 15.0 72.2 ± 6.6 107.9 ± 20.0 
Within this series, only the indomethacin derivative 138 inhibited mPGES-1 and 
5-LO product formation remarkably (IC50= 6.4 µM for mPGES-1 and 2.9 µM 
for 5-LO, respectively). In contrast, 139, another indomethacine derivative, 
containing a methyl group instead of the more lipophilic tolyl (138), barely 
influenced 5-LO and mPGES-1 product formation at 10 µM. Indomethacin itself 
reduced neither 5-LO- nor mPGES-1 product formation at 10 µM (unpublished 
observations, not shown).  
In addition, a second set of compounds was synthesized based on lonazolac 
(Table 25). Lonazolac, an arylacetic acid derivative was approved in the early 
1980s and was used for the treatment of rheumatic diseases and pain. Anti- 
inflammatory properties of lonazolac were demonstrated in vitro by the 
inhibition of formation of LTB4, its isomers as well as LTC4 in PMNL and by 
the inhibition of histamine release in human basophils [263].  
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Table 25 5-LO and mPGES-1 Inhibition of lonazolac analogs  
PMNL were stimulated with 2.5 µM A23187, mPGES-1 activity was measured in microsomal 
preparations of A549 cells (20 µM PGH2); Data shown as % of remaining enzyme activity at 
10 µM (mean ±  SEM) versus vehicle (0.3% DMSO) or (*) IC50 (mean ± SEM); n ≥ 3 
N
N
O
R2
NH S
O
O
R1
 
# R1 R2 
mPGES-1  
(% of control 
at 10 µM) 
(*) IC50 [µM] 
5-LO PMNL  
(% of control at 
10 µM) 
(*) IC50 [µM] 
purified 5-LO 
(% of control at 
10 µM) 
141 
 
-Cl 
26.6  ± 1.4 
(*) 3.4 ± 0.8 µM 
3.3 ± 2.8 
(*) 2.5 ± 0.3 µM 
65.3 ± 9.3 
142 
 
-phenyl 
9.8 ± 1.7 
(*) 1.7 ± 0.2 µM 
0 ± 0 
(*) 3.5 ± 1.5 µM 
44.7 ± 13.7 
143 
 
-Cl 
20.7 ± 3.0 
(*) 2.3 ± 0.2 µM 
0 ± 0 
(*) 2.9 ± 1.1 µM 
53.8 ± 14.0 
144 
 
-Cl 
32.0 ± 2.5 
(*) 5.9 ± 0.1 µM 
27.6 ± 9.1 
(*) 6.8 ± 2.3 µM 
93.2 ± 4.9 
145 -CH3 -Cl 98.0 ± 26.9 70.7 ± 10.9 43.9 ± 16.2 
The presence of a lipophilic, aromatic residue at the sulfonamide appeared to be 
necessary for dual inhibitory action. Substitutents such as p-tolyl (141, 142) or a 
4-chlorophenyl (143) were advantageous compared to an unsubstituted phenyl 
moiety (144), leading to a potency towards mPGES-1 in the range of MK-886. 
Replacement of the aromatic moiety by a methyl group (145) strongly impaired 
the potency towards mPGES-1 as well as 5-LO. The best inhibitory potency for 
mPGES-1 was found when a biphenyl moiety (142) was present at the pyrazole, 
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resulting in an IC50 of 1.7 µM. However, nearly equal potency for both enzymes 
was realised with compound 143, underlining that the chlorophenyl substitution 
at the sulfonamide moiety is favorable for dual mPGES-1/5-LO inhibition 
compared to the p-tolyl moiety of 141. Recombinant, semi-purified 5-LO was 
not or only hardly inhibited by the compounds with IC50 values around 10 µM or 
higher.  
Further, no inhibition of COX-1 was observed for selected compounds, as the 
introduction of the sulfonamide moiety seems to lead to a loss of COX-1 
inhibition (data not shown). Introduction of a phenyl acetylene moiety at the 
indomethacin and lonazolac scaffold led to compounds with improved potency 
especially towards mPGES-1 [264]. The results suggest that structurally 
modified NSAIDs, especially based on the structure of lonazolac, may act as 
new leads for the development of dual inhibitors of 5-LO and mPGES-1. 
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5 Discussion  
The investigation of a candidate compound requires suitable assay conditions to 
determine the effect on 5-LO product formation. Numerous publications 
describe the in vitro screening of 5-LO-inhibiting compounds. However, in 
some studies the physiological concentration of AA is not considered and 
therefore AA concentrations up to the milllimolar range or high concentrations 
of the compounds that cannot be reached in vivo are used. Additional assay 
conditions that should be critically assessed include the type and concentration 
of the applied stimuli, the used cell type as well as recombinant non-human-LOs 
(e.g. mouse or rat) where the regulation of catalytic 5-LO activity might differ. 
A reliable system for the in vitro screening of 5-LO inhibitors is the combination 
of a cell-free assay with recombinant 5-LO or cell homogenates and a cell-based 
test system using PMNL or monocytes from human blood. The cell-free assay 
allows the identification of direct interactions between the enzyme and the test 
compound. In contrast, the cell-based assay provides information on the impact 
of a candidate compound to aspects that regulate cellular 5-LO activity such as 
LOOH, FLAP, CLP, kinases, membrane association or inhibition of associated 
enzymes (cPLA2, LTA4H) leading to reduced LT biosynthesis.  
5.1 5-Hydroxy-indole-carboxylates as 5-LO inhibitors 
Based on the results of a previous study by Landwehr et al., which described 2-
amino-5-hydroxy-indole carboxylates as 5-LO inhibitors [236], the indole core 
was synthetically modified at different positions and SAR studies were 
undertaken. The presence of a hydroxy group at C-5 of the indole core enhanced 
the inhibitory potency of the compounds probably by its anti-oxidative property 
which keeps the catalytic iron of 5-LO in the Fe2+ state and thus prevents LT 
formation. Nevertheless, 2-amino-indole-methyl-carboxylate derivatives devoid 
of the 5-hydroxy moiety inhibited 5-LO product formation moderately with IC50 
values from 2.4 µM to 12.5 µM in intact cells and in homogenates of E. coli 
with recombinant 5-LO. The SAR studies further indicated that the amino group 
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in position 2 of the indole is not necessary for potent inhibition in intact cells 
and thus substitution with an alkyl chain and linkage with a halogen-substituted 
phenyl moiety was advantageous.  
The largest improvement of the potency was achieved by anellation of a benzene 
to the indole yielding a benzo[g]indole carboxylate backbone. Variations at the 
esterified moiety at C-3, leading to voluminous benzyl carboxylate derivatives 
resulted in comparable IC50 values to the corresponding ethyl carboxylate 
derivatives. Substituents at N-1 led to reduced potency or total inactivity of the 
compounds especially in the cell-based assay, suggesting a hindered uptake in to 
the cells. Anellation of methoxybenzene, pyridine or introduction of a biphenyl 
residue to the indole backbone could not further improve the potency of the 
compounds. Especially modifications or replacement of the hydroxy group at C-
5 strongly reduced the potency, underlining the important role of this moiety for 
the inhibitory action. Finally, the 3-chlorobenzyl-substituted benzo[g]indole-3-
carboxylate 8a emerged as the most active compound in the cell-based as well 
as in the cell-free assay. Further in vitro experiments characterized compound 8a 
as a direct, non-competitive and reversible 5-LO inhibitor. A whole blood assay 
and an animal model of LT-mediated inflammation, both models resembling in 
vivo conditions, confirmed the anti-inflammatory actions of 8a [239]. In 
addition, studies by A. Koeberle in our workgroup revealed that some 
representatives of the benzo[g]indole-carboxylates inhibit mPGES-1-derived 
product formation which further expands the anti-inflammatory spectrum of 
these compounds [230]. 
5.2 Substituted 1,4-benzoquinones and related polyphenolic compounds 
that inhibit 5-LO product formation 
Polyphenolic compounds are able to interfere with the active site iron of 5-LO 
and interrupt the catalytic cycle or act by iron-chelating properties of the 
hydroxy groups and thus reduce 5-LO product formation.  
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Within the polyphenolic compounds, the catechol derivatives 18a and 18b 
showed a considerable inhibitory efficacy with IC50 values of 130 nM and 76 
nM towards recombinant 5-LO. The presence of two hydroxy groups and the 
high radical scavenging properties as observed in the DPPH assay suggest a 
redox-type mode for 5-LO inhibition. Accordingly, the presence of methoxy 
groups at 19a instead of hydroxy groups completely abolished the potency 
towards recombinant 5-LO compared to the corresponding derivative 18a. 
Surprisingly, although a redox-type mechanism seems likely, no significant 
inhibition of p12-LO and 15-LO product formation was observed for the 
polyphenolic compounds suggesting a selective interference with 5-LO [249]. 
A predominant reducing intracellular environment makes the 1,4-benzoquinone 
structure susceptible to reductive conversion to the diphenolic 1,4-hydroquinone 
which then acts as redox-active or iron-ligand inhibitor of 5-LO product 
formation. Interestingly, some of the investigated 1,4-benzoquinones were 
highly potent in the cell-free assay excluding any metabolic change and rather 
suggests a direct interaction with 5-LO. Indeed, molecular docking studies 
showed a direct interference of the compounds with 5-LO via hydrogen bonds 
and π-π interactions. Moreover, the inhibitory potencies obtained from the in 
vitro assays correlate with the observation from the docking studies that the 1,4-
benzoquinone series forms more stable interactions with 5-LO than the 
resorcinol compounds [249]. 
Within the 1,4-benzoquinone series, the decahydronaphthyl-substituted 
derivative 16d turned out to be very potent in human neutrophils (IC50= 0.58 
µM). In contrast, the cyclohexyl-substituted compound 16c could not reduce LT 
formation in both assays, demonstrating that the inhibitory potency of the 
compounds is determined by the lipophilic substitutent at the benzoquinone 
core. The DPPH assay showed that 16d itself has no radical scavenging 
properties and thus the cellular environment is required for its inhibitory action. 
In cell-free assays with recombinant 5-LO and cell homogenates the efficacy of 
16d was much weaker compared to intact cells. Further experiments revealed a 
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correlation between an elevated oxidative tone and the reduced inhibitory 
potency of 16d [248]. Therefore, the inhibitory mechanism of 16d is comparable 
to non-redox-type inhibitors such as ZM230487 or CJ-13,610 [139] and not 
based on interference with the catalytic redox cycle of 5-LO. p12-LO and 15-LO 
product formation were not affected significantly by 16d or any of the other 1,4-
benzoquinones at 10 µM which further supports an inhibitory mechanism 
independently from the redox cycle of 5-LO catalysis. Moreover, 16d failed to 
inhibit mPGES-1 or COX-1 activity and COX-2-derived 6-keto-PGF1α was 
blocked with 12-fold lower potency (IC50 = 7.3 µM) than 5-LO in neutrophils 
(IC50= 0.58 µM). In addition, the in vivo potency of 16d was demonstrated in the 
whole blood assay and in two animal models, where further anti-inflammatory 
actions were identified [248]. In a recent study, the 2,5-dihydroxy-1,4-
benzoquinone embelin was identified as potent dual inhibitor of 5-LO and 
mPGES-1 [265] which encourages to further investigations of the 1,4-
benzoquinones for the development of anti-inflammatory drugs. 
5.3 Pyrazol-propanoic acid derivatives as inhibitors of LT biosynthesis 
Within a series of 1,5-diaryl-substituted pyrazol-propanoic acid amide and ester 
derivatives, 4 compounds reduced LT formation significantly at 10 µM in 
PMNL after stimulation with A23187 and 20 µM AA. In order to define SAR, 
structural modifications of the 4 identified derivatives such as introduction of 
different aryl substituents at N-1 or N-2 of the central pyrazole, shortening of the 
propanoic acid side-chain and different substituents in para-position on C5-
phenyl of the pyrazole were made. The replacement of the chloropyridazine 
moiety at N-1 of the pyrazole by other aryl substituents such as phenyl, 
isoquinoline or benzyl and shortening of the side-chain yielded compounds with 
only weak or no efficacy towards recombinant 5-LO. In the cell-based assay, 
especially the phenyl- and isoquinoline-substituted compounds reduced LT 
formation significantly. Further structural variations at the tert-butyl-piperazine-
substituted compound 33 by introduction of different aryl substituents at N-1 of 
the pyrazole and variations at the para-position of the phenyl ring resulted in 
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compounds with IC50 values between 1.8 µM to 8 µM in the cell-based assay. 
Notably, all pyrazol-propanoic acid derivatives showed weak (IC50 ≥ 10 µM) or 
no efficiency in the cell-free assays with recombinant 5-LO, suggesting a point 
of attack at key steps of cellular 5-LO activity. 
In the next step, 9 compounds with different moieties at C-5 and N-1 of the 
pyrazole core were chosen for investigations on the pharmacological profile. 
With regard to the efficacy of the compounds, modifications of the substrate 
concentration resulted in heterogeneous outcomes and were not directly related 
to the structural properties at C-5 and N-1. Thus, the efficacy of the tert-butyl-
benzylpiperazine-substituted derivatives 33 and 44 was unaffected by the 
substrate concentration, whereas the corresponding isoquinolyl derivative 48 
and the chloropyridazinyl-substituted compounds 29 and 36 reduced LT 
biosynthesis only when exogenous AA was supplied, suggesting a competitive 
mode of inhibition. High amounts of AA perhaps bind to the regulatory site of 
5-LO and facilitate the interference of the pyrazol-propanoic acids with the 
catalytic activity. In contrast, the impaired efficacy when high amounts of AA 
were present as observed for the phenyl-substituted derivatives 45 and 46 as 
well as the remaining product formation at inhibitor concentrations > 10 µM 
was described for FLAP inhibiting-compounds such as licofelone or MK-886 
[238]. The increase of LT formation at concentrations > 3 µM of compound 50 
may be attributed to the formation of micelles consisting of AA and the 
compound leading to impaired access to the enzyme, since this aspect occurred 
only at high concentrations of  exogenous AA in the assay. 
Previous studies showed that the efficacy of non-redox-type inhibitors depends 
on the activation pathway of 5-LO. Osmotic cell stress such as hypertonic NaCl 
activates p38 MAPK and associated downstream kinases in a calcium-
independent manner leading to 5-LO activity [126]. Thus, cell-stress-induced 
product formation strongly impaired the potency of the non-redox-type 
inhibitors ZM230487 and L-739.010, but not of the iron-ligand inhibitor 
BWA4C [200]. While for 44 the inhibitory potency was unaffected by the 
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activation pathway of 5-LO, cell-stress-induced 5-LO activation strongly 
reduced the potency of 33. Obviously, the calcium-dependent activation of 5-
LO, but not the phosphorylation-dependent activation contributes to the 
inhibition of LT biosynthesis. Cell-stress-induced 5-LO product formation was 
also reduced by 45 and 46, but in the same manner as after stimulation with 
A23187 together with 40 µM AA (not shown). Taking into account that elevated 
AA concentrations and cell-stress-induced activation of 5-LO impaired the 
potency of 45 and 46, these compounds share also some in vitro chararacteristics 
of non-redox-type inhibitors. In contrast, the inhibitory effect of compound 48 
was dependent on the phosphorylation-dependent activation of 5-LO caused by 
cell-stress and high amounts of AA. For some compounds (29, 36) neither 
stimulation with A23187 alone nor stimulation by cell-stress led to reduced 5-
LO product formation, showing that the amount of exogenous AA influences the 
inhibitory effect in any way.  
The catalytic activity of 5-LO is determined by the activity of glutathione 
peroxidases which control the concentration of LOOH in the cell [136] and the 
in vitro potency of non-redox-type inhibitors was shown to depend on the 
cellular peroxide levels [139], [201]. However, addition of GSH to homogenates 
of PMNL in order to restore peroxidase activity and thus reduce the LOOH 
concentration had no influence on the efficacy of the chosen pyrazol-propanoic 
acid derivatives. These data clearly show that the compounds reduce 5-LO 
product formation independently from the cellular LOOH concentration and act 
in a different manner other than non-redox type inhibitors. 
The efficacy of the pyrazol-propanoic acid derivatives, was much higher in 
intact PMNL than in the cell-free assays using recombinant 5-LO. Interestingly, 
for compound 33 and 48 the inhibitory effect was significantly stronger in 
40,000 x g homogenates of E. Coli compared to semi-purified recombinant 5-
LO protein, suggesting that remaining lipids or other cellular components 
improve the binding of the compounds to 5-LO. 
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The first step of LT biosynthesis requires the release of endogenous AA by 
cPLA2. The strong inhibitory effect of the phenyl- and isoquinolyl-substituted 
compounds 44 and 48 in the cell-free assay with recombinant cPLA2 was not 
confirmed in the cell-based assay by the measurement of AA-release in human 
monocytes. Moreover, compound 48 reduced 5-LO product formation in PMNL 
only after addition of exogenous AA which circumvents cPLA2 activation, but 
not upon stimulation with A23187 alone. These results question an interference 
with cPLA2 as mode of action for the inhibition of LT biosynthesis.  
Celluar 5-LO activity is not strictly dependent on the presence of intra- or 
extracellular calcium, since addition of exogenous AA to Ca2+-depleted PMNL 
induces 5-LO product formation accompanied by a rapid and strong 
phosphorylation of ERK 1/2 and p38 MAPK [143]. Interestingly, the reduced 5-
LO product formation in calcium-depleted PMNL of the tert-butyl-piperazine-
substituted derivatives 33 and 48 and to a lower extent of 44 suggests an 
interference with calcium-independent mechanisms of 5-LO activity. AA and 
some lipoxygenase-derived metabolites can stimulate further neutrophil 
functions such as degranulation, ROS generation or activate other kinases such 
as PKC or PI3K [266] and hence interactions of the compounds with these 
signaling pathways seem possible. 
A concomitant inhibition of LT and PG formation by interference with 5-LO 
and COX represents an efficient anti-inflammatory strategy by lowering the 
gastrointestinal and cardiovascular side effects of the classical NSAIDs. 
Accordingly, the observed strong inhibition of COX-1-derived 12-HHT 
formation in human platelets of the phenyl- and quinoline-substituted pyrazol-
propanoic acid derivatives results in an enhanced anti-inflammatory effect of 
these compounds. Considering the chemical structures, especially a phenyl or 
quinoline moiety at N-2 of the pyrazole in combination with the tert-butyl-
benzyl-piperazine (44, 48) or the isopropyl-phenyl-propanoate moieties (36, 50) 
favours a dual inhibition of 5-LO and COX-1 product formation. Moreover, the 
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formation of COX-2 and mPGES-1-derived 6-keto-PGF1α and PGE2 was not 
influenced by the compounds.  
The C2 domain of 5-LO mediates the calcium-dependent translocation of 
cytosolic 5-LO to the nuclear membrane [121]. An influence on the subcellular 
redistribution of 5-LO may lead to inadequate catalytic activity and reduced LT 
formation. Compared to the control compound hyperforin which potently 
reversed the binding to the nuclear membrane, some of the pyrazol-propanoic 
acid derivatives slightly increased the amount of 5-LO in the nuclear fraction, 
whereas others had no effect on the intracellular 5-LO distribution. An 
accumulation of 5-LO at the nuclear membrane caused by the compound may 
lead to reduced LT formation by anchoring the enzyme via the C2-domain at the 
membrane yielding in a modified orientation towards FLAP which impairs the 
conversion of AA. However, the accumulating effect in the nuclear fraction 
occurred at high concentrations of 30 µM of the compounds which points to a 
minor reason for the inhibition of LT biosynthesis in PMNL. 
Phosphorylation of 5-LO by ERK2 and the p38 MAPK-dependent MK2 is an 
important factor for AA-induced product formation in PMNL [267]. While an 
influence of the pyrazol-propanoic acid derivatives on the phosphorylation state 
of ERK2 was not apparent, 44 and 48 induced a strong phosphorylation of p38 
MAPK in fMLP-stimulated PMNL. This observed effect may be caused by an 
interference of the compounds with MAPK dephosphatases (MKP) [268], [269]. 
Accordingly, the hyperactivation of p38 MAPK as observed in MKP-deficient 
cells [270] leads to a loss of the kinase function and thus no 5-LO 
phosphorylation by the downstream kinase MK2. However, it has to be noted 
that the enhanced phosphorylation of p38 MAPK might be caused by the 
compounds itself without the need of activation of the cells by fMLP. 
Interestingly, the natural compound tryptanthrin which inhibits cellular LT 
biosynthesis also provokes enhanced p38 MAPK phosphorylation without 
affecting ERK phosphorylation [271]. 
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In addition, the efficacy of a compound in whole blood provides important 
informations about the in vivo behaviour. Therefore, the potency of a compound 
may be altered by plasma protein binding, fatty acids, phopholipids or other 
factors present in the blood plasma compared to its in vitro efficacy. 
Unfortunately, the pyrazol-propanoic acids had no effect on 5-LO product 
formation in the plasma of whole blood up to 10 and 30 µM, respectively. Due 
to the lipophilic character of the compounds, a binding to plasma proteins  or 
other components leading to impaired efficacy seems likely. Nevertheless, 
investigations in animal-based models might reveal other anti-inflammatory 
actions of the compounds.  
In total, the exact mode of LT biosynthesis inhibition of the pyrazol-propanoic 
acid derivatives remains unknown. In vitro experiments revealed no redox-
active or iron-ligand properties which can be further excluded by the inactivity 
towards recombinant 5-LO. Taken together, the pyrazol-propanoic acid 
compounds influence cellular LT biosynthesis in various ways which cannot be 
readily explained. With regard to the need of an intact cellular environment one 
might speculate about interactions of some representatives with FLAP, CLP or 
binding to the regulatory binding site of the enzyme and possible competition 
with phospholipids or calcium at the C2 domain of 5-LO. In addition, the dual  
COX-1/5-LO inhibitory properties of certain derivatives, the class of the 
pyrazol-propanoic acid derivatives provide a good basis for the further 
development of anti-inflammatory compounds. 
5.4 Identification of LT biosynthesis inhibitors by virtual screening 
The use of computer-aided structure- and ligand based strategies in the drug 
design of 5-LO inhibitors led to the identification of new lead molecules [272]. 
Here, a combined structure- and ligand-based virtual screening approach was 
used for the identification of novel chemical scaffolds with inhibitory activity on 
cellular LT biosynthesis. The applied strategy involved the collection of diverse 
known FLAP-inhibiting compounds followed by the generation of a ligand-
based pharmacophore model and virtual screening of a compound database, 
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subsequent refinement by docking and final selection of the test compounds 
based on chemical and literature knowledge [257]. Finally, a subset of 8 
structurally heterogenous compounds was tested for the ability to inhibit 5-LO 
product formation, whereof 4 compounds clearly reduced 5-LO activity in a 
cell-based assay using PMNL and in a cell-free assay with recombinant 5-LO at 
a concentration of 10 µM, suggesting a direct inhibition of 5-LO. 
The diarylmethylisoxazole compound 78 was identified as a potent and selective 
direct 5-LO inhibitor without significant effects on 12-LO and COX-1 product 
formation. Subsequent structural modifications of compound 78 indicated that 
the presence of an ethyl carboxylate at the isoxazole structure completely 
abolished the inhibitory potency, whereas the corresponding free acids tolerated 
alterations of the substituents at the aromatic rings of the molecule. Especially 
the presence of fluorine at the benzyloxy moiety (89, 92) improved the potency 
of the resulting 4,5-diarylisoxazole carboxylic acid derivatives in the cell-based 
assay around 3-fold compared to the lead compound 78. Under cell-free 
conditions with recombinant 5-LO, the IC50 values for the diarylisoxazole-
carboxylic acids were about twice lower compared to intact PMNL, suggesting a 
reduced inhibitory effect in cellular environment due to hindered uptake or 
attenuation by intracellular factors. 
On the other hand, the benzimidazole derivative 83 identified in the virtual 
screening almost completey blocked LT formation in intact PMNL (IC50= 0.31 
µM), but had weak influence on 5-LO activity under cell-free conditions. The 
fact that high amounts of exogenous AA impaired the potency and the weak 
efficacy of 83 in cell-free systems suggest FLAP as possible point of attack. 
Moreover, the apparent structural similarity of 83 with licofelone or MK-886 as 
well as the absence of redox and iron-ligand properties and no influence of 
reducing conditions in the cell-free assay lets FLAP therefore appear as potential 
target.  
Discussion  141 
Several compounds such as the FLAP inhibitor MK-886 [165], licofelone [238] 
or the natural compound hyperforin [204] were described to interfere with the 
translocation of 5-LO. Stimulation of PMNL with A23187 induces the 
movement from the cytosol to the nuclear membrane, where conversion of AA 
to LTs occurs with the participation of FLAP and cPLA2 [252]. In fact, 83 partly 
reversed 5-LO translocation to the nuclear membrane from the concentration of 
1 µM. However, a complete reversion was not achieved up to 10 µM. Further 
studies using immunofluorescence microscopy revealed that inhibition of 5-LO 
translocation does not necessarily correlate to the potency of a compound inLT 
suppression (observations by C. Pergola). 
Structural variations of the lead compound 83 were tolerated best in 2-position 
of the N-benzyl group with the exception of a free hydroxyl group, suggesting 
that hydrogen bond forming and/or the general increased polarity impairs the 
efficacy. Interestingly, a 2-acetoxybenzyl substituent enhanced the efficacy 
resulting in an IC50 value of 0.25 µM. On the other hand, substituents in 3- or 4-
position of the N-benzyl as well as multiple substituents mainly reduced the 
potency except the 2,4-dichlorobenzyl moiety. Moreover, the replacement of the 
N-benzyl moiety by heterocyclic rings caused a strong or total loss of inhibitory 
activity as in the case of N-benzoyl substitution (122-125) or alkyl carboxylic 
acids and esters (126, 127).  Together, other substituents than 2-substituted N-
benzyl appeared to be detrimental for potent inhibition of 5-LO product 
formation in PMNL. A slight decrease of the potency was also apparent after 
preparation of achiral derivatives by addition or complete removal of methyl 
groups on the chiral carbon of 83, proving that the inhibitory action of the 
racemic mixture is sufficient. Moreover, the isobutyl structure at the upper part 
of the lead molecule was found to be favorable, whereas the inhibitory potency 
was diminished around 10-fold when a methyl (130) or benzoyl group (131) was 
added. The resulting isobutylphenylethyl fingerprint, resembling the structure of 
ibuprofen might contribute to the anti-inflammatory effect of the benzimidazole 
compounds. 
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Further investigations included docking studies with the lead compound 83 and 
some analogues, where direct interferences of the compounds with the protein 
structure of FLAP could be shown [257]. Additional protein pull-down assays 
using derivatized 83 linked to an unsoluble matrix confirmed FLAP as a direct 
binding partner of 83 [273].  
In the human whole blood assay, which reflects more physiological conditions, 
83 suppressed LT formation upon stimulation with A23187 or LPS/fMLP with 
IC50 values of 10.1 µM and 3-6 µM [274], respectively. Additional anti-
inflammatory effectiveness of 83 could be demonstrated in the carrageenan-
induced pleurisy in rats and the zymosan-induced peritonitis in mice, two 
established in vivo models of acute inflammation. In both animal models, the 
amount of LTB4, LTC4 and the number of inflammatory cells was significantly 
reduced by 83, although not to the same extent as by the reference compound 
MK-886 [273]. 
Taken together, the applied virtual screening approach using a combined ligand- 
and structure-based pharmacophore model led to the identification of potent 5-
LO inhibitors. 4,5-diarylisoxazole derivatives were characterized as potent, 
direct 5-LO inhibitors with IC50 values in the low micromolar range. Moreover, 
the identification of the derivative 83 proposes the benzimidazole scaffold as 
new chemotype for LT biosynthesis inhibitors targeting FLAP. The potent and 
selective inhibition of 5-LO product formation of 83 without affecting 12- or 15-
LOs, COX-1/-2 or mPGES-1 and the demonstrated in vivo efficacy [257, 273] 
offers considerable potential for the further development of FLAP inhibitors. 
5.5 Derivatives of NSAIDs as dual 5-LO/mPGES-inhibitors 
Over time, concomitant inhibition of PG and LT biosynthesis turned out as 
alternative approach for anti-inflammatory therapy. The blockade of COX 
enzymes shifts AA metabolism towards 5-LO-derived LT formation. Since 
besides inhibition of COX, elevated LT levels seem also lead to gastric damage, 
the dual inhibition of PG and LT formation appears reasonable [219]. 
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Furthermore, a selective inhibition of mPGES-1-derived PGE2 formation seems 
to be superior over inhibition of the COX enzymes and may reduce side-effects 
of classical NSAIDs [30]. Together, a dual inhibition of mPGES-1 and 5-LO 
product formation promises broader anti-inflammatory efficacy and reduced 
gastrointestinal and cardiovascular side-effects.  
In fact, the modification of the carboxylic acid function with a sulfonamide 
group substituted with an aromatic moiety generated derivatives of the NSAIDs 
indomethacine and lonazolac which potently inhibited 5-LO and mPGES-1 
product formation (138, 141-144). The presence of a bulky and lipophilic, 
aromatic substituent such as phenyl, tolyl or chlorophenyl at the sulfonamide 
was found to be necessary, since the inhibitory potency towards both enzymes 
was abolished with a methyl group. Regarding mPGES-1 inhibition, a 
biphenylic moiety at the lonazolac derivative 142 improved the potency 2-fold 
compared to the 4-chlorophenyl substituted 143, but the efficacy towards 5-LO 
was slightly reduced. An adequate concomitant inhibition of 5-LO and mPGES-
1 was achieved with compound 143 (IC50 =2.9 µM for 5-LO and IC50 = 2.3 µM 
for mPGES-1), suggesting that the lipophilic 4-chlorophenyl moiety favors the 
dual inhibition. Regarding COX-1 inhibition, for 138 and 142 no significant 
effect on 12-HHT formation was observed at 10 µM in a cell-free assay, proving 
that the structural modification with the sulfonamide moiety, shifts the anti-
inflammatory effect from COX-1 inhibition towards 5-LO and mPGES-1 
inhibition. Further structural modifications of the indomethacin derivatives 
improved the potency compared to compound 138 (IC50= 2.9 µM for 5-LO and 
IC50= 6.4 µM for mPGES-1) up to IC50 values of 1.75 ± 0.6 µM and 0.9 ± 0.4 
µM for mPGES-1 and 5-LO, respectively [264].  
Taken together, the replacement of the carboxylic acid function of the NSAIDs 
indomethacine and lonazolac by a sulfonamide moiety leads to a loss of COX-1 
inhibition and enhances the inhibitory potency towards 5-LO and mPGES-1.  
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6 Summary 
Leukotrienes (LTs) represent important lipid mediators derived from the PUFA 
arachidonic acid (AA) with broad involvement in pathophysiological conditions. 
5-LO catalyzes the first two steps of LT formation from AA which is released 
from membrane phospholipids by cPLA2. In a first step, molecular oxygen is 
incorporated into AA by 5-LO resulting in 5-H(P)ETE followed by subsequent 
dehydration yielding the epoxide intermediate LTA4. Further enzymatic 
conversion of LTA4 by LTA4H and LTC4H results in the formation of LTB4 
and cysteinyl-LTs. LTs are associated with many diseases such as asthma, 
atherosclerosis, osteoporosis, cardiovascular diseases as well as certain types of 
cancer. Therefore, specific pharmacological intervention with LT synthesis is a 
promising strategy for the treatment of these diseases.  
The complex regulation of the catalytic activity of 5-LO allows various points of 
attack to inhibit LT formation. The cellular activity of the enzyme is regulated 
by several factors such as Ca2+, MAPK, phospholipids such as PC, glycerides 
and CLP. Furthermore, 5-LO activation depends on the presence of LOOH for 
the oxidation of the active site iron from the ferrous (Fe2+) to the ferric state 
(Fe3+). 
Hence, several pharmacological strategies are possible to intervene with 5-LO-
derived LT formation. Beside the direct inhibition of 5-LO, antagonism at the 
LT and Cys-LT receptors, inhibition of FLAP or other enzymes of the AA-
pathway (cPLA2, LTA4H, LTC4S) as well as interference with other key steps 
of LT formation is conceivable. For example, FLAP inhibitors inhibit the 
transfer of AA and reduce the availibility of AA as substrate for 5-LO. Direct 5-
LO inhibitors are classified into three types: (I) redox-type inhibitors that reduce 
the active-site iron und thus uncouple the catalytic cycle, (II) iron-ligand 
inhibitors that chelate the active-site iron and (III) non-redox-type inhibitors that 
compete with AA or LOOH. In addition, a novel, structurally heterogenous class 
of compounds with different or unknown mode of action was defined [202]. 
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However, most of the potential drug candidates failed due to severe side effects 
such as methemoglobin formation or other toxic effects, unspecific action or 
were ineffective under in vivo conditions. So far, only the iron-ligand inhibitor 
zileuton and Cys-LT receptor antagonists entered the market for the treatment of 
asthma and allergic diseases. Therefore, alternative concepts and novel lead 
structures for the therapy of LT-related diseases are required. 
In this study, different novel classes of LT biosynthesis inhibitors were 
identified. Since the efficacy of a test compound strongly depends on the assay 
conditions, detailed studies were performed in order to characterize the 
mechanistic aspects of 5-LO inhibition.  
Based on a previous study by Landwehr et al [236], compound 1a (methyl 2-(3-
chlorophenylamino)-5-hydroxy-1H-indole-3-carboxylate) was identified within 
a series of indole-3-carboxylates as potent 5-LO inhibitor in intact cells (IC50= 
2.4 µM) as well as in a cell-free assay using recombinant 5-LO (IC50= 0.3 µM). 
Structural modification of the indole-3-carboxylate core led to a series of 
benzo[g]indole-3-carboxylates with improved inhibitory potency. Subsequent 
investigations characterized compound 8a (ethyl 2-(3-chlorobenzyl)-5-hydroxy-
1H-benzo[g]indole-3-carboxylate) as a direct, non-competitive and reversible 5-
LO inhibitor (IC50= 0.23 µM in intact cells and IC50= 0.03-0.1 µM in the cell-
free assay). Furthermore, 8a reduced 5-LO product formation in the human 
whole blood assay (IC50= 1.6 µM) and showed anti-inflammatory actions in vivo 
in the carrageenan-induced pleurisy model in rats with comparable potency to 
the well-known iron-ligand inhibitor zileuton. Additional studies by A. Koeberle 
in our workgroup further characterized the benzo[g] indole-3-carboxylates as 
potent dual inhibitors of 5-LO and mPGES-1 without significant effects on COX 
enzymes. In this context, the 2-chlorophenyl-substituted derivative 8b was the 
most potent compound (IC50= 0.1 µM for mPGES-1 and 1.2 µM for 5-LO) 
among the benzo[g]indole-3-carboxylates [230]. 
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SAR studies with 1,4-benzoquinone and respective polyphenolic derivatives 
revealed that the type of the substituent at the 1,4-benzoquinone or polyphenolic 
backbone determines the overall potency. Especially bulky groups such as 
naphthyl or dibenzofuranyl substituents favor the inhibition of 5-LO product 
formation. Surprisingly, some 1,4-benzoquinone compounds directly inhibited 
recombinant 5-LO, hence excluding bioactivation to the 1,4-diphenol structure 
and suggesting an inhibitory mode other than redox activity. Since 12- and 15-
LO product formation were not significantly affected by selected potent 
compounds, an interference with the common redox cycle of the mammalian 
LOs can be excluded. Interestingly, the in vitro inhibitory potencies correlated 
with the results from molecular docking studies, where more stable interactions 
of the 1,4-benzoquinone derivatives with 5-LO were found than for the 
polyphenolic compounds [249]. The 1,4-benzoquinone 16d showed high 
inhibitory efficacy in PMNL (IC50= 0.58 µM), but was less active in neutrophil 
homogenates and recombinant 5-LO (IC50=11 µM). No radical scavenging 
properties of 16d itself were apparent, but seemingly the reducing intracellular 
conditions are required for its inhibitory action. cPLA2, COX-1 and mPGES-1 
were not affected, whereas 16d inhibited COX-2, but with weaker potency 
(IC50= 7.3 µM) than 5-LO [248]. In the human whole blood assay, resembling in 
vivo conditions, 16d and the catechol derivative 18b were active (IC50= 9.1 µM 
and 8-9 µM, respectively) and more anti-inflammatory efficacy of 16d was 
demonstrated in vivo in two established animal inflammation models [248]. 
Following SAR studies with pyrazol-propanoic acid derivatives, 9 derivatives  
with different substituents at C-5 and N-1 of the pyrazole scaffold were chosen 
for mechanistic investigations. In general, the inhibitory potency of the 
compounds was higher in intact cells than in cell-free systems such as PMNL 
homogenates or recombinant 5-LO. For 2 compounds (33, 48) a stronger 
inhibitory effect was observed in homogenates of E. coli expressing 
recombinant 5-LO, whereas semi-purified recombinant 5-LO was not affected, 
indicating an influence of cellular components on the efficacy. Heterogenous 
mechanistic properties were observed at varying substrate concentrations or 
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different celluar 5-LO activation by calcium or osmotic cell stress. Interestingly, 
some phenyl- and quinoline-substituted compounds (44, 46, 48-50) potently 
reduced COX-1-derived 12-HHT formation in platelets (IC50= 1.8 µM for 44, 
0.3 µM for 46 and 0.014-1 µM for 48-50, respectively) without effects on COX-
2 and mPGES-1 product formation. Thus, the dual 5-LO/COX-1 inhibition 
expands the anti-inflammatory effectiveness of the compounds.The observed 
effects of some compounds on the subcellular distribution of 5-LO required high 
concentrations in vitro and the extent was not comparable to the positive control 
hyperforin. Upon stimulation with fMLP, the compounds 44 and 46 caused a 
strong upregulation of p38 MAPK phosphorylation in PMNL, but this effect 
cannot clearly explain the inhibitory action. In total, the pyrazol-propanoic acid 
derivatives are inhibitors of cellular 5-LO product formation and partly inhibit 
COX-1-derived PG formation.  
The use of a combined ligand- and structure-based pharmacophore model 
yielded a set of 8 structurally diverse compounds (Table 19).  
The 4,5-diarylisoxazole derivative 78 inhibited LT formation in A23187-
stimulated PMNL (IC50= 4.4 µM) and in semi-purified 5-LO to around 40 % at 
30 µM. Inclusion of 40 µM exogenous AA lowered the inhibitory potency in 
PMNL (IC50= 6 µM). The presence of flourine at the outer phenyl ring and 
replacement of a methyl group by carboxylic acid function at the isoxazole core 
(89, 92) enhanced the potency about 3-fold in the cell-based assay and almost 5-
fold towards recombinant 5-LO, respectively.  
In contrast, the benzimidazole derivative 83 potently reduced A23187-induced 
LT formation in PMNL (IC50= 0.31 µM), but under cell–free conditions, the 
inhibitory potency was nearly absent. Since mechanistic properties of non-
redox-type inhibitors and radical scavenging properties could be excluded, 
FLAP was investigated as potential target of 83. In fact, the interaction of 83 and 
related derivatives with FLAP was confirmed in docking studies and protein 
fishing experiments using immobilized compound [257], [273]. Moreover, 83 
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partly reversed 5-LO translocation, a fact which was described for other FLAP 
inhibitors before. Subsequent structural modifications and SAR studies based on 
83 yielded more potent analogues [257], disclosing the benzimidazole scaffold 
as new chemotype for further development of anti-LT drugs. 
The simultaneous inhibition of LT and PG biosynthesis is supposed to lead to 
better gastrointestinal tolerability and anti-inflammatory efficacy. Therefore, 
dual 5-LO/mPGES-1 inhibitors promise a good alternative to NSAIDs. 
Structural modification of common NSAIDs by introduction of a sulfonamide 
scaffold connnected with a lipophilic aromatic substituent led to potent dual 5-
LO/mPGES-1 inhibitors with IC50 values of 1.7-6.4 µM for mPGES-1 and 2.5-
6.8 µM for 5-LO, respectively. Equal inhibition of both enzymes was achieved 
by the 4-chlorophenyl substituted lonazolac analogue 143 (IC50 =2.9 µM for 5-
LO and IC50= 2.3 µM for mPGES-1, respectively). Simultaneously, the  
structural modifications led to a loss of the inhibitory potency towards COX-1. 
Thus, the development of dual inhibitors targeting LT and PG formation based 
on lead structures of known anti-inflammatory drugs offers the chance to a more 
specific and safe anti-inflammatory therapy. 
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7 Zusammenfassung 
Leukotriene (LTs) stellen wichtige, von der mehrfach ungesättigten Fettsäure 
Arachidonsäure (AA) abstammende Lipidmediatoren mit einer umfassenden 
Beteiligung an pathophysiologischen Vorgängen dar. Das Enzym 5-
Lipoxygenase (5-LO) katalysiert die ersten beiden Schritte der LT-Bildung aus 
AA, die aus Membranphospholipiden durch cPLA2 freigesetzt wird. Im ersten 
Schritt wird dabei molekularer Sauerstoff auf AA übertragen, wobei 5-H(P)ETE 
entsteht, welches anschließend zum Epoxid-Zwischenprodukt LTA4 dehydriert 
wird. Die weitere Umwandlung von LTA4 durch die Enzyme LTA4H und 
LTC4S führt zur Bildung von LTB4 sowie Cysteinyl-LTs. LTs werden mit 
vielen Erkrankungen wie Asthma, Atherosklerose, Osteoporose, 
kardiovaskulären Erkrankungen sowie verschiedenen Krebsarten in 
Zusammenhang gebracht. Dementsprechend stellt ein gezielter 
pharmakologischer Eingriff in die LT-Synthese einen vielversprechenden 
Ansatz zur Behandlung dieser Erkrankungen dar.  
Die komplexe Regulation der katalytischen 5-LO-Aktivität ermöglicht 
verschiedenartige Angriffspunkte für die Hemmung der LT-Bildung. Die 
zelluläre Aktivität des Enzyms wird durch mehrere Faktoren wie Ca2+, MAPK, 
Phospholipide (z.B. PC), Glyceride und CLP gesteuert. Desweiteren hängt die 
Aktivierung der 5-LO von der Konzentration an Lipidhydroperoxiden (LOOH) 
ab, die zur Oxidation des Eisenions im aktiven Zentrum notwendig sind. 
Dementsprechend sind mehrere pharmakologische Vorgehensweisen zum 
Eingriff in die LT-Bildung durch 5-LO möglich. Neben einer direkten 
Hemmung der 5-LO sind ein Antagonismus an den LT bzw. CysLT-Rezeptoren, 
die Hemmung von FLAP oder anderen Enzymen des AA-Wegs wie cPLA2, 
LTA4H, oder LTC4S sowie ein Eingriff in andere Schlüsselschritte der LT-
Bildung denkbar. Beispielsweise hemmen FLAP-Inhibitoren die Übertragung 
der Arachidonsäure und verringern dadurch die Verfügbarkeit als Substrat für 5-
LO. Die direkten 5-LO-Inhibitoren lassen sich in drei Arten unterteilen: (I) 
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Inhibitoren vom Redoxtyp reduzieren das Eisenion im aktiven Zentrum und 
entkoppeln dadurch den katalytischen Zyklus, (II) Eisenligand-Inhibitoren, 
welche das Eisenatom chelatieren und (III) Inhibitoren vom Non-Redox-Typ, 
die mit AA oder LOOH am Enzym konkurrieren. Desweiteren wurde eine vierte 
Art von Verbindungen mit einer andersartigen oder bis dato unbekannten 
Wirkungsweise definiert [202]. Allerdings scheiterten die meisten potentiellen 
Wirkstoffkandidaten aufgrund schwerer Nebenwirkungen wie 
Methämoglobinbildung oder anderer toxischer Effekte, unspezifischer Wirkung 
oder waren in vivo nicht wirksam. Bis heute sind nur der Eisenligandinhibitor 
Zileuton sowie Cys-LT-Rezeptorantagonisten zur Behandlung von Astma und 
allergischen Erkrankungen auf dem Markt. Dementsprechend bedarf es 
alternativer Konzepte und neuer Leitstrukturen für die Behandlung von LT-
assozierten Erkrankungen. 
In dieser Arbeit wurden neuartige Klassen von Hemmstoffen der 
Leukotrienbiosynthese identifiziert. Da die Wirksamkeit einer Testsubstanz 
stark von den Versuchsbedingungen abhängt, wurden ausführliche 
Untersuchungen durchgeführt, um den Mechanismus der 5-LO-Hemmung 
aufzuklären. 
Ausgehend von früheren Untersuchungen von Landwehr et al. [236] wurde 
innerhalb einer Serie von Indol-3-carboxylaten die Verbindung 1a (methyl 2-(3-
chlorophenylamino)-5-hydroxy-1H-indole-3-carboxylate) als potenter 
Hemmstoff der 5-LO in intakten PMNL (IC50= 2.4 µM) als auch im zellfreien 
Testsystem mit rekombinanter 5-LO (IC50= 0.3 µM) identifiziert. Strukturelle 
Veränderungen des Indol-3-carboxylat-Gerüstes brachte eine Reihe von 
Benzo[g]indol-3-carboxylaten mit wesentlich verbesserter Wirksamkeit hervor. 
Verbindung 8a (ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-
carboxylate) stellte sich in nachfolgenden Untersuchungen als direkter, nicht-
kompetitiver und reversibler Hemmstoff der 5-LO (IC50 = 0.23 µM in intakten 
PMNL und IC50= 0.03-0.1 µM im zellfreien System) heraus. Desweiteren 
verringerte Substanz 8a die 5-LO-Produktbildung im humanen Vollblutassay 
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und zeigte in vivo bei der Carrageen-induzierten Brustfellentzündung in Ratten 
antiinflammatorische Wirksamkeit mit einer vergleichbaren Wirkstärke wie der 
bekannte Eisenligand-Inhibitor Zileuton. In weiteren Untersuchungen von A. 
Koeberle in unserem Arbeitskreis wurden die Benzo[g]indolcarboxylate als 
potente duale Inhibitoren von 5-LO und mPGES-1 ohne nennenswerten Einfluss 
auf COX-Enzyme charakterisiert. In diesem Zusammenhang war die 2-
chlorophenyl-substituierte Verbindung 8b (IC50= 0.1 µM für mPGES-1 und 1.2 
µM für 5-LO) die wirksamste Substanz unter den Benzo[g]indolcarboxylaten 
[230]. 
Untersuchungen zur Struktur-Wirkungsbeziehung von 1,4-Benzochinonen und 
entsprechenden polyphenolischen Verbindungen ergaben, dass die Art des 
Substituenten am 1,4-Benzochinon- bzw. polyphenolischen Gerüst die 
insgesamte Wirkstärke der Substanz bestimmt. Insbesondere voluminöse 
Gruppen wie Naphthyl- oder Dibenzofuranylsubstituenten begünstigen die 
Hemmung der 5-LO-Produktbildung. Erstaunlicherweise hemmten einige 1,4-
Benzochinonverbindungen rekombinante 5-LO direkt, was die Bioaktivierung 
zur 1,4-Diphenolstruktur ausschließt und auf einen anderen inhibitorischen 
Mechanismus als Redoxaktivität hinweist. Da weder 12- noch 15-LO-
Produktbildung durch ausgewählte Verbindungen signifikant beeinflusst wurde, 
kann eine Wechselwirkung mit dem gemeinsamen Redoxzyklus der Säugetier-
LOs ausgeschlossen werden. Interessanterweise korrelierten die Wirkstärken in 
vitro mit den Ergebnissen aus Docking-Untersuchungen, in denen für die 1,4-
Benzochinonverbindungen stabilere Wechselwirkungen mit 5-LO gezeigt 
wurden als für die polyphenolischen Substanzen [249]. Die 1,4-
Benzochinonverbindung 16d wies eine hohe inhibitorische Wirkung in PMNL 
auf (IC50= 0.58 µM), aber war in Homogenaten von Neutrophilen und 
rekombinanter 5-LO (IC50= 11 µM) weniger aktiv. Die Substanz 16d zeigte 
selbst keine Radikalfängereigenschaften, aber anscheinend sind die 
reduzierenden intrazellulären Bedingungen für die inhibitorische Wirkung 
notwendig. cPLA2, COX-1 und mPGES-1 wurden nicht beeinflusst, wohingegen 
16d die COX-2 hemmte, wenn auch mit niedrigerer Potenz (IC50 = 7.3 µM) als 
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5-LO [248]. Im humanen Vollblutassay, welches den in vivo-Bedingungen 
ähnelt, waren 16d sowie die polyphenolische Catecholverbindung 18b aktiv 
(IC50=  9.1 µM bzw. 8-9 µM) und die weitere antiinflammatorische Wirksamkeit 
von 16d in vivo wurde in zwei etablierten Tierentzündungsmodellen gezeigt 
[248]. 
Im Anschluss an Untersuchungen der Struktur-Wirkungsbeziehungen von 
Pyrazolpropansäurederivaten wurden 9 Substanzen, die verschiedenartig an C-5 
und N-1 des Pyrazolgerüsts substituiert sind, für Untersuchungen zum 
Wirkmechanismus ausgewählt. Generell war die Hemmwirkung der Substanzen 
in intakten Zellen höher als in zellfreien Systemen wie PMNL-Homogenaten 
oder rekombinanter 5-LO. 2 Substanzen (33, 48) zeigten eine stärkere 
Hemmwirkung in Homogenaten von E.coli mit rekombinanter 5-LO beobachtet, 
wohingegen aufgereinigte rekombinante 5-LO nicht beeinflusst wurde, was 
einen Einfluss zellulärer Komponenten auf die Wirkung nahelegt. Bei 
variierenden Substratkonzentrationen sowie unterschiedlicher Aktivierung der 5-
LO durch Calcium oder osmotischen Zellstress wurden uneinheitliche 
mechanistische Eigenschaften der Verbindungen beobachtet. Interessanterweise 
verminderten einige Phenyl- und Chinolin-substituierte Verbindungen (44, 46, 
48-50) potent die COX-1-vermittelte 12-HHT-Bildung in Thrombozyten (IC50= 
1.8 µM für 44, 0.3 µM für 46 and 0.014-1 µM für 48-50) ohne Einfluss auf 
COX-2 oder mPGES-1. Diese duale 5-LO/COX-1-Hemmung erweitert damit 
die antiinflammatorische Wirkung der Substanzen. Der bei einigen 
Verbindungen beobachteten Einfluss auf die subzelluläre Verteilung der 5-LO 
erforderte in vitro hohe Substanzkonzentrationen und das Ausmaß war nicht 
vergleichbar mit der Positivkontrolle Hyperforin. Nach der Stimulation mit 
fMLP verursachten die Substanzen 44 und 46 eine starke Hochregulation der 
p38 MAPK-Phosphorylierung in PMNL, allerdings erklärt dieser Effekt die 
Hemmwirkung nicht. Insgesamt sind die Pyrazolpropansäurederivate als 
Hemmstoffe der zellulären 5-LO-Produktbildung anzusehen, wobei sie auch 
teilweise die COX-1-vermittelte PG-Bildung hemmen. 
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Die Anwendung eines kombinierten Liganden- und Strukturbasierten 
Pharmakophormodells brachte eine Gruppe von 8 strukturell unterschiedlicher 
Verbindungen hervor (Table 19). Die 4,5-Diarylisoxazolverbindung 78 hemmte 
die LT-Bildung in A23187-aktivierten PMNL (IC50= 4.4 µM) sowie in 
aufgereinigter rekombinanter 5-LO bei 30 µM bis auf 40%. Die Zugabe von 40 
µM exogener AA verringerte die Hemmwirkung in PMNL (IC50= 6 µM). Durch 
die Einführung von Fluor am äußeren Phenylring und der Austausch einer 
Methylgruppe durch eine Carboxylfunktion konnte die Potenz um das dreifache 
im zellbasierten Assay und um das fast fünffache in rekombinanter 5-LO 
gesteigert werden. 
Im Gegensatz dazu hemmte die Benzimidazolverbindung 83 potent die A23187-
induzierte LT-Bildung (IC50= 0.31 µM), jedoch war unter zellfreien 
Bedingungen kaum eine Hemmwirkung zu beobachten. Da mechanistische 
Eigenschaften von Nonredoxtyp-Inhibitoren und Radikalfängereigenschaften 
ausgeschlossen werden konnten, wurde FLAP als potentielles Target von 83 
untersucht. Tatsächlich wurde eine Wechselwirkung von 83 und ähnlichen 
Verbindungen mit FLAP mit Hilfe von Dockingstudien und Protein-Fishing-
Experimenten mit immobilisierter Substanz nachgewiesen [257], [273]. 
Desweiteren machte 83 teilweise die 5-LO-Translokation rückgängig, ein Fakt, 
der für andere FLAP-Inhibitoren bereits beschrieben wurde. Nachfolgende 
Strukturvariationen und Untersuchungen zu Struktur-Wirkungsbeziehungen, 
brachten weitere potente Analoga hervor, die das Benzimidazolgerüst als neuer 
Chemotyp für die weitere Entwicklung von anti-LT-Arzneistoffen nahelegen. 
Die gleichzeitige Hemmung der LT- und PG-Biosynthese soll zu einer besseren 
gastrointestinalen Verträglichkeit und antiinflammatorischer Wirksamkeit 
führen. Deshalb verheißen duale 5-LO/mPGES-1-Hemmstoffe eine gute 
Alternative zu NSAIDs zu sein. Die strukturelle Veränderung bekannter 
NSAIDs durch die Einführung einer Sulfonamidgruppe verbunden mit einem 
lipophilen aromatischen Substituenten führte zu potenten dualen 5-LO/mPGES-
1 Inhibitoren mit IC50-Werten von 1.7-6.4 µM für mPGES-1 und 2.5-6.8 µM for 
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5-LO. Eine gleichmäßige Hemmung beider Enzyme wurde durch die 4-
chlorophenylsubstituierte Verbindung 143 (IC50 =2.9 µM für 5-LO and IC50 = 
2.3 µM für mPGES-1) erreicht. Gleichzeitig führten die strukturellen 
Veränderungen zu einem Verlust der Hemmwirkung auf COX-1. Folglich bietet 
die Entwicklung dualer Hemmstoffe der LT- und PG-Bildung, basierend auf 
Leitstrukturen bekannter antientzündlicher Arzneistoffe die Möglichkeit einer 
spezifischeren und sicheren antientzündlichen Behandlung. 
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